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The first part of this thesis describes efforts towards the Lycopodium alkaloids lycopladine H (I) 
and lycojaponicumin D (II) and the chemistry developed in the course of these studies. We 
pursued a divergent transannular Mannich reaction approach for both from the same starting 
material (VI). Extensive screening to suppress dimerization of IV, prepared from iodoenone III, 
eventually led to a ring-closing metathesis protocol that allowed us to investigate the final steps 
of the synthesis. Tetraol V could be obtained, but we were unable to access triketone VI to 
investigate the final step. 
 
Investigations for a RCAM approach with bisalkyne VII using Fürstner’s catalysts indeed 
yielded small quantities of VIII. While trying to more efficiently furnish the sidechain by basic 
isomerization of a butynyl moiety, we discovered a carbocyclization reaction which was the 
focus of the main part of this PhD work. 
When trying to isomerize terminal alkynes like IX to the internal alkyne, we observed clean 
cyclization to hydrindanones like X bearing an all-carbon quaternary stereocenter. Further 
investigations revealed that potassium tert-butoxide in DMSO efficiently mediates the ring 
closure to form a range of 5-5- and 6-5-systems. We also realized that hydrindanones like X 
form the core of many Lycopodium alkaloids, such as the aromatic fawcettimine-type natural 
product lycoposerramine R (XII). Via allylic oxidation to enone XI and Kröhnke-type pyridone 
synthesis, we accessed (−)-Lycoposerramine R (XII) in 7 steps overall. 
 
We were also able to apply similar chemistry to the other congeners lycopladine A (XVI) and 
carinatine A (XIX): cyclization of TMS-protected alkyne XIII gave hydrindanone XIV in good 
yield on gram scale. From central building block XV, we were able to access intermediate XVII 
in 8 steps overall, which intercepts Overman’s sieboldine A synthesis. Adapting the Ciufolini 
pyridine synthesis, the two pyridine-containing natural products lycopladine A (XVI) and 
carinatine A (XIX) were accessed with the fastest syntheses to date, the latter through a newly 
developed telescoped biscyclization via chloride XVIII. 
 
  
 
Glutamate is one of the most important neurotransmitters in neuroscience and deeply 
connected to all aspects of signal transduction, learning, behavior and memory. The latter is 
mainly associated with the NMDA receptor subtype. Based on previous SAR studies, we 
designed ATG (XXII), a selective agonist of NMDA receptors, which can be accessed from 
aniline XX and pyroglutamate (XXI). It can be switched into its active cis form using 740 nm 
light via two-photon irradiation. To further confirm its mode of action as a cis-agonist, a stilbene 
analog termed STG (XXIV) was also synthesized from XXIII and shown to be functionally 
equivalent. With these tools, NMDA receptors could be reversibly activated in Xenopus oocytes 
as well as murine brain slice preparations and retinae with the unmatched temporal and spatial 
precision of visible light. 
 
As an extension, we also studied photoswitchable NMDA antagonists to complement ATG and 
STG. As various subtypes are well-defined in NMDA pharmacology, we aimed to address the 
different types of subunits with selective azobenzene-modified antagonists. After investigating 
a variety of azologization templates, we finally developed PNRA (XXVII), the first 
photoswitchable antagonist of NMDA receptors. 
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18-c-6      1,4,7,10,13,16-hexaoxacyclooctadecane 
9-BBN      9-borabicyclo[3.3.1]nonane 
 
Å      Ångstrom 
Ac      acetyl 
acac      acetylacetonato  
ACCN      1,1'-azobis(cyclohexanecarbonitrile) 
ADDP      1,1'-(azodicarbonyl)dipiperidine 
AIBN      azobisisobutyronitrile 
AMPA  α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid 
Ar       unspecified aryl substituent 
ATA      α-tertiary amine 
ATR       attenuated total reflection (IR) 
 
BAIB      bis(acetoxy)iodobenzene 
BiPhePhos  6,6′-[(3,3′-di-tert-butyl-5,5′-dimethoxy-1,1′-
biphenyl-2,2′-diyl)bis(oxy)]-bis-
(dibenzo[d,f][1,3,2]dioxaphosphepin) 
Bn      benzyl 
Boc      tert-butyloxycarbonyl 
Bobbitt salt  4-acetamido-2,2,6,6-tetramethyl-1-
oxopiperidinium tetrafluoroborate 
Bu  butyl 
Bz      benzoyl 
 
°C      degree(s) Celsius 
CAN      cerium ammonium nitrate 
catBH      catecholborane 
Cbz      carboxybenzyl 
CHD      1,4-cyclohexadiene 
cod      1,5-cyclooctadiene 
 
COSY      correlated spectroscopy (NMR) 
cm      centimeter 
Cp      cyclopentadienide 
CSA       camphorsulfonic acid 
 
Δ      heating 
d.r.       diastereomeric ratio 
dba      dibenzylideneacetone 
DBU       1,8-diazabicyclo[5.4.0]undec-7-ene 
DCB      1,2-dichlorobenzene 
DCC      N,N'-dicyclohexylcarbodiimide 
DCE      1,2-dichloroethane 
DIBAL      diisobutylaluminum hydride 
DIPEA      diisopropylethylamine 
DMAP       4-(dimethylamino)pyridine 
DMDO      dimethyldioxirane 
DME       1,2-dimethyoxyethane 
DMF       dimethylformamide 
DMP       Dess–Martin periodinane 
DMSO       dimethylsulfoxide 
DMTST     dimethyl(methylthio)sulfonium triflate 
DPPA      diphenylphosphoryl azide 
dppb       1,4-bis(diphenylphosphino)butane 
dppe       1,2-bis(diphenylphosphino)ethane 
dppf       1,1´-bis(diphenylphosphino)ferrocene 
DTBPy      2,6-di-tert-butylpyridine 
 
E      opposite (trans) 
ee       enantiomeric excess 
EI       electron impact ionization (mass spectrometry) 
eq.      equivalent(s) 
ESI       electron spray ionization (mass spectrometry) 
Et       ethyl 
 
fod  6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-
octanedianato 
 
g       gram(s) 
G I       Grubbs first generation catalyst  
G II      Grubbs second generation catalyst  
 
h      hour(s) 
Hantzsch ester  diethyl 1,4-dihydro-2,6-dimethyl-3,5-pyridine-
dicarboxylate 
HG II      Hoveyda–Grubbs second generation catalyst  
HMBC  heteronuclear multiple-bond correlation 
spectroscopy 
HMPA      hexamethylphosphoramide 
HPLC      high performance liquid chromatography 
HSQC  heteronuclear single-quantum correlation 
spectroscopy 
Hz       Hertz (frequency) 
 
IBX      2-iodoxybenzoic acid 
iGluR      ionotropic glutamate receptor 
Im       imidazole 
Ipc      isopinocampheyl 
IR       infrared 
IUPAC   International Union of Pure and Applied 
Chemistry 
 
J  coupling constant (NMR) 
Jørgensen catalyst (S)-α,α-bis[3,5-bis(trifluoromethyl)phenyl]-2-
pyrrolidinemethanol trimethylsilyl ether  
 
KHMDS  potassium hexamethyldisilazide 
 
LDA lithium diisopropylamide 
 
LG unspecified leaving group 
LHMDS  lithium hexamethyldisilazide 
 
M  molar 
m-CPBA  meta-chloroperbenzoic acid 
Me methyl 
mGluR metabotropic glutamate receptor 
min minute(s) 
mL  milliliter(s) 
mmol  millimole(s) 
Mp  melting point 
MS       mass spectrometry or molecular sieves 
MsCl       methanesulfonyl chloride 
 
NBS       N-bromosuccinimide 
NIS       N-iodosuccinimide 
nm      nanometer(s) 
NMDA      N-methyl-D-aspartic acid 
NMO      N-morpholine N-oxide 
NMR       nuclear magnetic resonance 
NOESY   nuclear Overhauser effect correlation 
spectroscopy 
Ns  2-nitrobenzenesulfonyl 
 
Otera catalyst tetrachloridooctabutylstannoxane 
Oxone  potassium peroxysulfate 
 
p       para 
p-TsOH      para-toluenesulfonic acid 
PCC       pyridinium chlorochromate 
PCL      photochromic ligand 
PG      unspecified protecting group 
Ph       phenyl 
pin      2,3-dimethylbutane-2,3-diol 
Piv      pivaloyl 
PMP      para-methoxylphenyl 
PPAR      peroxisome proliferator-activated receptor 
ppm      parts per million 
PPTS      pyridinium para-toluenesulfonate 
PTL      photochromic tethered ligand 
py      pyridine 
 
R       unspecified substituent 
RCAM      ring-closing alkyne metathesis 
RCM      ring-closing metathesis 
Rf      retardation factor 
Rt      room temperature 
RuPhos 2-dicyclohexylphosphino-2′,6′-
diisopropoxybiphenyl 
 
SG II      Stewart–Grubbs second generation catalyst 
SIMes  1,3-bis(2,4,6-trimethylphenyl)-4,5-
dihydroimidazol-2-ylidene 
SIPr  1,3-bis(2,6-diisopropylphenyl)-4,5-
dihydroimidazol-2-ylidene 
SPhos  2-dicyclohexylphosphino-2',6'-
dimethoxybiphenyl 
 
TBA       tetrabutylammonium 
TBDPS      tert-butyldiphenylsilyl 
TBHP      tert-butyl hydroperoxide 
TBS      tert-butyldimethylsilyl 
tbs      N-tert-butylsalicylaldiminato 
TEMPO     (2,2,6,6-tetramethylpiperidin-1-yl)oxyl 
TES      triethylsilyl 
Tf      trifluormethanesulfonyl 
TFA      trifluoroacetic acid 
TFAA      trifluoroacetic anhydride 
 
TFE      2,2,2-trifluoroethanol 
THF      tetrahydrofuran 
TIPS      triisopropylsilyl 
TLC      thin layer chromatography 
TMS      trimethylsilyl 
TPAP      tetrapropylammonium perruthenate 
triphosgene     bis(trichloromethyl) carbonate 
Ts      4-methylbenzenesulfonyl 
TZD      thiazolidine-2,4-dione 
 
Wilkinson catalyst    tris(triphenylphosphine)rhodium(I) chloride 
wt%      weight percent 
 
Z      together (cis) 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
 
 
  
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lycopodium is the name of a genus of clubmoss, part of the Lycopodiaceae family, which 
comprises about a thousand vascular, terrestrial, flowerless plants. Their occurrence spans 
Africa, South America and Asia, but their use in folk medicine has been focused in Asia, where 
extracts are still commonly used as remedies in folk medicine for an eclectic array of conditions 
ranging from tissue inflammation and kidney disorders to cancer and memory loss.[1-7] In most 
cases, biological activity is (tentatively) ascribed to a particular subset of nitrogen-containing 
small molecules named Lycopodium alkaloids. The best-known representative of a small 
molecule that is used in modern medicine (as opposed to whole-plant extracts) is huperzine 
A (1.1) from Huperzia serrata (Figure 1.1).[8] This lycodine-type alkaloid (vide infra) is an 
inhibitor of acetylcholinesterase and as such currently evaluated for the treatment of early-stage 
Alzheimer’s disease.[8-11] 
 
The Lycopodium alkaloids are a structurally diverse family comprised of about 300 individual 
alkaloids. In 1881, Bödeker isolated the first family member, lycopodine, from Lycopodium 
complanatum.[12] It wasn’t until 1934 that Orechoff, followed by Muszynksi, identified a high 
alkaloid content in Lycopodium annotinum.[13-14] Since then, new members with a wide variety of 
skeletons are constantly identified and their structural connections investigated, pioneered by 
the Canadian school of Ayer and Manske from the 1940s until the 1970s and, nowadays, 
spearheaded by the Kobayashi group and a number of Chinese researchers.[15-23] Interestingly, 
the alkaloids isolated so far stem from a rather small fraction (50 species) of the Lycopodium 
genus, hinting at a large untapped source of natural products. Historically, they have been 
categorized by two complementary systems. The simpler one ignores the skeletal connectivity 
and oxidation states, focusing solely on the number of carbon and nitrogen atoms in the 
skeleton. Additional methylation of heteroatoms is also ignored in the carbon count. By this 
nomenclature, most are C16N and C16N2 alkaloids, but also C27N3 and other ratios are not 
 
unheard of. In order to address the obvious shortcomings of this nomenclature, Ayer, one of the 
most eminent figures in Lycopodium alkaloid chemistry, introduced another system in the 
1990s.[20] He assigned each Lycopodium natural product to one of four classes, each named after a 
prominent member of increasing complexity. These classes are named after phlegmarine (1.2), 
lycodine (1.3), lycopodine (1.4) and fawcettimine (1.5), as depicted in Figure 1.2. The two-
dimensional drawings in the first row stress the structural relations within the classes and the 
second row features the more commonly used three-dimensional representations. 
 
The phlegmarine (1.2) class contains the structurally least complex alkaloids that feature only 
three rings. Biosynthetically, most other Lycopodium alkaloids are thought to be derived from 
phlegmarine by a series of oxidations and rearrangements (chapter 1.1.2). In recent years, the 
phlegmarine class has also been named the “miscellaneous” class that holds all Lycopodium 
alkaloids that don’t clearly fit into any of the other three categories and thus arguably features 
the most structurally diverse set of natural products. The lycodine class is special insofar as all 
its members contain an aromatic moiety. It also features the medicinally most relevant 
Lycopodium alkaloid to date, huperzine A (1.1). The third class, the lycopodine (1.4) class, 
features the first family members ever to be isolated and is also the largest class. The 
fawcettimine (1.5) class, finally, is biosynthetically derived from the lycopodine class by 
oxidation and bond migration. 
Given the fact that many Lycopodium alkaloids can be interconverted by rather straightforward 
skeletal rearrangements and oxidations, it is becoming increasingly difficult to unambiguously 
sort newly isolated alkaloids into one of the four existing classes. It is that reason that has led to 
discussions about whether these four classes should be divided according to further unique 
bond cleavages or formations.[21] 
  
 
Most Lycopodium species cannot be readily cultivated in a laboratory setting,[24] reaching heights 
of only 15 cm after 5 or more years, thus complicating the investigation of their alkaloid 
biosynthesis. An early biosynthetic proposal suggested that phlegmarine, one of the most basic 
Lycopodium alkaloids, could be derived from connection of two coniine units,[25] or from 
multiple aldol reactions of triketooctanoic acid.[26] Others brought forth a biosynthesis that 
relied on sequential C2 building block additions to ∆1-piperideine (1.9), as is established in the 
biosynthesis of other alkaloids.[27] This cyclic imine is derived from lysine (1.6) via loss of carbon 
dioxide and water. It was Spenser who, over the course of three decades, established many 
important aspects of Lycopodium biosynthesis, some of which are summarized in Scheme 1.1.[25, 
28-32] Extensive field experiments with 13C and 14C-labeled building blocks injected into 
Lycopodium trystachum shoots established that the phlegmarine (1.2) and, by extension, 
lycopodine (1.4) skeleton are not formed by dimerization of two pelletierine (1.12) units.[25, 28, 33] 
While one equivalent of pelletierine is completely incorporated as the C-9 to C-16 portion, the 
C-1 to C-8 portion has to be supplied by a compound similar but not identical to pelletierine. In 
the final installment of a series of publications, Spenser demonstrated that a very plausible 
synthetic equivalent is 4-(2-piperidyl)acetoacetate (1.11), resulting from nucleophilic attack of 
acetonedicarboxylic acid (10) or a coenzyme A-derived conjugate thereof on ∆1-piperideine 
(1.9).[31-32] Piperideine is the product of decarboxylation of lysine (1.6) to cadaverine (1.7), which 
is then transaminated to 1.8 and finally condensed to 1.9. Pelletierine (1.12), the electrophilic 
portion for the fragment union, is obtained by decarboxylation of 1.11. A series of redox 
transformations and Mannich reactions leads to the phlegmarine skeleton, oxidation of which 
leads to the lycodane (1.13) skeleton. Though a few natural products feature this skeleton, 
lycodane mainly functions as a branching point between the lycodine (1.3) and lycopodine (1.4) 
classes. Direct aromatization yields lycodine-type alkaloids, whereas oxidation, piperidine ring 
rupture and reformation of a different piperidine ring leads to the lycopodine natural products. 
 
 
The lycopodine skeleton also serves as the starting point for the biosynthesis of the 
fawcettimine (1.5) skeleton (Scheme 1.2). Initial oxidation at C-12 to 12-hydroxylycopodine or 
lycodoline (1.14) gives a tertiary alcohol that is used as a leaving group in a 1,2-shift of the C-4-
C-13 bond to form the quaternary center at C-12. This leaves an iminium ion 1.15 that is trapped 
to give the hemiaminal form of fawcettimine (1.5). This rearrangement removes one of the key 
structural elements of many Lycopodium alkaloids, the α-tertiary amine.[34] Instead, a quaternary 
stereocenter two atoms further is established. 
 
While these biosynthetic proposals, especially the steps from phlegmarine (1.2) to lycopodine 
(1.4), have been supported by feeding studies, there is still very limited information about the 
gene clusters and enzymes involved in the individual steps. 
  
 
The first member of the fawcettimine family to be isolated was an alkaloid designated “Burnell 
Base A”, which was first discovered in the Blue Mountain Range in Jamaica in 1959 by 
Burnell.[35] This compound was later renamed fawcettimine (1.5) and became the namesake for a 
group of Lycopodium alkaloids with now more than 80 members. After the initial isolation, it 
took a few years before the structure of fawcettimine was unambiguously proven in 1967 by 
chemical correlation with serratinine (1.16) (Scheme 1.3). Serratinine is a related alkaloid whose 
structure was elucidated by X-ray crystallography of its p-bromobenzoate derivative.[36-37] 
 
The first synthesis of a fawcettimine-type alkaloid was completed by Inubushi in 1979, 
furnishing fawcettimine (1.5) in 26 steps and confirming the structural assignment 
(Scheme 1.4).[38] The last ambiguity regarding the configuration at C-4 and which of the two 
ketones is involved in the diketoamine-hemiaminal (or carbinolamine) tautomeric equilibrium 
was clarified by Heathcock’s classic synthesis in 1986 (Scheme 1.5).[39-40] These two syntheses 
laid the foundation and served as a blueprint for a host of syntheses in the following decades. 
Inubushi’s synthesis started from dihydroorcinol (1.17), and the quaternary stereocenter was 
elaborated by a Diels–Alder reaction of cyclohexenone 1.18 and butadiene to give 1.19. In a 
series of twelve steps, this decaline was transformed into hydrindane 1.20, setting up the 
formation of the nine-membered ring by lactamization to 1.21. A number of redox 
transformations, including a hydrogenation in the penultimate step, then led to the racemic first 
total synthesis of the natural product fawcettimine (1.5). 
 
 
The unselective hydrogenation and the resulting ambiguity regarding the C-4 stereochemistry 
were subsequently investigated by Heathcock. Using chemistry from his previous forays into 
Lycopodium alkaloid chemistry, he quickly accessed 1.24 by Sakurai allylation of 1.22 (made 
from dihydroorcinol 1.17) with functionalized allylsilane reagent 1.23.[41] Interestingly, it was 
during Heathcock’s classic lycopodine (Scheme 1.27) synthesis that he found the strong trans-
diastereoselectivity of nucleophilic additions to 5-substituted cyclohexenones. As this quickly 
gives rise to the 3,5-trans stereochemical pattern (cyclohexane numbering) most commonly 
encountered in Lycopodium natural products, countless variants of this opening step have been 
and are being used in all types of Lycopodium alkaloid total synthesis.[42] 
 
When the enal 1.25 was treated with a stabilized Wittig reagent, olefination was followed by 
selective 1,4-addition to give hydrindane 1.26 in accordance with Baldwin’s rules. The last 
missing carbon was introduced by a three-step Arndt–Eistert homologation before global 
reduction yielded the aminodiol 1.27. After extensive experimentation, selective bistosylation to 
1.28 was achieved. Ring closure to 1.29 under mildly basic conditions and final redox 
adjustments then gave fawcettimine (1.5) in 15 steps from dihydroorcinol (1.17). In addition to 
vastly improving the overall efficiency of fawcettimine synthesis, he was also able to 
definitively clarify the configuration at the C-4 stereocenter and demonstrate that it need not be 
strictly controlled by synthesis as it very readily converts to the correct epimer under mild basic 
or acidic conditions. Heathcock’s approach to introducing the central quaternary stereocenter 
with the pendant “C₃ -amine equivalent” sidechain at an early stage of the synthesis has served 
as a significant inspiration for later syntheses.[43] Over the years, few methods have surpassed 
his method to access the nine-membered ring by alkylation of a sulfonamide or carbamate. It is 
for this reason that his 6-5-9 system has been coined the “Heathcock-type tricycle”(30) 
(Figure 1.3).[44] In addition, as there is very little room to improve upon the endgame consisting 
of spontaneous condensation of an amine with a carbonyl, most research has focused on elegant 
and creative methods to furnish the 6-5-system. 
 
The last roughly fifteen years have seen a large number of creative approaches towards 
fawcettimine-type alkaloids, various aspects of which have been reviewed.[42, 44-47] After 
Heathcock’s fawcettimine synthesis, relatively little synthetic activity was recorded for about 20 
years as most synthetic attention shifted towards lycopodine-type alkaloids. The next major 
contribution appeared in 2002, when Zard showcased his proprietary synthesis of 
N-heterocycles by addition of N-centered radicals across olefins in a synthesis of 
13-deoxyserratine (1.36),[48] a heavily modified fawcettimine-type compound related to 
serratinine that, unlike most others, features an α-tertiary amine (Scheme 1.6).[34] Interestingly, 
his synthesis did not start from a methyl-substituted cyclohexanone derivative as the vast 
majority of syntheses do. Instead, the 6-5-system was obtained by a cobalt-catalyzed Pauson–
Khand reaction, an approach extensively used by Takayama, Mukai and, most recently, 
Trauner.[46, 49-54] Treating enyne 1.32, itself accessible in 4 steps from hex-5-yn-2-one (1.31), with 
dicobalt octacarbonyl and NMO gave the hydrindenone 1.33 in very good yield. 
 
Another four steps established the substrate for his key step. Heating benzoylated hydroxamic 
acid derivative 1.34 with a radical starter and tributyltin hydride led to selective 5-exo-6-endo 
 
cyclization. It is worth mentioning that the presence of the vinylic chloride was essential for the 
second ring closure to give 1.35. Because of steric reasons, it successfully suppressed a 5-exo-5-
exo reaction that became operational in its absence. With the tetracyclic skeleton assembled, all 
that remained was reduction of the lactam and deprotection to furnish 
(±)-13-deoxyserratine (1.36). 
Shortly after, two total syntheses by the Toste group defined the first enantioselective 
approaches toward fawcettimine-type alkaloids (Scheme 1.7). The first, more methodology-
oriented synthesis elegantly showcased Toste’s gold-catalyzed 5-endo-cyclization of silyl enol 
ethers onto alkynes and is discussed in detail in chapter 1.2.1.[55] The same methodology was 
subsequently utilized in the first enantioselective synthesis of fawcettimine itself 
(Scheme 1.7).[56] After pre-installation of the sidechain oxygen or nitrogen —similar to the 
lycopladine A synthesis (chapter 1.2.1, Scheme 1.42)— had failed, an organocatalytic Robinson 
annulation of 1.37 according to Jørgensen provided the six-membered ring of fawcettimine and 
delivered this key building block 1.18 on decagram scale in good yield and ee (88%). 
 
In this way, a scalemic version of Inubushi’s classic building block 1.18 was made available. 
Two steps led to alkynyl iodide 1.38, which smoothly cyclized under gold catalysis to give 
hydrindane 1.39 in gram amounts. A sequence of four steps delivered the precursor 1.40 for the 
next key step, the formation of the nine-membered ring. The iodide 1.40 could be cyclized with 
potassium tert-butoxide whereas mesylate and tosylate only delivered complex product 
mixtures. With a Heathcock-type tricycle 1.41 (vide supra) in hand, the natural product 1.5 could 
obtained in four more routine oxidation and deprotection steps. Additionally, the absolute 
configuration of (+)-fawcettimine could be established by crystal structure analysis of the 
hydrobromide salt 1.42. 
At almost the same time as Toste’s fawcettimine synthesis, Dake also utilized methodology 
developed in his own laboratories to furnish the quaternary stereocenter of a molecule closely 
related to fawcettimine called fawcettidine (1.51) (Scheme 1.8).[57] The only difference between 
these two molecules is the presence of an enamine resulting from formal elimination of water 
from fawcettimine (1.5). 
Like Toste in his lycopladine A synthesis, Dake used a pulegone-derived building block to 
obtain the enone 1.43 in enantiomerically pure form.[58] Addition of a C₄-alkyne building block 
delivered 1.44 as an inconsequential mixture of diastereomers. This δ-ketoester was heated with 
S-carbamoyl 2-thioethanolamine (1.45) to give a 10:1 mixture of regioisomeric enamides 1.46 
(major isomer shown). This enamide served as the nucleophile in a platinum(II)-catalyzed 
annulation. Remarkably, the pendant thiocarbamate did not interfere with the cyclization to 
give the quaternary stereocenter in the tricyclic enamide 1.47. The resulting exo-methylene 
group then was the handle for an allylic oxidation, yielding an enone before basic deprotection 
of the thiocarbamate led to hetero-Michael addition to yield 1.48. 
 
At this stage, all that remained was to excise the sulfur atom and contract the ring. Protection, 
sulfide to sulfone oxidation and Ramberg–Bäcklund ring contraction of 1.49 using highly 
optimized conditions gave 1.50, which could be transformed into fawcettidine (1.51) by 
standard redox manipulations. Dake’s synthesis features a few notable aspects. First of all, by 
avoiding popular aldol-like reactions used in many other Lycopodium alkaloid syntheses, little 
 
refunctionalization is needed for the cyclopentane ring. Second of all, his approach is the only 
one that furnishes the enamine functional group not by condensation of the azonane amine 
with the C-3 ketone, but introduces it very early on masked as a stable enamide. As a result, the 
six- and seven-membered heterocycles are constructed separately, and the cyclization occurs by 
S-alkylation rather than the conventional N-alkylation. 
Another milestone in Lycopodium synthesis was Mulzer’s approach toward a close relative of 
fawcettimine and fawcettidine, lycoflexine (1.54) (Scheme 1.9).[59] This alkaloid was isolated in 
1972 from Lycopodium clavatum.[60] It most probably arises from fawcettimine by Mannich 
reaction between an iminium formed from the secondary amine and formaldehyde and the C-5 
ketone. This results in a tetracyclic skeleton that is unique among fawcettimine alkaloids. 
Notably, it features two vicinal quaternary stereocenters at C-4 and C-12. 
 
In 2010, Mulzer and coworkers decided to emulate this sequence from a rapidly assembled 
Heathcock tricycle (Scheme 1.10). A three-component coupling consisting of Sakurai allylation 
of pulegone-derived enone 1.55 and in-situ aldol reaction of the resulting titanium enolate gave 
adduct 1.56 as a mixture of diastereomers. This aldol was oxidized to the dicarbonyl and 
alkylated with a primary iodide to give 1.57, setting the quaternary stereocenter of the 
fawcettimine alkaloids. In order to investigate their envisioned key step, the methyl ketone 
group was transformed into the alkyne by a high-yielding triflation-elimination sequence. With 
the dienyne 1.58 successfully assembled, the stage was set for the key biscyclization. Treatment 
with Grubbs II catalyst resulted in selective ring-closing enyne metathesis to first furnish the 
five-membered ring before closing the nine-membered heterocycle with a ring-closing 
metathesis (RCM) reaction. 
 
As it was known that ruthenium-based metathesis catalysts can also serve as hydrogenation 
catalysts, the reaction mixture was purged with hydrogen and stirred until the more accessible 
disubstituted double bond was successfully reduced to finally yield 1.59. This reaction cascade 
assembled the complete skeleton of fawcettimine (1.5), forming two rings at the same time. 
Hydroboration of the remaining double bond in 1.59 was followed by in situ treatment with 
IBX, a convenient replacement for the previously used chromium reagents, to yield Boc-
protected fawcettimine 1.60. At this stage, the synthesis branched. Simple treatment of 1.60 with 
methanolic HCl gave fawcettimine (1.5) by Boc deprotection and cyclization.[61] Further acidic 
treatment with p-TsOH in toluene resulted in elimination to fawcettidine (1.51). If 1.60 was 
refluxed with dilute aqueous HCl and excess aqueous formaldehyde in EtOH, Boc deprotection 
was followed by formation of an iminium ion that was trapped in a Mannich reaction to give 
lycoflexine in 64% yield from 1.59. The overall sequence yields fawcettimine and lycoflexine in 
only eight steps each from enone 1.55, significantly raising the bar for the following syntheses. 
In 2003, Kobayashi reported the isolation of one of the most popular alkaloid targets of the 
following years, sieboldine A (1.66).[62] [63] Alongside its isolation, Kobayashi proposed a 
biosynthesis starting from alopecuridine (1.61) (Scheme 1.11). N-oxidation of either the 
ketoamine or hemiaminal form of alopecuridine could give hydroxylamine 1.63 via the 
 
hydroxyammonium salt 1.62. H2O elimination would result in a presumably unstable imine 
1.64. 
 
At this stage, two pathways can be envisaged. Another N-oxidation would yield a very 
electrophilic cyclic nitrone 1.65 that could be intercepted by the tertiary alcohol to directly yield 
sieboldine A (1.66). Alternatively, cyclization could occur directly at the imine stage to give the 
N,O-aminal 1.67, oxidation of which would again give sieboldine A. Its most unusual feature is 
the THF ring that also contains an N,O-acetal formed from an hydroxylamine. 
The Overman group published the first, enantioselective synthesis of the highly competitive 
Lycopodium alkaloid target in 2010 (Scheme 1.12).[64-65][66]Apart from its intriguing biological 
activity, its interesting structure was attractive: it features a tetracyclic fawcettimine-type 
skeleton modified with an unusual additional tetrahydrofuran. Strategically very different from 
most other syntheses, Overman’s starting compound did not contain any of the carbocycles of 
the final product. Instead, he elaborated the first key intermediate 1.69 from the known 
enantiopure lactone 1.68 in 9 steps. When this enyne was treated with the gold(I)-JohnPhos 
complex 1.70, a pinacol-terminated cyclization developed in Overman’s laboratories 
occurred,[67] delivering hydrindane 1.71 featuring three of the natural product’s stereocenters in 
good yield. A hetero-Diels–Alder reaction to add the missing C₂ unit gave 1.72 and a series of 
functional group interconversions furnished the thioglycoside 1.73. Activation with DMTST salt 
1.74 was uniquely suited for the glycosylation of the MOM-protected hydroxylamine to give the 
penultimate intermediate 1.75 en route to sieboldine A (1.66). 
 
In 2009, Johnston disclosed the first synthesis of a heavily modified fawcettimine-type alkaloid 
called serratezomine A (1.86) (Scheme 1.13).[68-69] Biosynthetically, this unusual tetracyclic 
alkaloid is probably derived from serratinine (1.16), also isolated from Lycopodium serratum, via a 
Polonovski-type fragmentation.[70] The synthesis began with ethyl sorbate-derived aldehyde 
1.76. The relative and absolute chemistry was set by a Brown crotylation with 1.77 to give 
secondary alcohol 1.78. Four more steps were needed to access acid 1.79. After activation as the 
acid chloride, it was coupled with a vinyl stannane 1.81 which was accessed by an interesting 
free radical-mediated aminostannylation of imine 1.80.[71] 
 
 
This vinylogous amide 1.82 could be deprotected under oxidative conditions, directly inducing 
intramolecular Michael addition to the unsaturated ester to yield 1.83. The stereoselectivity was 
mainly guided by allylic strain of the nascent tetrasubstituted double bond, leading to a diaxial 
arrangement of the silyl ether and ethyl acetate substituents in 1.83.[72] The next key step was the 
introduction of the all-carbon stereocenter at C-12. Rather exotic oxidative conditions (cerium 
ammonium nitrate and allyltrimethylsilane) suppressed lactamization and allylated the 
vinylogous amide with high diastereoselectivity to the pyrroline 1.84. At this stage, all atoms of 
the natural product were assembled. The imine 1.84 was transformed into the natural product 
serratezomine A (1.86) in six more steps, including a stereoselective iminium reduction and 
final lactone formation by nucleophilic substitution of equatorial mesylate 1.85. 
Since 2010, a few groups have not only introduced new concepts for Lycopodium alkaloid 
synthesis, but have also increasingly demonstrated the generality of their strategies by 
synthesizing multiple alkaloids using common building blocks. Prime examples are the recent 
efforts by the Lei and Tu groups, which will be discussed in the following. Other notable efforts 
were undertaken by the groups of Mukai, Williams, Zhao, Zhai and Taniguchi.[52, 73-76] 
Lei disclosed an interesting approach to fawcettimine (1.5) and fawcettidine (1.51) by way of a 
more complex congener, 13-dehydro-8-deoxyserratinine (1.94) (vide supra for Zard’s very 
distinct approach to 13-deoxyserratine (1.36) in 2012 (Scheme 1.14).[77] The synthetic sequence 
began with the same pulegone-derived enone 1.55 employed by Toste and Mulzer.[55, 59] Similar 
to Mulzer’s Sakurai-aldol sequence, Lei generated an enolate by conjugate addition of an allyl 
cuprate and trapped it with an aldehyde 1.87 that was made in three steps to give aldol 1.88. 
Four steps converted it into diketone 1.89 that formed the quaternary stereocenter by 
intramolecular spirocyclization. Interestingly, the corresponding mesylate mainly gave O-
alkylation under these conditions. Selective reduction and Lemieux–Johnson oxidation of 1.90 
delivered ketoaldehyde 1.91 that underwent SmI2-induced pinacol coupling to furnish 1.92, the 
6-5-9 ring system of fawcettimine-type alkaloids. This intermediate was converted into 13-
dehydro-8-deoxyserratinine (1.94) by simple oxidation of the two secondary alcohols followed 
by treatment with thionyl chloride and triethylamine. 
 
Presumably, the α-chloroketone generated with thionyl chloride is electrophilic enough that it 
can be attacked by the carbamate nitrogen in close proximity to give the α-tertiary ammonium 
ion from which the Boc group is readily removed in situ.[78] Interestingly, efforts to alkylate the 
free secondary amine failed. From this common intermediate 1.94, three Lycopodium alkaloids 
could be obtained by three distinct reductions (Scheme 1.15). Regio- and stereoselective ketone 
reduction with sodium borohydride yielded 8-deoxyserratinine (1.95). Reduction under acidic 
conditions and high temperature resulted in C-N cleavage followed by hemiaminal formation 
and water elimination to give fawcettidine (1.51). 
 
When 1.94 was reduced with SmI₂, cleavage and aminal formation were observed without 
subsequent water elimination, yielding fawcettimine (1.5). In a follow-up study, Lei generalized 
 
his approach in the context of diversity-oriented synthesis, accessing four more Lycopodium 
alkaloids together with a range of complex natural product-like scaffolds (Scheme 1.16).[79] The 
starting point was the γ-hydroxylated enone 1.96, allowing access to a host of C-8-hydroxylated 
fawcettimine alkaloids. Chemistry similar to that in Scheme 1.14 led to 1.97, one of the key 
branching points. 
 
nd
A benzoin reaction promoted by the NHC derived from triazolium salt 1.99 led to tricycle 1.100, 
albeit with low yield due to poor selectivity between the two ketones. However, this 
circumvented the pinacol coupling-oxidation sequence previously used. From this Heathcock 
tricycle, three alkaloids were accessible, namely lycoposerramine U (1.101), serratinine (1.16) 
and 8-hydroxyfawcettimine (1.102). These natural products represent more oxidized versions of 
the alkaloids synthesized as shown in Scheme 1.14 and were made available by similar 
reductive methods. A completely different scaffold, however, could also be obtained from key 
intermediate 1.97; Pinnick oxidation delivered δ-hydroxyacid 1.103. When the acid was treated 
with trifluoroacetic anhydride followed by trifluoroacetic acid and sodium cyanoborohydride, a 
reductive amination occurred to yield serratezomine A (1.86), one of the more heavily modified 
fawcettimine-type Lycopodium alkaloids (vide supra for the Johnston approach). Another 
representative of the so-called “seco-fawcettimines” is lycojapodine A (1.104),[80] which was 
accessed together with alopecuridine (1.61) by Lei with a closely related “tautomer locking” 
approach,[81] which was recently reviewed.[47] The last installment was geared at the C-16-
oxidized congeners huperzine Q (1.108) as well as lycopladine B (1.109) and C (1.110) 
(Scheme 1.17). Following their well-explored chemistry, the spirocyclic intermediate 1.106 was 
furnished, this time starting from a building block that only differed from methylcyclohexenone 
1.55 in the oxidation of the stereogenic methyl group at C-16.[82] This time, the cyclopentanone 
was furnished by an interesting carbonyl-olefin metathesis using Schrock’s catalyst as a reagent 
to give the key intermediate 1.107. A deprotection-cyclization sequence led to huperzine Q 
(1.108) while an interesting late-stage bromofunctionalization then led to lycopladines B (1.109) 
and C (1.110). It is instructive to compare this strategy to Takayama’s synthesis of huperzine 
Q.[51] 
 
The Tu group published their efforts to alopecuridine (1.61) two years prior to Lei, in 2011 
(Scheme 1.18).[83] In three steps each, two building blocks 1.111 and 1.113 were furnished. The 
vinyl iodide 1.112 was synthesized from racemic 1.111 and not from pulegone, as the 
stereoinformation was lost in the following steps. Fragment coupling and epoxidation gave the 
epoxide 1.114, which could be converted to 1.115 in a BF3·Et2O-mediated semipinacol 
rearrangement to furnish 1.115 bearing the nine-membered ring of the Lycopodium alkaloids as 
well as the quaternary stereocenter. Two steps later, the cyclopentane portion was forged in a 
Sm(II)-mediated pinacol coupling of 1.116 to yield the Heathcock tricycle 1.117. Interestingly, 
the stereochemistry of the C-4 tertiary alcohol could be defined by the stereochemistry of the 
C-13 alcohol, presumably depending on whether intramolecular coordination to samarium by 
the alcohol was possible or not. With the five-membered ring formed, all that remained was to 
remove the MOM group, oxidize the secondary alcohols and remove the nitrogen protecting 
group to furnish racemic alopecuridine (1.61)·TFA in 13 steps. 
 
 
With a synthesis of alopecuridine completed, they were in a position to examine Kobayashi’s 
proposed biosynthesis of sieboldine A (1.66) (see Scheme 1.11).[62] Alopecuridine (1.61) was thus 
oxidized with m-CPBA to the unstable N-oxide, which presumably either isomerizes to the free 
hydroxylamine or eliminates H2O to give the imine proposed by Kobayashi (Scheme 1.19). 
Treatment of the crude mixture with mercury oxide in MeOH resulted in nitrone formation and 
intramolecular cyclization to yield sieboldine A in 60% over two steps, validating the 
biosynthesis put forth. 
 
With a slightly more step-intensive approach, Tu’s general synthesis could be rendered 
enantioselective and also extended to the synthesis of lycojapodine A (1.104) (Scheme 1.20).[84] 
Zhao proposed that alopecuridine (1.61) could be in equilibrium with its hemiacetal form 1.119, 
oxidative diol cleavage of which would yield lycojapodine A (1.104).[80] To their delight, treating 
alopecuridine TFA salt with manganese dioxide indeed yielded lycojapodine A in very good 
yield, validating their and Kobayashi’s proposal (Scheme 1.20). 
 
Tu also completed the first total synthesis of the recently isolated lycojaponicumin C (1.129) 
from Dake’s enone (1.43) and the donor-acceptor-substituted diazo compound 1.120.[85] In an 
impressive sequence consisting of Mukaiyama-aldol reaction, cyclopropanation/fragmentation 
and Krapcho decarboxylation, the hydrindane 1.121 could be forged on gram scale without the 
isolation of intermediates (Scheme 1.21). Indeed, the two-pot sequence was more efficient than 
isolating every intermediate.[86] In another one-pot operation, Dieckmann condensation and 
allylation could be combined to forge the second quaternary stereocenter in the triketone 1.122. 
The allyl group was transformed into the azide of 1.124 next, which, together with its C-13 ketal 
1.123, represented the key intermediates. Triketone 1.124 could be treated with tin(IV) chloride 
to trigger an Aubé–Schmidt rearrangement that furnished the tertiary α-tertiary amine 1.125 of 
the serratinine (1.16) class of alkaloids. In two more steps, it was transformed into 1.94, the 
intermediate previously used by Lei to access fawcettimine (1.5), fawcettidine (1.51) and 8-
deoxyserratinine (1.95) (Scheme 1.21).[77] 
 
Alternatively, the ketal could be submitted to Staudinger reaction and reduction (to 1.126), ketal 
hydrolysis and N-protection to yield tetracyclic intermediate 1.127 (Scheme 1.22). Two-step α,β-
dehydrogenation to 1.128 was followed by hydrolysis and N-methylation to yield 
lycojaponicumin C (1.129). 
 
 
Overall, the construction of the 9-membered ring by N-insertion into a 5-5 system offers great 
flexibility, arguably more so than the established Heathcock tricycles. 
Given the maturation of the field, most of the synthetic attention has turned to more heavily 
modified fawcettimine-type alkaloids. This includes, for example the series of alkaloids where 
the C-15 methyl group is inverted or oxidized. As these are not easily obtained from pulegone 
or derivatives thereof, groups have devised very interesting strategies to access alkaloids like 
lycopalhine A (1.130) or palhinines A (1.140) and D (1.141). 
Exemplary is Williams and Trauner’s approach to the unusual hexacyclic Lycopodium alkaloid 
lycopalhine A (1.130),[53] which was isolated recently from Palhinhaea cernua.[87] At the time, it 
represented the first alkaloid to feature the C-6-C-16 linkage as well as C-9-N-2’ (Figure 1.4, 
highlighted in bold), similar to its presumed biosynthetic precursor obscurinine (1.131),[88] 
which was coisolated from the same sample by the Zhao group. 
 
The retrosynthetic analysis led them back to a hydrindane system similar to the other 
fawcettimine alkaloids, but with an inverted and oxidized C-16 methyl group. Taking 
inspiration from the work of Zard,[48] Mukai[50, 52] and Takayama,[51, 89] a Pauson–Khand retron 
was identified.[46] Starting from the bulk chemical L-glutamate (1.132) that conveniently contains 
one of the required nitrogen atoms, the two ester functionalities in 1.33 could be differentiated 
via selective reduction to the lactol 1.134 (Scheme 1.23). Two more steps furnished the enyne 
1.135, which was transformed into the hydrindane 1.136 with very high diastereoselectivity, 
avoiding the adjustments at C-7 necessitated in Takayama’s synthesis.[89] After the quaternary 
stereocenter had been set by conjugate addition, a global deprotection to 1.137 and 
condensation with aldehyde 1.138 resulted in an unusual 5-endo-trig Mannich reaction when 
L-proline was added. With the tricyclic core set, only the aminal and aldol bonds remained to be 
forged. In four steps, the natural product lycopalhine A (1.130) was obtained in good overall 
yield. Through this synthesis and deuteration studies, it was confirmed that lycopalhine A 
indeed exists in equilibrium with its C-16 epimer. 
 
This notion was later confirmed by Fukuyama’s monumental 41 step synthesis that resulted in 
an identical 5.5:1 mixture.[90-91] 
Quite recently, a related natural product that also features an inverted and oxidized methyl 
group, palhinine A (1.140), was isolated.[92] It was the first Lycopodium alkaloid of what is now a 
small family of natural products from Palhinhaea cernua, all bearing a highly functionalized 
isotwistane system, such as palhinine D (1.141) (Figure 1.5).[92-95] A novel feature is the 
additional C-4-C-16 bond, resulting in two vicinal all carbon stereocenters at C-4 and C-12. It is 
not surprising that their caged, highly congested structures have garnered significant attention 
from the scientific community.[96-101] 
 
Very recently, Fan and coworkers reported the completion of the first, racemic total synthesis of 
palhinine-type natural products, namely palhinines A and D (Scheme 1.24).[102] Starting from 2-
cyclohexenone (1.142), nine steps gave the precursor 1.143 for an intramolecular Diels–Alder 
 
reaction, a strategy also recognized by others as a means to construct isotwistane systems.[99, 103-
107] The reaction occurred at elevated temperatures without catalyst, giving the functionalized 
tricycle 1.144. Eight further steps were necessary to refunctionalize the core to the 
hydroxylamine 1.145. When condensed with formaldehyde and subsequently heated in 
dichlorobenzene, an intramolecular (3+2)-nitrone-alkene-cycloaddition took place to furnish 
1.146 bearing the nine-membered ring of the fawcettimine-type Lycopodium alkaloids. 
 
In this way, the medium-sized ring and the oxygenation at C-3 were introduced 
simultaneously, albeit with the wrong diastereoselectivity. This strategy was pursued because 
all standard techniques such as Mitsunobu alkylations using Fukuyama'’s method,[108-110] simple 
alkylation methods[39-40] and ring-closing metathesis failed. Reductive N,O-cleavage and alcohol 
inversion then led to the two natural products. It is interesting to see how the conformational 
restraints of the isotwistane core render many of the established methods ineffective, 
necessitating the development of creative new routes. 
Somewhat distinct amongst the fawcettimine alkaloids are the magellanine alkaloids 
paniculatine (1.147), magellanine (1.148) and magellaninone (1.149) isolated from Lycopodium 
magellanicum (Figure 1.6). Probably derived from fawcettimine, they feature an additional C-C 
bond between C-5 and C-10. Because of the resulting unique diquinane substructure, quite 
different strategies have been employed for their synthesis, pioneered by the Overman and 
Paquette groups.[111-113] 
 
In recent years, multiple groups have significantly contributed with elegant approaches that can 
access multiple members of this subclass of Lycopodium alkaloids.[49, 114-118] However, as they are 
of relatively little significance to this PhD thesis, they are not discussed in the context of this 
work. 
 
The lycopodine family of Lycopodium alkaloids features the oldest member of the family, the 
namesake lycopodine (1.4), which was first isolated by Bödeker in 1881.[12] After a few decades 
of constant isolation of new lycopodine-type alkaloids, the first synthesis of the lycopodane 
skeleton was put forth by Wiesner, who synthesized epi-lycopodine in 1967 (not shown).[119-120] 
One year later, Ayer and Stork simultaneously completed the first syntheses of lycopodine 
itself.[121-122] Through their and others’ efforts, it quickly became apparent that one of the key 
challenges would be the efficient construction of the tertiary α-tertiary amine. The synthesis 
began with a three-step sequence to furnish vinylogous ester 1.151, the D-ring of lycopodine, 
from p-methoxybenzaldehyde (1.150) (Scheme 1.25). Three further steps set up the key step in 
Stork’s synthesis, an N-acyliminium cyclization of 1.152 using a tethered anisole as the 
intramolecular nucleophile (Pictet–Spengler-like), to attach the B-ring of lycopodine and the α-
tertiary amine to a bicyclic moiety, giving 1.153.  
 
 
The anisole portion was reduced to diene 1.154, which was cleaved via ozonolysis to reveal the 
C₃ chain of the lycopodine A-ring (1.155). Five more steps, including a Baeyer–Villiger oxidation 
to turn the enal into a ketone, then furnished synthetic lycopodine (1.4) for the first time. The 
success of the strategy (B-ring closure onto the D-ring) rendered this synthesis a blueprint for 
multiple later syntheses that followed similar general strategies. Ayer’s synthesis also started 
from an anisole derivative 1.156, but added the D-ring last (Scheme 1.26). Unfortunately, while 
the addition of Grignard reagent 1.158 to iminium ion 1.157 is a conceptually interesting 
approach, it resulted in the wrong stereochemistry at C-4, which required nine steps to correct. 
The last ring was finally closed by intramolecular alkylation of mesylate 1.160 to give 1.161 (no 
yield given). As the ketone was now at C-6 rather than C-5, tedious functional group 
interconversions were necessary and resulted in a rather lengthy synthesis (26 steps overall). 
 
After these initial efforts, no significant synthesis efforts were published until Heathcock’s 
landmark synthesis of lycopodine in 1978, followed by a second generation approach and 
syntheses of lycodoline (1.14) and lycodine (1.3) in 1982.[41, 123] He was, surprisingly, the first to 
utilize the Mannich retron in the lycopodane skeleton (Scheme 1.27). Starting from 
dihydroorcinol (1.17), a three step sequence delivered enone 1.162. Derivatives that bear 
different “head-groups” at the end of the C₃ chain have since seen a host of applications in both 
fawcettimine and lycopodine synthesis (vide supra). A C₃ unit was then attached either via allyl 
cuprate or, more efficiently, Sakurai addition to give 1.163 with perfect anti selectivity. The 
α-stereocenter was not controlled, which was of no consequence as both diastereomers 
converged at a later point. Five redox and protection steps then furnished the bisketal 1.164. 
Upon heating in methanolic HCl for two weeks, smooth Mannich cyclization was observed, 
furnishing the almost complete lycopodine skeleton 1.165. Debenzylation, a modified 
Oppenauer oxidation followed by aldol condensation and final reduction led to (±)-lycopodine 
(1.4) in 13 steps, a vast improvement over previous approaches. A second generation synthesis 
further shortened the route by incorporating the C₃ A-ring unit into the hydrazone used for the 
conjugate addition (as the hydrazone azaenolate), arriving at one of the shortest and most 
efficient synthesis to date. Moreover, slight modifications resulted in very short syntheses of 
lycodine (1.3) (8 steps) and lycodoline (1.14) (11 steps).[123] 
 
Unlike the fawcettimine-type alkaloids, the lycopodine-type alkaloids, especially lycopodine 
itself, remained popular synthesis targets over decades. In the 1980s, notable efforts came from 
Schumann (1982) and Kraus (1985).[124-129] Kraus’ synthesis used an acetoacetate addition to 
popular enone 1.18, followed by Dieckmann cyclization to give the B-D system 1.166. Functional 
group interconversion led to tertiary bromide 1.167 (Scheme 1.28). 
 
N
This labile compound could be transformed to Heathcock’s penultimate intermediate 1.168 very 
efficiently by double N-alkylation of 3-hydroxypropylamine under both acidic (AgBF₄) and 
 
basic (DBU) conditions. Presumably, AgBF₄ leads to a SN1 pathway whereas the basic conditions 
give a highly strained bridgehead enone and hetero-Michael addition.[130] 
Schumann delivered a very straightforward synthesis of lycopodine (1.4) and, subsequently, a 
range of related alkaloids (Scheme 1.29).[124-127] Starting from the same compound 1.17 as 
Heathcock, global reduction to 1.169 followed by allylic oxidation and condensation delivered a 
very sensitive α,β-unsaturated imine 1.170. When this intermediate was heated with 
acetonedicarboxylic acid (1.10), conjugate addition was followed by decarboxylative Mannich 
reaction to give the B-C-D system 1.171 of lycopodine and a short (7 steps) formal synthesis of 
racemic lycopodine (1.4) after alkylation to 1.168; the last two steps were performed according 
to Heathcock’s method.[41, 123] The α,β-unsaturated imine 1.170 was the cornerstone for the 
synthesis of other Lycopodium alkaloids of great structural variety, including acetylflabellidine 
(1.172),[125] α-obscurine (1.173)[126] and luciduline (1.174).[127] The latter had previously been 
synthesized by Oppolzer in a succinct manner using a strategic nitrone-alkene cycloaddition 
similar to the one used decades later in the total synthesis of palhinine A (1.140).[102, 131-132] 
 
It wasn’t until 2008 that the first enantioselective synthesis of lycopodine was published by 
Carter, surprising given that enantiopure versions of many of the starting materials presented 
here were already available at the time.[133-134] Carter’s key transformation in essence represents a 
two-step variant of Heathcock’s strategy that separates the closure of the C and B-rings 
(Scheme 1.30). In contrast to virtually all other syntheses that either started from cyclic materials 
or constructed them in the first step, Carter opted to install the crucial C-15 methyl stereocenter 
in 1.176 that subsequently directs all others via conjugate addition to a linear acylated Oppolzer 
sultam 1.175. Three more steps to add a C₄ chain and extend the alkene 1.176 to an enone gave 
an α-sulfonyl ketone 1.177 that underwent base-mediated diastereoselective Michael addition to 
the first cyclic intermediate 1.178. Staudinger reduction and silyl enol ether formation set up the 
key Mannich reaction of 1.179. Activation of the imine with zinc triflate gave tricycle 1.180 with 
concomitant phenyl sulfone 1,3-shift. After this key step, reductive desulfonation gave 
Heathcock’s tricyclic intermediate 1.171 that was transformed to the natural product 1.4 with 
chemistry similar to Heathcock’s. This general approach was subsequently used in the 
enantioselective synthesis of the more oxidized congeners 10-hydroxylycopodine (1.181) and 
(acetyl-)paniculine (1.182 and 1.183).[135] 
 
Since Carter’s first enantioselective synthesis, only one further synthesis has been published. 
Very recently, in 2016, the She group employed an interesting amalgamation of the Stork and 
Heathcock approaches (Scheme 1.31).[136] Starting from Dake’s enone 1.43, conjugate 
propargylation followed by condensation with homoallylamine furnished the bicyclic enamide 
1.184. Upon treatment with a mixture of formic and phosphoric acid, the N-acyliminium 
(similar to Stork’s) was trapped in an alkyne-Prins cyclization reminiscent of Heathcock’s 
Mannich reaction. With the tricycle 1.185 constructed in a very rapid fashion, the fourth ring 
was closed via aldol condensation to 1.186. Redox adjustments delivered the natural product 
(−)-dihydrolycopodine (1.187) and by oxidation (−)-lycopodine (1.4). The group simultaneously 
published another paper detailing the identical construction of the tricyclic framework followed 
by a different oxidative endgame to arrive at (−)-lycospidine A (1.188).[137] The most interesting 
facet of this natural product is its rare C15N skeleton, as all except one other C15 Lycopodium 
 
alkaloids are of the C15N2 type, like huperzine A (1.1).[138] Given that its skeleton can’t be 
converted into one of the other four classes by skeletal rearrangements, it could be debated 
whether it should be considered the founding member of its own class and what the 
biosynthetic origin of this C-5-nor-alkaloid is.[138] 
 
Apart from lycopodine itself, many other lycopodine-type alkaloids have been targeted. This 
includes for example Evans’ enantioselective total synthesis of clavolonine (1.189) or 8-
hydroxylycopodine (Figure 1.7), which was isolated from Lycopodium clavatum.[139] 
 
 This followed the early efforts of Wenkert, who accessed clavolonine as part of a collective 
synthesis of six lycopodine-type alkaloids.[140] Another noteworthy example are Breit’s and 
Fujioka’s enantioselective total synthesis of the same alkaloid to showcase Breit’s directed 
hydroformylation and Fujioka’s chiral acetal methodology, respectively.[141-142] Like Evans, they 
opted for the de novo construction of all rings. This highlights the usefulness of non-chiral-pool-
based approaches for enantioselective lycopodine-type Lycopodium alkaloid synthesis, allowing 
access to oxidation patterns not easily accessible from pulegone-derived building blocks. 
Another example for this is Snider’s racemic 7-hydroxylycopodine (1.190) synthesis.[143] 
A few final examples which will be discussed in the following are lycodine-related Lycopodium 
alkaloids. Even though they are not part of the lycopodine class, some of the chemistry bears 
strong similarity and allows for very creative syntheses. In 2010, Siegel[144] and Sarpong[145] 
simultaneously disclosed their strategies for the total synthesis of complanadine A (1.199), a 
structurally interesting and highly bioactive[146] dimeric Lycopodium alkaloid from Lycopodium 
complanatum.[147] It is worth noting that the natural product is not C₂-symmetric because the 
pyridine units are connected at different positions. Siegel started with a pulegone-derived 
enone 1.191[58] that was transformed into a tertiary propargylic acetate 1.192 in four steps 
(Scheme 1.32). Another four steps delivered the bicyclic δ-cyanoalkyne 1.193. When this 
compound was treated with bis-TMS-butadiyne (1.194) in the presence of a cobalt(I) catalyst, 
cyclization to the lycodine derivative 1.195 occurred. After a few manipulations, 1.196 could be 
coupled with δ-cyanoalkyne 1.197, a differentially protected variant of 1.193, in another cobalt-
catalyzed cyclotrimerization to give arylsilane 1.198. This bipyridine was converted to the 
natural product 1.199 in three more steps. The choice of N-protecting groups and solvents was 
crucial for regioselectivity in the cyclization.[144, 148] 
 
Sarpong used a very different approach, utilizing Schumann’s method[126] for the rapid 
construction of an obscurine derivative 1.203 (Scheme 1.33). However, by using the enantiopure 
amine 1.201 derived from pulegone (1.200), he was able to render the synthesis enantioselective. 
The dihydropyridone 1.202 efficiently condensed with 1.201, which probably forms Schumann’s 
imine 1.170 under the reaction conditions (see Scheme 1.29). With tetracyclic intermediate 1.203 
available on multigram scale, it took three more steps to obtain the first coupling partner, 
pyridyl triflate 1.204. Two more steps from this building block, including an iridium-mediated 
C-H borylation, yielded the second coupling partner, pyridylboronic ester 1.205. Suzuki cross-
coupling and deprotection gave the natural product complanadine A (1.199).[145] 
 
 
A second study expanded this general approach to complanadine B, an oxidized congener. [149-
150] A related pyridine N-oxide arylation toward complanadines A and B was published by 
Hirama in 2013 (not shown).[151] Their synthesis started from lycodine (1.3) itself, which was 
furnished by a distinct Diels–Alder- and Heck-based approach.[152-153] 
In 2014, Takayama disclosed a biogenetically inspired cascade cyclization that furnished (+)-
flabellidine (1.209) and (−)-lycodine (1.3) (Scheme 1.34).[154] Starting from acylated Evans’ 
auxiliary 1.206, the complete linear sidechain 1.207 was established in eight steps. When this 
linear molecule was heated with camphorsulfonic acid, a spectacular cyclization cascade 
occurred to furnish the complete lycodine skeleton (1.208) in one step. It presumably occurs via 
a series of Michael additions and a final Mannich reaction. Quite remarkably, the single methyl 
group stereocenter was sufficient to direct the correct conformation of the entire cascade. In 
three more steps each, flabellidine (1.209) and lycodine (1.3) were accessed. 
  
Similarly ambitious cyclization cascades were explored for the synthesis of fastigiatine (1.216), a 
lycodine-type Lycopodium alkaloid that features a rare C-4-C-10 bond, adding considerable 
strain and synthetic challenge to the molecule.[155] The first synthesis was disclosed by the Shair 
group 25 years after it was first isolated (Scheme 1.35).[156] Starting from (S)-epichlorohydrin 
(1.210), the building block 1.211 was furnished in six steps, then coupled to the cuprate 1.212, 
again derived from Cassell’s building block, to give 1.213.[58] In seven steps, this intermediate 
was elaborated into the vinylogous carbamate 1.214. In aqueous hydrochloric acid, the ketal was 
deprotected, unmasking an enone that was first attacked in a 1,4-addition followed by 1,2-attack 
to furnish the tetracyclic intermediate 1.215 featuring all rings but the pyrrolidine. 
 
After a one-pot nosyl-methyl exchange, a facile retro-Aldol reaction followed by intramolecular 
Mannich cyclization under neutral conditions gave the full ATA-bearing skeleton 1.216 and the 
natural product fastigiatine (1.217) after final protecting group manipulations. Subsequently, 
this approach was shown to be rather general for the total synthesis of five other seven-
membered-ring-containing Lycopodium alkaloids such as lyconadin A and C.[157] Especially 
lyconadin A[158] and C[159] had previously received significant synthetic attention as well.[160-167] 
  
 
 
A related Aldol-Mannich cyclization cascade was used by Rychnovsky in his 2016 synthesis of 
fastigiatine (1.217) (Scheme 1.36).[168] The Diels–Alder adduct 1.219 of enone 1.55 and diene 1.218 
could be transformed into bicycle 1.220 through cyclopropanation followed by ring expansion. 
Conjugate addition of 1.221 followed by aldol addition yielded the tricyclic intermediate 1.222. 
Similar to Shair’s strategy, heating in acid, albeit at much higher temperature, brought about the 
double cyclization, yielding the natural product 1.217 after acetylation. 
  
 
 
Lycoposerramine R (1.223) is a fawcettimine-type alkaloid that was isolated in 2009 by 
Takayama from Lycopodium serratum, a prolific source of Lycopodium alkaloids.[169] High-
resolution mass spectroscopy in combination with UV-Vis and IR analysis suggested the 
presence of a pyridone moiety as part of a tetracyclic system that also features a piperidine unit. 
Extensive 2D NMR analysis finally allowed them to assign the structure of lycoposerramine as 
shown in Figure 1.8. 
 
As far as the biosynthesis is concerned, three possible pathways were suggested. An unusual 
C-4-C-12 cyclization from a phlegmarine (1.2) skeleton could cyclize to give a fully reduced 
version 1.224 of the lycoposerramine R skeleton. 
 
 
This would potentially occur through an oxidative coupling of two enamines. These oxidation 
states are known, but rare among the phlegmarine-type alkaloids.[170-171] A second, more 
plausible pathway could be envisaged via lycodine (1.3): similar to the oxidation in the 
biosynthesis of lycopodine to fawcettimine, lycodine could be oxidized in the C-1 and C-12 
positions, leading to C-12-oxygenated N-desmethyl-β-obscurine (1.225), a known Lycopodium 
alkaloid in its own right.[172] A 1,2-shift followed by reduction of the resulting iminium ion 
would lead directly to lycoposerramine R. A third approach would start from fawcettimine (1.5) 
itself. N-C-1 bond scission followed by introduction of a second nitrogen atom and imine 
formation would lead to a compound like 1.226 that could give lycoposerramine R after redox 
manipulations. 
At the time of its isolation, lycoposerramine R (1.223) was the only fawcettimine-type alkaloid 
featuring a pyridone unit, a structural unit mostly limited to lycodine (1.3) natural products. It 
therefore came as no surprise that only one year after its publication, the first synthesis was 
documented by the Sarpong group.[173] His approach was based on the realization that 
methoxypyridines serve as convenient synthetic equivalents of α-pyridones without the highly 
polar nature resulting from the strong hydrogen bonding, a concept previously explored in the 
context of the total synthesis of lyconadin A.[162-163] In addition, methoxypyridines are aromatic 
and can therefore be used in reactions such as Heck couplings that are unavailable to α-
pyridones. A Stork–Danheiser reaction between vinylogous ester 1.227 and pyridine 1.228 
yielded enone 1.229, setting up a Heck reaction that gave tricycle 1.230 in 79% yield. 
 
Three steps including a remarkably effective Eschenmoser–Claisen rearrangement were used to 
arrive at dimethylamide 1.231 bearing the quaternary stereocenter of lycoposerramine R. At that 
point, the side chain was homologated and the oxygenation at C-13 introduced over five steps. 
All that remained was a double reductive amination of ketoaldehyde 1.232 and final 
methoxypyridine deprotection to complete the first synthesis of (±)-lycoposerramine R (1.223) in 
13 steps from vinylogous ester 1.227. Five years later, a second racemic and quite different 
synthesis of this alkaloid was published by the original isolation group.[174] In contrast to 
Sarpong’s approach, Takayama elected to construct the pyridone ring last and set the 
quaternary stereocenter in an intermolecular reaction. In a forward sense, enone 1.233 and 
Rawal diene 1.234 were reacted neat to give hydrindanone 1.235 after acid treatment. Wharton 
transposition followed by oxidation and conjugate addition of a methyl cuprate gave diketone 
1.236, bearing three of the four stereocenters present in lycoposerramine R (1.223). 
 
Interestingly, the following reductive amination was completely regio- and diastereoselective to 
give the tricyclic intermediate 1.237 featuring all the stereoinformation of the natural product. In 
order to append the pyridone, 1.237 was elaborated to δ-hydroxyketone 1.238. Jones oxidation 
followed by heating the δ-ketoacid with O-methylhydroxylamine hydrochloride in acetic acid 
delivered the free pyridone 1.239 in low yield and, after Cbz deprotection, lycoposerramine R 
(1.223). Half a year later, Takayama published a second approach to the same target, delivering 
the first enantioselective synthesis of lycoposerramine R.[175] While the general synthetic 
approach remained unchanged, the pyridone synthesis was revisited and the hydrindane was 
nowsupposed to be furnished by Helquist annulation. This cyclization had previously been 
established by Yang as an efficient entry into the fawcettimine series.[176-178] Enone 1.240 was 
accessed in four steps from pulegone (1.200). Conjugate addition of Grignard reagent 1.241 
followed by aqueous hydrochloric acid gave the hydrindane 1.242. Four more steps including a 
reductive amination gave 1.237, an intermediate of the racemic Takayama synthesis. 
Interestingly, the differentiation between the two ketones in the reductive amination was much 
less effective in this case, most probably a result of the slightly different protecting group 
pattern. 
 
 
Minor modifications of their previously reported procedures led to greater efficiency in the 
delivery of intermediate 1.243. Given that the previous Knoevenagel-type pyridone synthesis 
had resulted in a very low yield, an interesting modification was made: the δ-ketoacid obtained 
by Jones oxidation was transformed into the acyl azide 1.244, then submitted to Staudinger 
reduction to give a dihydropyridone that autooxidized during isolation. After deprotection, the 
absolute configuration of lycoposerramine R (1.223) could be established With 54% over the 
final steps, this procedure provided a significant improvement.[175] 
Three years before lycoposerramine R, lycopladine A (1.245) was isolated in Hokkaido from 
Lycopodium complanatum by Kobayashi and coworkers.[179] Extensive 2D NMR and HRMS 
analysis suggested the presence of a disubstituted pyridine ring as well as 6-5-system bearing a 
primary alcohol and a ketone. 
 
Careful analysis revealed a second minor compound in equilibrium with the main natural 
product. HMBC analysis of both compounds finally revealed that lycopladine A (1.245), whose 
structure is depicted in Scheme 1.40, occurs as a 7:1 mixture of open chain and hemiketal 
isomers. Biosynthetically, Kobayashi et al suggested a biosynthesis starting from 
phlegmarine (1.2) where the C-13-N bond is cleaved to 1.246 (Scheme 1.41). However, a detailed 
conversion of 1.246 into lycopladine A was not specified. One could also speculate about a 
biosynthesis that degrades the azonane ring of fawcettimine (1.5) by N-C-1 oxidation and 
cleavage followed by transamination and condensation of the nitrogen with the C-5 carbonyl. 
Aromatization would yield the natural product.[62] 
 
Remarkably, an enantioselective synthesis of lycopladine A was completed only three months 
later by Toste.[55] Starting from Caine and Procter’s popular pulegone-derived enantiopure 
enone 1.55,[58] three steps delivered iodoalkyne 1.247, a substrate for a variation of the 
cyclization of enolate equivalents onto alkynes that Toste had previously developed.[180-181] 
Treatment with AuPPh₃Cl/AgBF₄ delivered the hydrindane 1.248 in excellent yield within 
minutes, showcasing the ability of gold(I) to access different reaction manifolds than other d10 
metals like Pd(0). The reactivity of Pd(0) was subsequently utilized for the synthesis of the 
pyridine ring by an interesting cascade. Cross-coupling with 1.249 gave hydrazone 1.250 which, 
upon heating to 190 °C, isomerized to the cis-isomer, then underwent 6π-electrocyclization 
followed by elimination of dimethylamine to furnish the pyridine moiety. Debenzylation under 
transfer hydrogenation conditions yielded (+)-lycopladine A (1.245) in 8 steps.  
 
Four years later, Martin published the shortest synthesis of lycopladine A to date.[182] Instead of 
building up the pyridine by aromatization from an aliphatic precursor, this fragment was 
 
introduced by diastereoselective conjugate addition of a cuprate derived from 3-chloropicoline 
(1.251) to a known racemic enone (1.252) (Scheme 1.43). Treating the resulting with potassium 
tert-butoxide followed by a Pd-SPhos catalyst smoothly yielded the tricyclic core 1.254 of 
lycopladine A. In order to introduce the quaternary stereocenter, a challenging 
transesterification was carried out and the resulting allyl ester 1.255 was submitted to 
decarboxylative allylation. In the last step of the synthesis, the double bond in 1.256 was 
hydroborated using catecholborane and Wilkinson’s catalyst to yield (±)-lycopladine A (1.245) 
in 5 steps from enone 1.252. 
 
In 2011, a second asymmetric, methodology-based synthesis was described by the Hiroya 
group.[183] The synthetic plan hinged on the differentiation of two carbonyls by 
diastereoselective ketalization.[184] In the event, treatment of 1.257 with aqueous HCl led to 
almost exclusive formation of 1.258. With the two groups differentiated, six further steps led to 
diketone 1.259, which was cyclized to hydrindane 1.260 using potassium tert-butoxide. A 
number of steps delivered ketoaldehyde 1.261, which delivered the pyridine 1.262 in a Kröhnke 
synthesis upon heating with NH4OAc and spontaneous oxidation. Another eight steps were 
needed for introduction of the methyl group and functional group interconversions. 
 
With 23 steps, it is the longest synthesis to date. Yang and coworkers published their approach 
toward (+)-lycopladine A in 2013.[185] A building block 1.263 that had previously been utilized in 
a (−)-8-deoxyserratinine synthesis served as the platform for their synthesis of lycopladine A 
(1.245).[177] With the quaternary stereocenter furnished by a Helquist annulation,[176] most of the 
attention was focused on refunctionalizing the right-hand side. Seven steps furnished a 
ketoaldehyde 1.264 very similar to Hiroya’s (1.261). Essentially identical conditions delivered 
the pyridine ring and, after global deprotection, lycopladine A. This work highlights the 
challenges associated with refunctionalizing the five-membered ring. 
 
Very recently, two very short syntheses have appeared. In 2016, Meng described a divergent 
enantioselective synthesis of (+)-lycopladine A (1.245) and (−)-carinatine A (1.266), the first 
synthesis of this natural product (Scheme 1.47).[186] Carinatine A was isolated in 2014 by Zhao 
from Phlegmariurus carinatus.[187] Its fawcettimine-derived skeleton is remarkable insofar as it 
features both a pyridine and a cyclic nitrone unit, structural elements otherwise most 
commonly found in phlegmarine- or lycodine-type Lycopodium alkaloids. Its biosynthesis is 
probably quite similar to lycopladine A (Scheme 1.46). The first pathway would be identical to 
lycopladine A (1.245) with the exception that the primary ring closes back on the C-13 ketone. A 
fawcettimine (1.5) pathway through C1-N fission followed by aromatization to the natural 
product is also plausible. 
 
 
Starting from the same enone 1.18 as Yang, a Mukaiyama–Michael addition with 1.268 directly 
rendered 1.269 containing a functionalized sidechain. Rhodium-catalyzed oxidation of the diazo 
group gave a tricarbonyl 1.270 that could be aldolized and acetylated under Lewis-acidic 
conditions to 1.271. 
 
Strategically, the Yang and Meng syntheses bear some similarity, given the central quaternary 
stereocenter is formed via an aldol reaction that builds the hydrindane core of the targeted 
natural product. A decarboxylative allylation and elimination yielded dienone 1.272, which was 
then heated in a microwave with hydroxylamine, leading to 6π-electrocyclization and 
aromatization to 1.273. Hydroboration-oxidation yielded the penultimate intermediate 1.274. At 
this stage, a modified Mitsunobu reaction gave carinatine A (1.266) in good yield, whereas 
reductive oxime cleavage yielded lycopladine A (1.245). Meng’s synthesis demonstrated how 
introducing an already functionalized sidechain can circumvent laborious functional group 
interconversions encountered in the Hiroya and Yang syntheses. 
During the preparation of this thesis, another synthesis of lycopladine A, this time of the 
unnatural (−)-antipode, was disclosed by You.[188] Conceptually quite different from all other 
syntheses, this methodology showcase is the only one to date that doesn’t start with a 
functionalized cyclohexanone building block that serves as a template to forge all other rings. 
Instead, it starts with 3-bromopicoline (1.275) that acts as the nucleophile in an iridium-
catalyzed enantioselective allylic substitution with allylic carbonate 1.276. After 
hydroboration/oxidation of the terminal double bond to 1.278, an intramolecular Heck reaction 
delivered the five-membered ring featuring an alkene (1.279) from which the ketone was 
liberated by ozonolysis. After the quaternary stereocenter had been set by allylation and the six-
membered ring closed by aldol reaction, the tricyclic system 1.281 was complete. 
 
Finally, methylation and oxidation gave ent-lycopladine A (1.245) in 9 steps. It is remarkable 
that You’s synthesis is the only catalytic enantioselective synthesis to date, as all others 
ultimately rely on enantiopure starting materials. 
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In addition to the results detailed in sections 1.2.2 and 1.2.3, a number of other cyclization 
precursors were assembled, which will be presented in the following. 
We first wanted to explore the formation of other ring systems. More specifically, we were 
interested to see whether other substrate classes such as non-activated lactams or lactones could 
also act as nucleophiles in our carbocyclization reaction. Therefore, we first accessed lactam 
1.283 and lactone 1.287 by double methylation and Baeyer–Villiger oxidation of 1.282 and 1.286, 
respectively. The alkynylated compounds 1.285 and 1.288 were obtained by alkylation with 4-
pentynyl iodide (1.284) in moderate yield. 
 
Furthermore, we wanted to extend our chemistry to linear substrates, which had proven 
reluctant to cyclize with propiophenone-derived material. We thus treated benzoin (1.289) with 
acid 1.290[189] or alcohol 1.292 to obtain cyclization substrates 1.291 and 1.293. The low yield of 
the etherification can be explained by the competing oxidation of benzoin to benzil, which was 
isolated as the major product. 
 
Under standard conditions, no conversion was observed for either one of the substrates. 
However, when treated with two equivalents of KOt-Bu, 1.291 largely decomposed and only 
traces of 1.294 were observed. The cyclization of 1.293 indeed occurred, albeit with low 
efficiency, to give the five-membered heterocycle 1.295 (Scheme 1.51). Consistent with the 
 
observations made with cyclic α-aryl ketones (chapter 1.2.2), this cyclization was significantly 
slower than those of α-alkyl ketones. 
 
A major drawback of the preliminary substrate scope (chapter 1.2.2) was the absence of internal 
alkynes, with the notable exception of one chloroalkyne. We thus set out to prepare a range of 
substrates bearing various substituents on the alkyne. The methyl-capped alkyne 1.296 was 
prepared analogously to our general conjugate addition procedure. When submitted to our 
standard conditions, no reaction to 1.297 was observed. We next turned to bromoalkyne 1.298, 
prepared by silver-catalyzed bromination. This substrate was of interest because the vinyl 
bromide resulting from a successful cyclization could serve as a synthetic handle for a range of 
follow-up transformations. Under our standard conditions, the bromide indeed cyclized to 
1.299, but the product was obtained in low yield (Scheme 1.52). The bulkier nature of the 
bromide (compared to the chloride) presumably precludes a more efficient cyclization. 
 
Furthermore, we accessed three arylated alkynes 1.301, 1.303 and 1.304 by efficient Sonogashira 
couplings of the two alkynes 1.300 and 1.302 with iodobenzene and p-bromoiodobenzene. 
  
 
The majority of substrates explored in chapters 1.2.2 and 1.2.3 were carbocyclic. We thus wanted 
to increase the structural span by exploring heteroatom-containing ring systems. More 
specifically, we reasoned that our method could be suitable for the synthesis of pyrrolizidines 
and indolizidines. Our method seemed well-suited for the preparation of the carbon skeleton of 
pyrrolizidine alkaloids like platynecine (1.305), turneforcidine (1.306) or hastanecine (1.307), 
which only differ in the stereochemistry at the tertiary and hydroxymethyl stereocenters 
(Figure 1.10). Other potential targets could be retronecanol (1.308) and the unusual natural 
product danaidone (1.309). All five compounds could arise from the cyclization product via 
simple redox manipulations. 
 
To this end, we prepared two substrates bearing nitrogen atoms at the ring junction 
(Scheme 1.54). Alkylation of 3-hydroxypyrrolidine hydrochloride (1.310) with 1-bromobut-4-
yne (1.311) or diethyl bromomalonate (1.314) gave the corresponding tertiary amines 1.312 and 
1.315, the latter of which was propargylated to give 1.316. After oxidation of the secondary 
alcohol, two ketones 1.313 and 1.317 were obtained. 
 
 
When subjecting the two substrates to our carbocyclization conditions, both reactions indicated 
product formation. However, isolation of the products was not met with success so far. 
Interestingly, in the case of substrate 1.317, one of the isolated products was diethyl 2-propargyl 
malonate, a possible mechanism for the formation of which is presented in Scheme 1.55. It was 
assumed that enolate formation occurred as intended (1.318). However, this was followed by β-
elimination under extrusion of malonate 1.320 as well as imine 1.319, which probably 
decomposed under the reaction conditions. 
 
In addition to these two nitrogen-bearing substrates, we also prepared the compounds 1.321 
and 1.323 by conjugate addition to the corresponding vinylogous amides (not shown). An 
interesting aspect of this chemistry was to see whether the carbocyclization would outcompete 
the retro-Michael addition. When trying to cyclize 1.321 and 1.323, mixed results were obtained. 
Piperidinone 1.321 gave the desired product 1.322, albeit in low yield and purity. Substrate 
1.323, which is identical to one of the published substrates (see compound 32 in chapter 1.2.2) 
save the α-methyl group, did not react to 1.324. 
 
The last class of substrates contained those bearing quaternary stereocenters in the β or γ 
position to the ketone (Scheme 1.57). As a result, these would products bearing two (adjacent) 
quaternary stereocenters upon cyclization. The tetralone-derived building substrate 1.327 was 
prepared by malonate alkylation with bromide 1.325, the ketones 1.330 and 1.332 were 
synthesized from 1.328 and 1.331 by our general method for the preparation of cyclization 
precursors. 
 
Finally, we undertook first steps of a mechanistic study. More specifically, we were interested to 
see whether the reaction occurs via trans addition or a concerted Conia–Ene-like cyclization 
(Scheme 1.58). The first pathway (a) from 1.333 would proceed via a coordination of the alkyne 
to a potassium ion (1.334) followed by attack of the nearby enolate. This would give 
vinylpotassium species 1.335 and finally product 1.336. The second pathway (b) would be a 
concerted metalla-Conia–Ene reaction via 1.337, resulting in vinylpotassium species 1.338 and 
product 1.339. Of course, the two products 1.336 and 1.339 would be identical using a substrate 
where R = H, as was the case for most substrates investigated. A third plausible pathway (c) 
could consist of isomerization to an allene 1.340 followed by cyclization to an allylpotassium 
species 1.341 and protonation to 1.342. In this case, determination of the double bond geometry 
is harder to predict. As detailed in chapter 1.2.2, most internal alkynes proved unreactive, but a 
cyclization using a chloroalkyne occurred in good yield and complete diastereoselectivity to 
give a product consistent with the trans addition pathway. 
 
 
Aware that the chloro substituent might bias the outcome of this reaction, we decided to 
investigate deuterated substrates. First, we attempted the preparation of a deuterated alkyne 
1.343, which we wanted to prepare from our optimization substrate 1.300. This was rendered 
more difficult than expected by the fact that basic conditions used for deuteration induced 
cyclization instead. Finally, Bew’s method proved mild enough, providing about 50% 
deuterium incorporation (Scheme 1.59).[190] When submitting this material to our standard 
conditions, we didn’t observe any deuterium incorporation in the product 1.344, hinting at a 
facile deprotonation of the alkyne. We next applied our standard cyclization conditions again, 
but used deuterated solvent. As expected, the reaction took place under our standard 
conditions. However, we isolated 1.345, the product of double deuteration. This finding 
clarified that the alkynyl proton is readily exchanged under the reaction conditions. 
 
Furthermore, the resulting anionic species is protonated from the solvent, not another molecule 
of 1.300 or t-BuOH, both of which are more acidic than DMSO. The fact that no deuteration was 
observed in the allylic position of 1.345 speaks against an allene pathway, as the allylpotassium 
species would either be protonated directly or isomerize to the primary position first. This 
would result in an internal double bond, which could not be detected either. 
  
 
 
Note: As most of the compounds in the following section are published in peer-reviewed journals and 
additionally appear in other chapters, roman numerals are used in this section. 
 
In summary, a new base-mediated carbocyclization has been developed and applied to 
Lycopodium alkaloid synthesis. After its serendipitous discovery (Scheme 1.60), systematic 
investigation of the reaction conditions allowed for the establishment of an efficient method to 
form five-membered rings in an intramolecular Conia–Ene-like carbocyclization reaction 
between ketones and alkynes. 
 
Remarkably, it occurs in the absence of transition metal catalysts or carbonyl-activating groups 
such as (silyl) enol ethers or electron-withdrawing groups in the α-position. The 
carbocyclization was demonstrated on a range of substrates, delivering bi- and tricyclic 
 
products in moderate to good yields (VI–XV, Scheme 1.61). While α-substituted cyclic ketones 
were the most thoroughly studied substrate class for our reaction, oxindoles and 
tetrahydroquinolinones were also viable. Aside from 6-5- and 5-5-fused systems, 6-5-
spiroannulated systems like VII and IX could also be obtained. In addition, we were able to 
construct synthetically useful enones XVII bearing tetrasubstituted double bonds using our 
method (Scheme 1.62). 
 
Having successfully demonstrated the viability of our methodology, we sought to employ it in 
natural product synthesis. Our synthesis of hydrindanes seemed especially suited for 
fawcettimine-type Lycopodium alkaloids and we first focused on the aromatic congeners 
lycoposerramine R (XXV). 
 
We used the exo-methylene group of hydrindane building block (XV) resulting from the 
carbocyclization to quickly elaborate the aromatic portion by Kröhnke-type pyridone synthesis 
of enone XXIV, thus circumventing extensive functional group interconversions necessary in 
some other approaches. We next wanted to apply our carbocyclization to two other congeners, 
lycopladine A (XXIX) and carinatine A (XXXII). For their total synthesis, we demonstrated that 
silylated alkynes like XXVI were just as efficient in the carbocyclization to as free alkynes, 
 
further streamlining the reaction sequence. In order to furnish the aromatic portion of the two 
alkaloids, we used the Ciufolini pyridine synthesis, which in the case of carinatine A (XXXII) 
could nicely be telescoped to furnish both pyridine and cyclic nitrone ring in one operation. 
 
With seven steps each from well-known building blocks, all three syntheses are the shortest 
enantioselective reported to date. Additionally, we demonstrated the suitability of our general 
approach to the “non-aromatic” fawcettimine-type alkaloids with a formal synthesis of 
sieboldine A (1.66) through intermediate XXX, reducing the step count for Overman’s 
intermediate significantly. Future work will focus on further expanding the protocol. This 
would include, for example, synthesis of internal alkynes like XXXIII and XXXIV, and first 
positive results toward this end have been obtained. A very important extension to the 
carbocyclization will be the synthesis of other ring sizes. Research will focus on Thorpe–Ingold-
modified sidechains such as in XXXV to enable the closure of six-membered rings and other yet 
unattainable motifs such as linear substrates XXXVI or unbiased esters or lactones like XXXVII. 
 
Substrates belonging to these classes have been prepared and are currently being tested, as are 
deuterated substrates geared at elucidating the exact mechanism of the carbocyclization in 
combination with computational studies.  
 
Furthermore, we want to demonstrate the usefulness of our reaction for the synthesis of further 
Lycopodium natural products such as fawcettimine (XXXVIII) or other alkaloids, such as 
dendrobine (XXXIX) of the Orchidaceae family or the pyrrolizidine alkaloids retronecanol (XL) 
and danaidone (XLI). 
 
  
 
 
 
Lycopladine H (1.351) was isolated by the Kobayashi group from Lycopodium complanatum in 
2009,[191] sharing the natural source with lycopladine A (1.245). From a structural standpoint, 
however, it is not closely related to lycopladines A to G, as a matter of fact, its skeleton is unique 
amongst the Lycopodium alkaloids, bearing a very unusual C-6-C-14 bond. At this stage, no 
attempts to elucidate the biosynthesis have been reported, but a biogenesis starting from the 
phlegmarine (1.2) skeleton has been put forth. A phlegmarine-like imine 1.346 could be ring-
opened to furnish a bicyclic intermediate 1.347. α-Oxidation and activation of the resulting 
primary amine or alcohol would give an electrophile (1.348) for an intramolecular cyclization to 
an iminium species 1.349. This iminium species could furnish the lycopladine H skeleton after a 
Mannich cyclization to 1.350. Finally, oxidation of the C-4 position (lycopodine numbering) 
would yield lycopladine H (1.351). Interestingly, oxidation in this position is quite common 
amongst both fawcettimine and lycopodine alkaloids, albeit to the alcohol, not to the ketone 
oxidation stage. 
 
Its [2,2,2] core that bears all five stereocenters of the molecule makes lycopladine H a unique 
natural product amongst the Lycopodium alkaloids, even though it retains the classic C16N gross 
formula. In addition to its unusual core, it features two more rings: The first is a unique 3- 
piperidone spiro-fused to the [2,2,2] core, the second is an azocane unit. A final noteworthy 
structural feature is the sterically quite hindered tertiary α-tertiary amine that is characteristic of 
the lycopodine-type alkaloids. 
Given its interesting and challenging structure, it is not surprising that efforts have been 
directed towards the total synthesis of lycopladine H. The efforts of the Weinreb group have 
been documented in a sequence of three publications.[192-194] Their retrosynthetic analysis 
remained unchanged throughout and always relied on the construction of the core 1.354 via a 
Diels–Alder reaction of an ortho-quinone ketal, obtained by oxidative dearomatization of 
phenol 1.352, with the highly reactive dienophile nitroethene (1.353).[192, 195] In six more steps, 
this adduct was elaborated into the amine 1.355. The α-tertiary amine was introduced via 
nitroaldol reaction with formaldehyde, highlighting the need for strongly activated reaction 
partners to furnish α-tertiary amines in an intermolecular fashion. With the δ-vinylamine in 
hand, Weinreb and coworkers proceeded with their key step, an intramolecular 
hydroaminomethylation, in essence a hydroformylation followed by reductive amination. 
Using this reaction, a tricyclic intermediate 1.356 bearing the azocane moiety was furnished in 
eleven steps from isovanillin or eight steps from phenol 1.352.[193] 
 
Two years later, the second approach was disclosed.[194] This time, instead of aiming for 
sequential ring closures, the piperidine and azocane rings of lycopladine H (1.351) were 
supposed to be furnished by simultaneous double hydroformylation and reductive amination. 
Again starting from phenol 1.352, they accessed the [2,2,2] core 1.357 in seven steps, this time 
with the methyl stereocenter already set. Another ten steps delivered the diolefin 1.358, which 
was hydroformylated twice when treated with a rhodium(I) catalyst under a H2/CO 
atmosphere, giving dialdehyde 1.359. Hydrogenolysis of the Cbz group also triggered the 
desired double reductive amination to finally give the tertiary amine 1.360. At this stage, two 
protecting groups had to be removed and two secondary alcohols oxidized to the 
corresponding ketones to arrive at lycopladine H (1.351). The benzylidene acetal of 1.360 could 
be removed under Birch conditions and the diol oxidized to the α-hydroxyketone, which was 
deprotected to 1.362. 
 
 
Unfortunately, this sequence was very low-yielding and only furnished minute amounts of 
intermediates that were not fully characterized. Attempts at oxidation of the secondary alcohol 
in 1.362 to lycopladine H (1.351) were met with failure. 
After the experimental work of this thesis had been concluded, another, strategically distinct 
approach toward the lycopladine H skeleton was described in a Master’s thesis.[196] During a 
failed attempt to access the lycopodine (1.4) skeleton by transannular aza-Prins cyclization, it 
was realized that the same strategy with a more oxidized precursor could potentially give rise 
to lycopladine H (1.351). Suzuki coupling of well-established α-iodoenone 1.111 with a C₁₀ 
building block 1.363 gave enone 1.364. Conjugate addition using an allyl cuprate gave 
unstable silyl enol ether 1.365 in moderate yield. The tertiary alcohol could be introduced by 
Rubottom oxidation with m-CPBA to give 1.366, albeit in rather modest selectivity and yield. 
Under very high dilution conditions, the twelve-membered ring 1.367 could be furnished by 
ring-closing metathesis using second-generation Grubbs catalyst, even though the authors 
noted that the structure 1.367 was not firmly established yet. Oxidation of the cis-alkene 1.367 to 
a diketone could furnish the substrate for the desired transannular Mannich cyclization. 
 
In addition to lycopladine H, another potential target was disclosed three years later; 
Lycojaponicumin D (1.371) was identified as a minor component of Lycopodium japonicum by 
Shi-Shan Yu and coworkers.[197] With its tetracyclic skeleton bearing a tertiary α-tertiary amine, 
it resembles the lycopodine-type alkaloids. It differs, however, by a formal 1,2-alkyl shift of the 
C-4-C13 bond to C-3, resulting in a 6-6-7-5 system instead of the common 6-6-6-6 system. 
Biosynthetically, it is has been suggested that lycojaponicumin D does not arise from oxidation 
of a lycopodine precursor, but instead from fawcettimine (1.5) or alopecuridine (1.61) 
(Scheme 1.69), where 1,2-diketones are not unheard of. Retroaldol rupture of the C-4-C-12 bond 
would lead to a diketone 1.368, which could cyclize onto the iminium ion 1.369 in an 
intramolecular Mannich cyclization to give the carbon skeleton (1.370) of lycojaponicumin D 
and the natural product 1.371 after oxidation of C-12. 
 
In summary, no complete total synthesis of lycopladine H (1.351) has been disclosed until now. 
However, the previous approaches showcase the challenges associated with its compact and 
 
sterically encumbered structure. Surprisingly, no efforts toward lycojaponicumin D have been 
disclosed this far.[198] 
The goal of this thesis was to develop an approach suitable for both alkaloids via a late-stage 
transannular Mannich cyclization and complete the first total synthesis of lycopladine H (1.351) 
and lycojaponicumin D (1.371). 
 
We envisioned a concise, convergent route to lycopladine H and lycojaponicumin D that would 
rely on a late-stage Mannich reaction to furnish the skeleton of the two natural products 
(Scheme 1.70). We realized that disconnection of the Mannich retron in both cases led to a 
macrocycle 1.372 bearing an α-diketone and a secondary amine. The selectivity would mainly 
be governed by the reversible condensation of the secondary amine on either C-5 for 
lycopladine H or C-13 for lycojaponicumin D. This would be followed by nucleophilic attack of 
the enol tautomer corresponding the C-13 ketone (lycopladine H) or C-4 ketone 
(lycojaponicumin D), respectively. 
 
We were intrigued to investigate which cyclization mode would be favored and whether it 
could be influenced by choice of the reaction conditions. Therefore, we wanted to pursue an 
unprotected or minimally protected triketone as the penultimate intermediate. 
 
The presumably unstable α-diketone 1.373 was supposed to be furnished by a one- or two-step 
oxidation of a macrocyclic alkene 1.374 (Scheme 1.71). Given the advances over the last two 
decades, it seemed promising to furnish the twelve-membered macrocycle 1.374 by a ring-
closing metathesis, even though examples for this particular ring size are scarce.[199-201] 
Interestingly, alkene 1.374 and diketone 1.373 bear resemblance to a synthetic intermediate 
proposed by Heathcock in his seminal synthesis of lycopodine.[123] However, Heathcock 
discarded this “most straightforward” disconnection, citing the lack of reliable synthetic 
methods to access an unsaturated macrocycle that was no less complex with regard to the 
natural product lycopodine (1.4). The bisalkene 1.375 necessary for the ring-closing metathesis 
could be obtained via conjugate addition or an equivalent process to append the allyl side chain 
to a suitable enone 1.376. Ideally, trapping of the enolate would give a handle to introduce the 
tertiary alcohol of the two target alkaloids. Enone 1.376 could be obtained via a B-alkyl Suzuki 
coupling[202] between two building blocks, 1.111 and 1.377, both of which are accessible on 
multigram scale.[203] 
In the forward sense, we started with the fragment coupling of the Boc-protected side chain 
1.364 to the known iodoenone (1.111).[58] As disclosed previously,[203] the side chain was 
available in gram quantities in five steps from but-3-en-2-ol (1.378) through a high-yielding 
sequence consisting of Johnson-Claisen rearrangement to 1.379, ester hydrolysis to 1.380, amide 
coupling with allylamine to 1.381, reduction and Boc deprotection to finally give 1.363 
(Scheme 1.72). Other protecting groups were easily introduced in the last step of the sequence. 
 
In this way, nosyl (Ns) and benzyl carbamate (Cbz) side chains 1.383 and 1.384 were accessed, 
giving some flexibility in the final protecting group manipulations of our synthesis. The B-alkyl 
Suzuki coupling gave the three enones 1.364, 1.385 and 1.386 in good to very good yield 
(Scheme 1.73). 
 
 
However, to first probe the most rapid route, we explored the following steps with the Boc 
protected amine 1.364. The next step, a conjugate addition of an allyl group turned out to be a 
major hurdle. Some representative results of the screening are shown in Table 1.1. 
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Sakurai’s TiCl₄ conditions resulted in decomposition (entry 1).[204-205] Milder Lewis acids like 
FeCl₃ in conjunction with TMSCl did not result in appreciable conversion (entry 2), even when 
the more reactive stannane was used (entry 3).[206] I₂ was not sufficiently Lewis-acidic to induce 
reaction (entry 4).[207] Barbier-type radical addition did not work with an activated species like 
allyl iodide.[208] Various copper-catalyzed methods (entries 6–9) were moderately successful only 
when TMSCl was present as a promoter.[209-210] We then turned back to stannane-based methods 
and found some success with TBSOTf as the Lewis acid.[211] 
After extensive screening, a modification of an allylation-triflation methodology developed by 
Trauner originally in the context of a total synthesis of haouamine B[212] proved to be most 
suitable for the synthesis of allylated silyl enol ether 1.388 (entries 11 and 12).[213-214] In essence, 
simply exchanging the electrophilic component from triflic anhydride to tert-butyldimethylsilyl 
triflate allowed for the smooth synthesis of a silyl enol ether that was stable enough to be 
isolated by column chromatography; this stability is most probably conferred by its significant 
steric demand. NOE experiments revealed that the conjugate addition had occurred with 
complete (>20:1) trans selectivity, which is in line with earlier work on the related Sakurai 
allylations by Heathcock.[205] With this activated carbonyl in hand, we proceeded to the 
introduction of the tertiary alcohol by Rubottom oxidation or a related method (Table 1.2).[215-218] 
Treatment of TBS enol ether 1.389 with m-CPBA indeed resulted in slow conversion to the α-
hydroxylated ketone 1.391, alongside a significant amount of hydrolysis to the ketone 1.393 
(entry 1). Modification of the solvent did not have a major influence on the reaction outcome 
(entries 2 and 3). Using purified m-CPBA (99%) and lowering the reaction temperature slightly 
improved the yield (entry 4). However, a major drawback was the modest diastereoselectivity, a 
2.5:1 d.r. being the best result. In order to facilitate product isolation, we attempted the 
deprotection of the silyl ether obtained by Rubottom oxidation with tetrabutylammonium 
fluoride (TBAF) and the free α-hydroxyketone 1.392 was isolated in low yield (entry 5), which 
prompted us to investigate other oxidants. In the 1980s, Davis reported the use of (chiral) 
oxaziridines for the oxidation of electron-rich double bonds, mostly enamines and enolates.[219] 
The use of these oxidants for silyl enol ethers is less common and requires higher temperatures 
than for enolates.[220] In our case, this oxidant led to no conversion (entry 6). We therefore 
attempted Yu’s enolate generation from silyl enol ethers with potassium ethoxide.[221] 
Disappointingly, while clean deprotection was observed, no oxidation took place when Davis’ 
oxaziridine was added (entry 7), and only ketone 1.393 was obtained. No oxidation was 
observed when the same enolate generation method was followed by treatment with an oxygen 
atmosphere and triethyl phosphite as a reducing agent (entry 8).[222] We also briefly looked at 
TIPS enol ether 1.390, but unsurprisingly, it was less reactive than its TBS counterpart 1.389 
(entry 9). 
 
An osmium tetroxide system was ineffective, as was the Sharpless AD system (entries 10 and 
11).[223] Remarkably, no oxidation of the two other double bonds in the substrate was observed 
under these conditions. Sarpong described the in situ generation of the highly electrophilic 
dimethyldioxirane (DMDO) in a biphasic medium.[224] While clean conversion was observed, 
DMDO preferentially attacked the disubstituted double bond at room temperature and at 0 °C 
(entries 12 and 13). This came as a surprise given the highly electron-rich nature of the silyl enol 
ether. Using a preformed DMDO solution in dichloromethane/acetone did not result in 
appreciable conversion (entry 14). 
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At this point, it was evident that bulky enol ethers like 1.389 and 1.390 could not be oxidized 
with sufficient efficiency. It is perhaps not surprising that while a plethora of other oxidants is 
available for Rubottom-like oxidations of silyl enol ethers, all of them utilize the much less 
hindered trimethylsilyl enol ethers.[225-227] 
Alternatively, we explored the α-oxygenation from the ketone 1.393 obtained by 
straightforward TBAF treatment, hoping that the lower reactivity would be offset by the lower 
steric hindrance. 
 
To this end, we submitted the ketone to conditions originally developed by Moriarty (Table 1.3), 
which were completely ineffective (entries 1–3).[228-229] We next explored Jiao’s very simple 
hydroxylation conditions with cesium carbonate as a base and DMSO as the solvent 
(entry 4).[230] Under these and Gardner’s related conditions,[222] partial conversion to the α-
hydroxyketone was observed, but the isolated yield was low and the stereoselectivity poor, not 
exceeding 1.5–2:1 (entry 5). 
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Given these mixed results, we reasoned that a bicyclic intermediate 1.394 could be better suited 
for selective oxidation due to its lower flexibility. We thus began to investigate the key ring-
closing alkene metathesis to form a twelve-membered ring. We were aware that twelve-
membered rings are amongst most difficult macrocycles to form due to their significant 
transannular strain.[231-233] The results of our screening with the TBS enol ether 1.389 are 
summarized in Table 1.4. 
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As can be seen from Table 1.4, the product 1.394 could be obtained with Grubbs 2nd generation 
and Hoveyda–Grubbs 2nd generation catalysts as well as the Grela catalyst.[234-236] However, the 
product was consistently contaminated with compounds that could not be cleanly isolated, but 
were identified as dimers and trimers by high-resolution mass spectroscopy. Given that 
oligomers were obtained even at very high dilutions, we deemed the silyl enol ether 1.389 
unsuitable for further experiments. As a testament to its stability, the silyl enol ether moiety was 
left untouched under all conditions and no hydrolysis was observed. 
With these mixtures of desired product and oligomers, we wanted to investigate whether the 
silyl enol ether could be dihydroxylated in conjunction with the alkene obtained by RCM. While 
isolation of pure product was again unfeasible, we were able to identify that even with excess 
oxidizing agents, the disubstituted double bond had been dihydroxylated exclusively. 
 
 
Given these findings, we reevaluated our retrosynthesis. Postponing the oxidation of the silyl 
enol ether to the α-hydroxyketone to the post-metathesis stage did not render the reaction more 
efficient, and the metathesis itself had only yielded variable mixture of product and oligomers. 
Therefore, we next pursued an approach in which the oxidation pattern of the skeleton would 
be introduced from an almost fully reduced bicycle. Tracing it back the same way as before, this 
led to the identical side chain 1.363 and a cyclohexene building block 1.398. This building block 
is readily available in racemic form,[83] but enantioselective variants are available as well in a 
more step-intensive fashion.[84] 
 
Starting from racemic iodoenone 1.111, Luche reduction to 1.396 and acetylation gave the allylic 
acetate 1.397. Even though these transformations were very clean, it was mandatory to purify 
the material via column chromatography at this stage to obtain a satisfactory yield in the next 
step. Treatment of allylic acetate 1.397 with excess allyltrimethylsilane and boron trifluoride 
diethyl etherate at elevated temperature gave vinyl iodide 1.398, presumably via the Cs-
symmetric cation. In accordance with the literature, the diastereoselectivity was 2.8–3.0:1, the 
desired trans diastereomer predominating.[83] This building block was coupled to the side chain 
1.363 under our previously established conditions to yield 1.399 in quantitative yield (d.r. 3.0:1). 
At this stage, the diastereomers could be separated, giving the desired diastereomer in 72% 
yield. 
 
With this molecule in hand, we were in a position to reinvestigate our metathesis reaction with 
a less oxidized precursor (Table 1.5). 
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It quickly became apparent that all second generation catalysts were not well-suited for this 
particular ring-closing metathesis. Also, compared to the screening in Table 1.4, all reactions in 
Table 1.5 were much slower. The Hoveyda–Grubbs catalyst gave a mixture of products that was 
not easily separated (entry 1), as did the isopropyl-Hoveyda–Grubbs variant that bears the SIPr 
NHC ligand instead of the regular SIMes NHC (entry 2).[237] Reasoning that a less hindered 
variant could display different reactivity, we switched to the Stewart-Grubbs catalyst that 
contains o-tolyl instead of mesityl substituents on the NHC.[237-238] After screening 
dichloromethane (HPLC grade or dry over molecular sieves), toluene and dichloroethane, we 
established dichloroethane as the best solvent, giving a single product in high yield (entries 3–
6). Unfortunately, after some experimentation, we found that the dimer had been formed in this 
and other reactions using second generation catalysts, even at extremely high dilution (entries 7 
and 8). After this setback, we hoped that a very catalyst scaffold could furnish the desired 
twelve-membered ring. We thus turned to the NHC-free first generation Grubbs catalyst, which 
performed as poorly as the others at 3 mM, giving a moderate yield of multiple products 
(entry 9). However, upon careful optimization, it was found that lowering the concentration 
further to 0.2 mM, an acceptable yield could be obtained (entry 10), even slightly higher (and 
experimentally more convenient) concentrations were detrimental to the reaction yield (entries 
12 and 13). Extending the reaction time was beneficial (entry 11). It was also found that vigorous 
degassing by freeze-pump-thaw was not necessary and sparging with argon was sufficient, as 
was using dichloromethane recycled from previous metathesis experiments (entry 14). 
Increasing the catalyst loading further to 30 mol%, added in three portions over three days 
(entry 15), slightly increased the yield to 70% (78% based on recovered starting material). 
Pleased to have finally closed the macrocycle, we immediately pressed on to the following 
oxidations (Table 1.6). Unfortunately, the twelve-membered ring 1.400 was obtained as a 1:1 
mixture of E and Z alkene isomers that were inseparable at this stage. 
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Osmium-based methods[239] provided the desired tetraol in modest (entry 1) to good (entry 2) 
yield, with additives like pyridine[240] and 2,6-lutidine[241] (entries 3 and 4) giving worse results 
and intractable side products. An Os(III)-based system developed by Warren as a racemic 
Sharpless variant offered no benefit in terms of yield (entry 5).[242] Sharpless’ AD-mixes in 
different ratios provided low conversions (entries 6–8).[243-244] A dihydroxylation using 
ruthenium trichloride resulted in oxidative cleavage of the disubstituted double bond 
(entry 9).[245] While the transformations were generally rather clean, the identity of the product 
1.401 could only be established by mass spectroscopy and LC-MS. 1H NMR showed peaks that 
were plausible for a tetraol like 1.401, but did not allow for analysis of diastereoselectivity. It 
was unclear whether this was a result of the E/Z mixture of isomers in the starting material or 
an inherent lack of selectivity in the double dihydroxylation. Nevertheless, we were pleased to 
have introduced the tertiary alcohol, which had been a major problem in the previous approach. 
Furthermore, we hoped that the mixture of diastereomers obtained in the oxidation would be 
inconsequential once the three secondary alcohols were oxidized to ketones. Our results for the 
oxidation are summarized in Table 1.7. 
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Initial experiments using Dess–Martin periodinane[246] (entries 1 and 2) provided small amounts 
of material bearing the correct mass of triketone 1.402, accompanied by C–C cleavage products. 
It was reported by Santagostino that the closely related IBX smoothly oxidizes 1,2-diols to the 
corresponding 1,2-diketones without C–C cleavage.[247] The crucial insight was that IBX, which 
had previously only been used for the preparation of DMP due to its low solubility in virtually 
all organic solvents, is quite soluble in DMSO. Indeed, we obtained an improved yield and no 
side products originating from C–C cleavage (entries 3 and 4). Under all these conditions, we 
were unable to isolate a single reaction product, with 1H NMR indicating the presence of at least 
three structurally similar products. We therefore investigated other procedures. A pyridine-
NBS-based method (entry 5)[248] resulted in a very complex mixture, possibly arising from 
partial formation of an enone by α-bromination and elimination. A much cleaner reaction 
profile was obtained using a NMP·HBr₃ in combination with hydrogen peroxide as the 
stoichiometric oxidant. However, the major product was again the enone (entry 6).[249] 
Methyltrioxorhenium/H₂O₂[250] as well as thiourea dioxide/TBHP mainly led to decomposition 
(entries 7 and 8).[251] We next turned to oxoammonium-mediated or -catalyzed oxidations, which 
have more recently been developed as convenient and mild metal-free alternatives to most 
classic oxidations.[252] We thus turned to Zhao’s procedure utilizing stoichiometric amounts of 
iodobenzene dichloride in conjunction with TEMPO and pyridine (entry 9).[253] Unfortunately, 
only decomposition was observed. Banwell’s procedure for the in situ disproportionation of a 
TEMPO derivative under acidic conditions provided some product alongside various side 
products (entry 10).[254] Reasoning that this disproportionation was not efficient enough, we 
turned to stoichiometric oxoammonium salts as described by Bobbitt.[255], resulting in a complex 
mixture (entry 11). However, adding silica gel to the reaction mixture (entry 12) drastically 
improved the reaction (entry 12).[256] Given that these oxidations also yielded various products 
all bearing the desired mass according to LC-MS, we returned once more to IBX-mediated 
procedures in the hope of getting a single identifiable product. Finney disclosed an oxidation 
protocol that makes use of its low solubility at room temperature.[257] He found that IBX is 
 
slightly soluble in a range of organic solvents at higher temperatures, thus combining the 
advantages of homogenous (fast reactions) and heterogeneous (easy workup by filtration) 
reactions. A small screening (entries 13–16) established ethyl acetate as the solvent of choice, 
giving the usual mixture in a good combined yield after simple filtration. 
At this stage, we had performed three consecutive steps without complete assignment of 
structure. On the other hand, the putative product represented our final intermediate en route to 
lycopladine H (1.351) and lycojaponicumin D (1.371). Therefore, we submitted the mixture 
obtained by IBX oxidation to acidic conditions, expecting to induce the Mannich reaction after 
Boc deprotection. To our disappointment, neither trifluoroacetic acid[56], amberlyst-15[258] nor 
HCl in methanol[41] or dioxane resulted in appreciable conversion, let alone natural product 
formation. This complete lack of reactivity shed serious doubt on the structural assignment. We 
therefore decided to explore a different, more stepwise approach that would allow for 
unambiguous establishment of all intermediates along the way. 
 
 
Given the problems with the oxidation steps in our previous approach to triketone 1.402 
(chapter 1.3.2), we decided to pursue a slightly different tactic that would hopefully address its 
shortcomings. While the overall Mannich strategy from triketone 1.402 remained the same and 
the diketone would be furnished by oxidation,[259] we wanted to close the challenging twelve-
membered ring in 1.402 by a ring closing alkyne metathesis (RCAM). In recent years, alkyne 
metathesis has transitioned from a method primarily used for industrial interconversion of 
hydrocarbons to a powerful methodology to install triple bonds in highly functionalized 
molecules in completely orthogonal fashion to alkene metathesis.[260-262] In particular, with the 
advent of Fürstner’s silyloxy-substituted tungsten- and molybdenum-based catalysts, which are 
available as reasonably air- and moisture phenanthroline adducts (Figure 1.13), alkyne 
metathesis has become an increasingly attractive alternative to olefin metathesis for total 
synthesis purposes.[263-264] We were aware that the ring strain induced by the two sp-hybridized 
atoms of an alkyne in a twelve-membered ring like 1.403 would be significantly higher 
compared to its sp2-hybridized alkene counterpart.[265-266]  
 
The remainder of the synthesis would be largely similar to the first RCM route, with the 
obvious difference that the conjugate allylation would be replaced with a conjugate 
propargylation to give 1.404 after α-oxidation.[56, 267] It was not clear whether the alkyne 
introduced this way had to be methyl-capped or not.[268-272] Furthermore, the synthesis of the 
side chain 1.405, again thought to be coupled to iodoenone 1.111 via B-alkyl Suzuki coupling, 
would have to be revised to accommodate the necessary internal alkyne. 
With a new retrosynthesis defined, we set out to synthesize the alkyne-bearing side chain 1.405 
with R = H or Me. Treatment of γ-butyrolactone (1.406) with PPh3/CCl4 resulted in 
dichloromethylenation to 1.407.[273] Treatment of this compound with excess methyllithium and 
catalytic Fe(acac)3 according to Fürstner’s method[274] resulted in formation of hex-4-yn-1-ol 
(1.408) in moderate yield (Scheme 1.79). 
 
 Mainly because of the large amounts of PPh3 and CCl4 needed for larger scales, we decided to 
explore a more practical route where the methyl group would be introduced in the final step. To 
this end, pent-4-yn-1-ol was mesylated under standard conditions (MsCl, Et3N) (1.409) and also 
transformed into the corresponding chloride 1.410 and iodide 1.284 by standard Appel 
conditions (not shown). With these alkylating agents 1.411 in hand, we proceeded with the 
alkylation of Boc-allylamine (1.412) (Table 1.8). The mesylate was unreactive when treated with 
the anion of 1.412 (entry 1), but a moderate yield was obtained in the presence of catalytic TBAI 
(entry 2). No reaction was observed when unprotected allylamine was reacted with 1.409 
 
(entry 3). The same trends were observed with chloride 1.410 (entries 4–6). The best yield was 
finally obtained with iodide 1.284, which gave a good yield of 1.413. 
 
1 →
2 →
3 
4 →
5 →
6 →
7 →
 
The methylation of the terminal alkyne in 1.413 was accomplished by deprotonation followed 
by quenching with the electrophilic methyl sources methyl iodide and methyl triflate to give the 
full side chain 1.413 (Table 1.9). 
 
1 
2 →
3 →
4 
5 
 
Even though the synthetic sequence was short and appreciable amounts of the side chain 1.414 
were obtained with MeI (entries 1–4) as well as MeOTf (entry 5), the low efficiency of this route 
and use of toxic methyl triflate rendered the sequence inconvenient on larger scale. Therefore, 
we decided to introduce the methyl group at an earlier stage. Using a slightly modified 
literature procedure, 5-chloro-1-pentyne (1.410) was methylated with methyl iodide to give 
6-chlorohex-2-yne (1.415).[275] The crude product was transformed into the iodide (1.416) under 
classic Finkelstein conditions in good overall yield (Scheme 1.80). 
 
 
Under the conditions we had previously optimized for the alkylation of 1.412 with 
5-iodopent-1-yne (1.284), we could access the full side chain 1.414 in very good yield on multi-
gram scale. With the side chain in hand, the fragment coupling by B-alkyl Suzuki reaction could 
be investigated, the results of which are summarized in Table 1.10. In all cases, the side chain 
1.414 was hydroborated with 1.2–1.5 equivalents 9-BBN in THF at room temperature or 40 °C, 
which had a negligible effect on the reaction outcome. 
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Surprisingly, the seemingly minor modification within the side chain had a major impact on the 
coupling efficiency. Under the Trost conditions that had served us very well in the alkene series 
(86%),[276] the target enone was obtained in only 50% yield (entry 1). Suzuki’s original 
conditions, that were also previously used for similar B-alkyl Suzuki couplings in Lycopodium 
alkaloid total synthesis (entries 2–4),[277-278] did not offer much improvement and were 
irreproducible on larger scale. Suzuki’s protocol using potassium phosphate as base did not 
perform better, either.[279] Modification of the reaction temperature improved the yield on small 
scale (entry 6), but offered no advantage in scalability (entry 7). We also prepared the Cbz-
protected side chain, which performed worse than its Boc-protected counterpart (entry 8), and a 
BPin sidechain by iridium-catalyzed hydroboration,[280] which only led to decomposition 
(entry 9). Combination of the conditions in entries 1 and 4) gave no improvement. However, 
switching to Buchwald’s RuPhos ligands and Pd(OAc)2 as the palladium source allowed for a 
much better reaction yield (entries 11–13).[281] Finally, switching to Buchwald’s 2nd generation 
precatalyst with added SPhos enabled an efficient coupling on 4 mmol scale 
(entries 14 and 15.[282-284] 
We also attempted the synthesis of enone 1.417 by alkylation of the known pulegone-derived 
ketone bearing an α-thiophenyl or α-phenylsulfinyl group. To this end, we prepared the 
unstable primary iodide 1.418 via Brown’s hydroboration-iodination sequence.[285-287] 
  
 
Under conditions established by Dake,[57] the sulfoxide was treated with DBU and iodide 1.418 
at low temperature, followed by heating to induce sulfoxide elimination (entry 1) This resulted 
in decomposition, but a slower increase in temperature provided traces of the desired product 
with both DBU (entry 2) and NaH (entry 3) as base. Siegel’s conditions for the alkylation were 
attempted next.[144, 148] Using the sulfide 1.419, no notable conversion was observed before 
decomposition of iodide 1.418 set in (entries 4–6). 
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Even though the alkylation approach was not successful, the Suzuki approach supplied ample 
material, so we proceeded to the conjugate propargylation (Table 1.12). Application of our 
previously established allylation conditions, using the technical grade allenyl- instead of the 
allylstannane, gave a small amount of the desired silyl enol ether 1.421 (entry 1). 
When fresh allenyltributylstannane prepared according to Torii’s procedure was used,[288] the 
yield was significantly improved compared to the commercially available stannane (entry 2). 
However, the reaction yield was highly variable, limiting effective material throughput. Under 
Haruta’s original conditions without base and molecular sieves or at higher temperatures, 
decomposition was observed (entries 3 and 4).[267] 
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The two alternative solvents acetonitrile and THF provided low conversion (entries 5 and 6). 
Lee’s conjugate propargylation under different Lewis-acidic conditions only resulted in 
decomposition (entries 7 and 8).[289-290] Given the lack of reactivity with the indium-based 
reagents, we returned to allenylstannane reagents. To our disappointment, the 
allenyltriphenylstannane proved much less reactive than its tributyl counterpart (entries 9 and 
10). We also attempted the synthesis of the propargylated ketone via TiCl₄ catalysis (entries 11 
and 12), which resulted only in decomposition. Copper-catalyzed propargylations resulted in 
clean formation of the 1,2-adduct with TMS-protected propargyl Grignard (entries 13 and 14) 
and no reaction when propargylmagnesium bromide was used (entries 15 and 16). Cognizant of 
the limitations of our current approach, we wanted to press on to the RCAM step. Therefore, we 
wanted to cap the terminal alkyne just introduced with a methyl group, even though some 
examples of alkyne metathesis reactions that are compatible with one terminal alkyne have 
recently surfaced.[270-271] This was achieved with n-BuLi followed by treatment with methyl 
iodide to yield the 2-butynylated silyl enol ether 1.422 in moderate yield. LHMDS did not result 
in appreciable conversion. 
 
At this point, we were in a position to attempt the ring-closing alkyne metathesis (Table 1.13). 
Reasoning that added conformational flexibility could be beneficial to forge the strained 
cyclododecyne ring, we also prepared the ketone 1.423 by simple TBAF deprotection and used 
it for initial investigations. The focus first was on protocols using the ill-defined molybdenum 
catalysts introduced by Mortreux in the 1974,[291] which are experimentally convenient. They 
have undergone many rounds of improvement, mostly by empirical screening of additives and 
phenolic ligands.[292-300] Under the original Mortreux conditions, only decomposition was 
observed (entry 1).[291] Grela’s 2-fluorophenol ligand provided traces of the desired ketone 1.424 
(entry 2).[296] Encouraged by this result, we investigated his more thoroughly optimized 
protocol,[297] but this only resulted in very low conversion (entry 3). The addition of molecular 
sieves was not beneficial (entry 4).[298] Bunz’ conditions that are based on 4-chloro- or 4-
trifluoromethylphenol as the ligand only gave starting and polymeric material (entries 5–7).[292-
295] At this point, we realized that these ill-defined complexes were not active enough for our 
challenging transformation. We therefore turned to the latest generation of Fürstner’s catalysts 
that combine high catalytic performance with unmatched functional group tolerance 
(Figure 1.13).[263-264, 301] The triphenylsilyloxy ligands play a crucial role in their reactivity profile, 
modulating the Lewis acidity of the Mo(VI) centers without compromising the reactivity of the 
alkylidyne unit.[301] 
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Furthermore, it was found that one of the main drawbacks, the sensitivity towards moisture 
and air, could be addressed by simple complexation with 2,10-phenanthroline (1.426 and 1.428). 
These catalytically inactive adducts can be weighed in air and returned to their active state 
(1.427 and 1.429) by simple treatment with a mild Lewis acid like MnCl2.[264, 301] Unsurprisingly, 
these catalysts have largely supplanted Schrock’s trialkoxytungsten(VI)-alkylidyne complex 
1.430[302-303] or the more functional-group-compatible 1.431[304-305] in total synthesis 
applications.[306-311] 
 
To our surprise, no reaction was observed with the two precatalysts (entries 8 and 9). We thus 
turned to the other possible substrate 1.422, but realized it was unreactive at room temperature 
and not compatible with the active catalyst at elevated temperatures (entries 10–12). 
At this stage, we were forced to reevaluate our synthetic route. While the enone 1.417 could be 
obtained in good yield after optimization of the Suzuki coupling, the propargylation and the 
methylation reactions were not reliable enough to supply sufficient material to screen the 
RCAM thoroughly. We therefore looked at alternative ways to introduce the 2-butynyl moiety. 
The introduction of a 3-butynyl chain followed by isomerization was identified as a viable 
option encouraged by reports from Taylor and Jamison.[312-314] Again aiming for the ketone 
instead of the silyl enol ether first, we synthesized the 3-butynylated cyclohexenone 1.433 by 
copper-catalyzed addition of 1.432 followed by double TMS deprotection with TBAF 
(Scheme 1.83). 
 
When Jamison’s conditions were applied to our ketone 1.433, a rapid conversion to one product 
was observed. However, to our surprise, the isolated product was not the internal alkyne 1.423 
resulting from isomerization to the internal alkyne; we isolated a hydrindane 1.434 bearing an 
exo-methylene group. 
 
 
This finding inspired a research project exploring this largely unprecedented carbocyclization 
transformation and its application in Lycopodium alkaloid total synthesis.[315] The results of this 
project are summarized in chapter 1.2. 
  
 
As the two metathesis-based approaches did not furnish the desired cyclization precursor in 
pure form, we decided to change the order of ring-closing events. Instead of a late-stage 
Mannich cyclization to construct the piperidone and azocane rings, we decided to attempt the 
Mannich at an earlier stage. This would, in the case of lycopladine H (1.351), lead to a tricyclic 
structure 1.435 or, in the case of lycojaponicumin D (1.371), 1.436. These intermediates would be 
obtained via divergent Mannich reactions of triketone 1.437 that, in turn, could be obtained from 
alkene 1.438. Ultimately, it could be furnished via cross-metathesis and conjugate addition-
oxidation to ketone 1.439, which should be accessed from known and previously used enone 
building block 1.440 (see chapter 1.2.2). While more step-intensive, we expected this more 
conservative approach to be more reliable. 
 
With ample quantities of 1.440 in hand through a high-yielding B-alkyl Suzuki coupling 
(see chapter 1.2.2), we were in a position to screen the conjugate addition. Given our experience 
with the very sterically hindered TBS enol ethers 1.389 and 1.390 in the subsequent Rubottom 
oxidation, we wanted to focus on TMS enol ether 1.441, expecting a more facile 
α-hydroxylation. We thus investigated cuprate additions as the most viable option, even though 
allyl additions to 2-substituted cyclohexenones are notoriously challenging.[209-210] 
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In our case, the major obstacle was to improve 1,4-selectivity over 1,2-addition which occurred 
with copper catalysis (entries 1–3). After screening various copper sources and reaction 
temperatures, it was established that only stoichiometric quantities of copper(I) bromide 
dimethyl sulfide complex gave the desired crude TMS enol ether 1.441 in appreciable quantities 
(entries 4 and 5). Conducting the reaction at −100 °C (entry 6) or with two equivalents Grignard 
reagent relative to copper (entry 7) did not improve the yield, and simply increasing 
the equivalents of organomagnesium reagent led to side products and partial hydrolysis of the 
silyl enol ether. The optimized conditions used 2.3 equivalents of allylmagnesium bromide and 
slightly more copper bromide dimethyl sulfide to ensure complete cuprate formation and 
suppress 1,2-addition. The crude reaction product was then used in the Rubottom oxidation 
without further purification. At this point, we faced the same diastereoselectivity issues first 
encountered in the RCM route (chapter 1.3.2): with m-CPBA, we obtained a 2.5:1 ratio of 
inseparable diastereomers and combined yield of 45%. 
  
 
This section detailed our progress toward the Lycopodium alkaloids lycopladine H (1.351) and 
lycojaponicumin D (1.371). 
 
We were able to quickly furnish the first precursor to explore the key ring-closing metathesis via 
allylation conditions specifically developed for this purpose. A thorough screening revealed 
that silyl enol ether 1.389 was not suitable for the ring-closing metathesis to 1.394, yielding a 
complex mixture of desired product as a mixture with dimers and decomposition products. 
Therefore, we next investigated an approach that would proceed through a reduced bicyclic 
system 1.399. 
 
Extensive condition screening of this bisalkene revealed Grubbs’ 1st generation catalyst to be 
optimal for the transformation to 1.400, even though high catalyst loadings were necessary. The 
product, an inseparable mixture of E and Z isomers, was taken on to subsequent oxidation 
steps. While double dihydroxylation of the two alkenes to the tetraol 1.401 was possible, the 
resulting mixture of diastereomers rendered analysis at this stage very challenging. While the 
tetraol 1.401 could be oxidized to the triketone 1.402, it could never be purified to 
unambiguously assign the structure or examine the key Mannich reaction. 
We thus investigated an approach featuring RCAM for the macrocyclization. With the enone 
1.417 in hand, we proceeded to the propargylation step, which turned out to be a major 
bottleneck due to reproducibility issues. With the product obtained via this route, we carried 
out preliminary investigations toward the key RCAM reaction. 
 
 
While investigations indicated the presence of the desired macrocyclic alkyne 1.424, these 
results could not be confirmed due to paucity of material. It was during efforts to streamline the 
precursor synthesis that we found a base-mediated carbocyclization, which was subsequently 
investigated as the main topic of this thesis (chapter 1.2). A future approach could consist of a 
monocyclic precursor for the key Mannich cyclization. Ideally, this would result in a tricyclic 
intermediate for the two Lycopodium alkaloids with only a five- or six-membered ring closure 
remaining. First steps to this end were undertaken and have yielded promising results 
(chapter 1.3.4). 
 
We also realized that a compound like 1.439 could serve as a branching point toward many 
other Lycopodium C-4 and C-6-oxidized lycopodine derivatives (Scheme 1.88). Replacing the 
metathesis with an oxidative cleavage would give an aldehyde 1.442 that could be attacked by a 
bifunctional nucleophilic reagent to yield a ketone 1.443 after oxidation. This would circumvent 
potential problems associated with regioselective oxidation of the double bond. Lycodoline 
itself could serve as a platform to access a range of C-12-oxidized Lycopodium alkaloids, such as 
obscurumine A (1.445), diphaladine A (1.446) and lycoposerramine G (1.447), none of which 
have been synthesized to date. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The study of neuronal networks is one of the most important frontiers in today’s medical, 
biological and chemical research.[316] In order to address questions of high relevance for medicinal 
research, it is crucial to first gain a detailed understanding of the fundamental principles and 
dynamics of neuronal transmission and related processes. Remarkable progress has been 
achieved in elucidating the basic mechanisms of signal transduction in terms of molecular 
interactions. Yet many processes remain poorly understood in detail, such as temporal and spatial 
requirements for the precise and exact integration of signal cascades. To study these highly 
regulated processes in more detail, a large number of techniques have been explored. One 
method consists of genetically silencing some components, allowing the subsequent study of the 
effect by their absence. Another method is the genetical engineering of components to study their 
basic mode of action. Complementary to these biological approaches, conventional pharmacology 
has produced a vast variety of drugs, agonists and antagonists specifically for many types of 
receptors, to non-invasively study a wide variety of targets.[317] All these methods have their 
specific scope of application, yet they share one main disadvantage, namely their global 
application: they affect whole cell composites, organs or organisms. Accordingly, there is a need 
for novel tools that are able to modulate and control biological function in a more 
spatiotemporally precise manner. One approach to resolve this issue is the combination of non-
invasive light as an activating agent, chemistry and genetics. This new way of manipulating 
biological targets is called “photopharmacology”.[318-320] 
A promising method to achieve dynamic control of receptors is the use of molecular 
photoswitches in combination with light.[321] Light as the inducer of switching has the unique 
advantage that it can be applied with unmatched spatial and temporal precision.[322-323] 
Furthermore, visible light is non-invasive and not inherently toxic. As a matter of fact, significant 
efforts have been devoted to shifting the absorption spectrum of all types of photoswitches to the 
red in order to increase tissue penetration and decrease the harmful effects of short-wavelength 
light, both by chemical and biochemical methods.[324-334] With light, the desired signal can be 
generated in a dosed fashion by varying the intensity and exposure time at the exact location by 
simply focusing with an illumination device. In addition, most biological systems are not 
inherently sensitive to light, therefore a light pulse does not interfere with the system itself. One 
approach to confer light sensitivity is to use “caged” compounds, biologically inactive molecules 
such as 2.1 that are activated by the removal of a photoreactive protecting group 2.2 to reveal the 
target molecule 2.3 (Scheme 2.1). [335] This method has, for example, allowed in-depth studies of 
the kinetics of glutamate receptors using caged glutamate and the dissection of neuronal 
circuitry.[336] One drawback of this method is the irreversible nature of the uncaging process, thus 
necessitating the addition of more substrate and clearance of the uncaged active agent to repeat 
the uncaging process. Furthermore, the cleaved protecting group can be toxic or have undesired 
side effects.[337] 
 

In the last decade, a novel class of photosensitive compounds has emerged to control biological 
function with light. In contrast to caged compounds, these reversible photoswitches feature a 
photosensitive moiety that can be switched back and forth with discrete and orthogonal 
wavelengths of light. Apart from inherently photosensitive proteins, such as channel- and 
halorhodopsins that use retinal as the photoswitchable unit, azobenzene photoswitches have 
attracted considerable attention.[338] These synthetic photoswitches can be divided in two classes 
according to the nature of their interaction with the target protein (Figure 2.1). 
 
The first class consists of so-called photochromic ligands (PCLs), which are freely diffusible 
azobenzene units connected to ligands for specific targets that can bind to wild-type proteins. The 
 
second class are so-called photochromic tethered ligands (PTLs), which follow a different design 
principle. A maleimide moiety (blue) covalently attaches the photoswitch to the protein of interest 
via residual or, more commonly, genetically engineered cysteine moieties (Figure 2.1). In both 
cases, their azobenzene portion (red) can be isomerized back and forth between its cis- and trans-
state using light with two different wavelengths. In terms of photopharmacology, the 
conformational change reduces or enhances the efficacy of the ligand (PCL) or allows the ligand 
to be unleashed towards or withdrawn from its binding site (PTL), thus modulating the activity of 
the protein under investigation. 
It is key to the success of a photoswitch to determine the correct position of the photochromic 
moiety within the ligand. Looking at the available ligands, one has to identify compounds that 
could fit the guidelines laid out in the so-called “azologization” concept (Scheme 2.2).[339] In short, 
this entails the identification of motifs within known bioactive compounds that could be replaced 
with an azo unit (2.4). Ideally, properties like shape and size of the molecule are not drastically 
changed by this modification, the obvious exception being the introduction of a light-sensitive 
unit that can subsequently be used to change the drug’s efficacy with light. These “azosteric” 
units include for example stilbenoid compounds 2.5 and diphenylethanes 2.6, benzyl (thio-)ethers 
and amines 2.7 as well as diaryl (thio-)esters and amides 2.8. The first example for this approach 
was the azologization of the channel blocker fomocaine (2.9) to the photoswitchable fotocaine 
(2.10).[339] 
 
In the absence of an obvious azologization site, one con take to structure-activity relationship 
studies in order to identify positions that could accommodate an additional bulky hydrophobic 
azobenzene moiety protruding from the ligand. This complementary approach is referred to as 
azo-extension.[319, 340-341] 
This approach was applied by the Trauner group to several biological systems in vitro and in vivo, 
showing the versatility of this method. Using a glutamate-based PTL approach, control of an 
ionotropic glutamate receptor (iGluR6) could be achieved, turning a “blind” receptor into the 
light-gated, photosensitive receptor “LiGluR” (Figure 2.2).[342] 
 
Upon irradiation with  = 380 nm, the azobenzene is converted to its cis-state, moving the 
glutamate portion in proximity of the ligand-binding domain, which causes binding and 
subsequent pore opening. Irradiation with  = 500 nm reverses this process and therefore closes 
the pore. Recently, this concept has been extended to three metabotropic receptors (mGluRs).[343] 
The most thoroughly characterized “LimGluR2” was used, inter alia, to control the escape reflex in 
zebrafish larvae. More recently, the sometimes capricious cysteine-maleimide combination[344-345] 
was replaced with the SnAP-Tag methodology.[346] 
Apart from glutamate receptors, the azobenzene photoswitch concept has been successfully 
applied to the development of PCL and PTL potassium channel blockers with implications for 
vision restoration in mice models.[347-350] Other notable applications include the inhibition of 
bacterial survival and the reversible blocking of P2X channels, with other targets constantly being 
added.[318, 320, 338, 351-354] While these examples clearly show the potential of azobenzenes and related 
photoswitches, some receptors of high interest have remained untouched until recently. One 
example is another class of glutamate receptors which play a highly important role in the brain, 
namely the NMDA receptors (NMDARs). 
  
 
 
In the last decades, one main field of research has been the biology and chemistry of glutamate 
receptors.[355] Throughout the nervous system and especially the brain, the amino acid glutamate 
(2.3) mediates the majority of excitatory neurotransmission as it acts on two main types of 
membrane receptors, metabotropic and ionotropic glutamate receptors. The iGluRs are cation-
permeable ion channels, divided into three subclasses, each named after a selective synthetic 
agonist: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (2.11, AMPA receptors), kainic 
acid (2.12, kainate receptors) and N-Methyl-D-aspartic acid (2.13, NMDA receptors), as shown in 
Figure 2.3.[355-356] 
 
Sequence similarity suggests they all share the same overall structure, consisting of four 
semiautonomous domains: the extracellular N-terminal domain (ATD), the extracellular ligand-
binding domain (LBD), the transmembrane domain (TMD) and the intracellular C-terminal 
domain.[357-358] The recently published first crystal structure of a full NMDA receptor with all four 
subunits is shown in Figure 2.4.[359] NMDARs have kept fascinating neuroscientists due to their 
central role in the functioning of the central nervous system.[355] They possess the unique feature 
of being both voltage- and ligand-gated ion channels and are so-called coincidence detectors. The 
NMDA receptors are essential for the induction and maintenance of synaptic plasticity, in the 
process of learning and memory, but also in neurological diseases, where they play an important 
role in excitotoxicity.[360] In this process, an excess of glutamate release results in overexcitation of 
neurons, eventually inducing cell death by a large influx of calcium ions.[361] Therefore, it comes as 
no surprise that treatments for a wide variety of neurological and psychiatric disorders are 
focused on the modulation of NMDA receptors. 
 
These include widespread neurodegenerative conditions such as Alzheimer’s, Huntington’s and 
Parkinson’s diseases, but also acute clinical conditions such as stroke.[362-364] The development of 
selective antagonists is a complex and challenging task due to the multitude of binding sites and 
the structural diversity of NMDA receptors. All NMDARs are tetrameric complexes that are 
composed of several homologous subunits, the NR1 subunit with eight splice variants (NR1a-h), 
the NR2 subunit with four subtypes (NR2A-D) encoded by four different genes and the NR3 
subunit with two subtypes NR3A and NR3B that are encoded by two separate genes.[357, 365] 
Functional NMDARs consist of at least one NR1 subunit bearing the glycine-binding site and one 
NR2 subunit bearing the glutamate binding site. The composition of the NMDARs varies 
depending on the location within the nervous system, but also as a function of age, yielding 
receptors with a wide pharmacological variety.[357, 365] Therefore, it would be highly beneficial to 
selectively control NMDA activity with photopharmacology in order to further study these 
important channels in a reversible manner. This would lead to deeper insights into their function, 
ultimately paving the way to understand their role in health and disease. 
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As part of a research program related to the photopharmacology of nuclear receptors, we 
became interested in the so-called peroxisome proliferator-activated receptors (PPARs).[366-367] 
These are ligand-activated nuclear receptors that function as transcription factors and share a 
high degree of structural homology with many other nuclear hormone receptors such as 
retinoid X receptors, with which they form obligate heterodimers.[368] PPARs play a vital role in 
many metabolic pathways that reaches far beyond the stimulation of peroxisome proliferation 
for which they were initially named.[369] There are three PPAR isotypes called PPARα, PPARβ/δ 
and PPARγ. These receptors are widely expressed across many tissue types, but the expression 
level of the three subtypes depends strongly on the tissue. PPARα is mostly expressed in tissues 
with high fatty acid metabolism; PPARβ/δ features a much broader and variable expression 
pattern, depending on the extent of cell proliferation and differentiation. Metabolic functions of 
this subtype were assigned in the gut, skin and brain, amongst others. 
PPARγ is found in most tissues except muscles, but its main functions are in adipose tissue and 
the large intestine. PPARγ plays a key role in the regulation of genes related to adipogenesis, 
energy balance, and lipid biosynthesis.[370-372] Physiologically, the ligands for PPARγ are fatty 
acids such as arachidonic acid and derivatives like the prostaglandins. Given the implication of 
this nuclear receptor in a variety of fatty acid-related diseases like obesity and diabetes, it comes 
as no surprise that significant attention has been devoted to the development of synthetic 
ligands for PPARγ. A particularly well-developed class of ligands, whose members act as 
insulin sensitizers, is the thiazolidinedione (TZD) family.[373] While quite diverse in structure, all 
members of the TZD class bear this polar head group (see 3.1–3.4, Figure 3.1). Attached to this 
moiety is a benzyl unit, from which a diverse set of spacers and other substituents protrude.[374] 
In many cases, the linker is a short (C1–C3) alkyl chain connected to another aromatic portion, 
often a N-heterocycle. 
We were attracted to this class of nuclear hormone receptors because of the side effects 
associated with TZD[375-376] and the potential benefits of photoswitchable derivatives thereof. 
Furthermore, in a more general sense, photoswitchable TZDs hold promise as general tools for 
the optical control of gene expression. A third reason is that X-ray crystal structure of the 
                                                          
 
1In vitro assays in HEK cells were performed by Dr. Johannes Broichhagen and Philipp Leippe; in vitro 
assays in preadipocytes were performed by Lisa Suwandhi, PhD student in the Ussar group at the 
Helmholtz Zentrum München. 
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PPARγ ligand binding domain possesses a large binding pocket, explaining the large structural 
variety of ligands and increasing the probability of a photoswitch to be accommodated.[377] 
 
 
Following our azologization rationale,[339] we reasoned that rosiglitazone (3.1), an FDA-
approved insulin sensitizer, would represent a good template for the incorporation of an 
azobenzene unit (Scheme 2.2). The synthesis of our derivatives was straightforward: Following 
a modified literature procedure, aniline 3.9 was accessed in four steps.[378] 
Thiazolidine-2,4-dione (3.6) was obtained by condensation of chloroacetic acid (3.5) with 
thiourea, then condensed with p-nitrobenzaldehyde in a Knoevenagel-like reaction to give 3.7. 
A range of reduction conditions were explored to reduce the alkene and nitro group in one step, 
and ultimately, we settled for a 1,4-reduction using Hantzsch ester to give nitroaryl 3.8 followed 
by palladium-catalyzed hydrogenation to the aniline 3.9. With this intermediate in hand, three 
azologs of rosiglitazone (3.1), FEH-2-107 (3.11), FEH-2-110 (3.10) and FEH-2-111 (3.12), were 
γ
obtained by azo or Mills coupling in moderate yields. These azobenzenes showed regular UV-
Vis absorption spectra: the unsubstituted and CF3-substituted compounds were most efficiently 
isomerized to the cis-isomer with 340 nm light and relaxed thermally to the trans-isomer within 
10 min in the dark, the NEt2-substituted photoswitch isomerized to the cis-form at 420 nm and 
relaxed back to the trans form within seconds. 
 
With a regular (3.11), an electron-poor (3.12) and electron-rich (3.10) azobenzene in hand, we 
evaluated our compounds using a PPARγ luciferase reporter assay in transfected HEK293T cells 
to see whether our compounds were able to activate PPARγ in vitro. As can be seen in 
Figure 3.2, all three compounds are functional mimics of rosiglitazone (3.1), which served as the 
positive control (not shown). From this first assay, FEH-2-110 (3.10) emerged as the most 
promising candidate, showing the largest difference between dark and irradiation even though 
it was irradiated at a wavelength quite distant from its absorption maximum. FEH-2-107 (3.11) 
and FEH-2-111 (3.12) showed activation at higher concentrations, but the effect was much less 
pronounced and we reasoned that the 370 nm irradiation needed would be problematic in long-
term in vivo applications. Therefore, we investigated FEH-2-110 further using 435 nm light. As 
can be seen in Figure 3.3, the photoswitch acts an activator at nanomolar concentrations under 
blue light whereas negligible activation is observed in the dark even at higher concentrations. 
The azologization template rosiglitazone (3.1) thus is about one magnitude more potent. 
γ
 
 
Therefore, our assumption guided by crystal structure analysis that an azobenzene in its cis 
state could act as a functional mimic rosiglitazone was confirmed. 
 
 
Given these encouraging results, we were interested in investigating our lead compound 
FEH-2-110 in a more advanced in vitro setting. An intriguing application would be the 
regioselective induction of cell differentiation, which is caused inter alia by PPARγ activation, 
with light. We thus tested whether our compounds could induce the differentiation of 
γ
preadipocytes into adipocytes with an Oil red O staining assay, which is commonly carried out 
with rosiglitazone. Here, it served as positive control. Oil red O is a lipophilic reagent which 
stains triglycerides and other lipids, which are enriched in adipocytes. The optical density 
recorded thus serves as a measure of preadipocyte differentiation. 
 
To our disappointment, none of the compounds showed significant induction of cell 
differentiation in a light-dependent manner. FEH-2-107 (3.11), the azo-TZD bearing an 
unsubstituted azobenzene, was the only compound to induce cell differentiation at 100 µM. 
Rosiglitazone (3.1), the positive control, induced differentiation at 2 µM. 
At this stage, it became apparent that the present compounds 3.10–3.12 were not suitable for 
this more advanced in vitro assay. Possible reasons include reductive cleavage by azobenzene 
reductase[379] Hence, two more azo-TZD were prepared for future testing.[380] In this series, we 
decided to keep the phenol commonly used in TZD synthesis and etherify it with three 
azobenzene-containing electrophiles. Their synthesis is depicted in Scheme 3.2. Again starting 
from TZD (3.6), condensation with p-hydroxybenzaldehyde gave 3.13, which was reduced to 
phenol 3.14 with Hantzsch ester. The phenol was then treated with two alkyl bromides 3.15 and 
3.16 to yield the two photoswitches 3.17 and 3.18 connected to the benzyl-TZD unit with a C2 
chain. A third photoswitch 3.20 was obtained with a similar method using electrophile 3.19. All 
three need to be purified further before they can be evaluated in in vitro or in vivo assays. 
 
γ
 
 
In addition to these TZD-based PPARγ activators, future work will consist of exploring 
azobenzenes based on other scaffolds, some of which are depicted in Scheme 3.3.[380-381] 
 
All three compounds are part of the fibrate class. Fibrates have long been used in combination 
with statins to reduce the risk of cardiovascular events, mainly by lowering triglyceride levels 
γ
and reducing insulin resistance.[382-385] In general, these compounds feature a carboxylic acid 
thought to be a bioisostere of the TZD heterocycle on one side of the molecule and bulky 
aromatic moieties on the other side. With an aliphatic linker inbetween, they are thought to 
bind to PPAR similarly to the thiazolidines (Figure 3.5). 
 
In both cases, the polar head group is thought to be involved in a hydrogen bond network, the 
central section shows hydrophobic interaction with helix 3 of PPAR and the large hydrophobic 
section mainly occupies the large cavity of the binding pocket.[377] Although they also act on 
PPAR, most fibrates activate PPARα rather than PPARγ.[386] However, 3.20,[387] 3.22[388] and 
3.24[389] were found to be powerful activators of PPARγ. An added advantage of these 
compounds over TZD-based agonists woulde be the possibility to prepare them as single 
enantiomers. It was shown that only one enantiomer of rosiglitazone (3.1) acts as an agonist of 
PPARγ, but it is administered as a racemate due to rapid isomerization under physiological 
conditions.[390] In the cases of molecules like 3.20 or 3.22, the homobenzylic position is much less 
prone to racemization. 
 
 
 
Unless stated otherwise, all reactions were performed with standard Schlenk techniques under 
an atmosphere of nitrogen in oven-dried glassware (100 °C oven temperature) that was further 
dried using a heat gun (set to 650 °C) for all water-sensitive reactions. Tetrahydrofuran (THF) 
and diethyl ether (Et2O) were distilled prior to use from sodium and benzophenone, 
triethylamine (Et3N), and dichloromethane (CH2Cl2) were distilled from calcium hydride. N,N-
dimethylformamide (DMF), acetonitrile (MeCN), and methanol (MeOH) were purchased from 
Acros Organics as 'extra dry' reagents under inert gas atmosphere and over molecular sieves. 
All other reagents were purchased from commercial sources and used without further 
purification. Reaction progress was monitored by analytical thin-layer chromatography (TLC), 
which was carried out using pre-coated glass plates (silica gel 60 F254) from Merck. Visualization 
was achieved by exposure to ultraviolet light (254 nm) where applicable followed by staining 
with potassium permanganate solution. Flash column chromatography was performed using 
Merck silica gel (40–63 µm particle size). Proton nuclear magnetic resonance (1H NMR) spectra 
were recorded on a Varian 400, Inova 400, Varian 600 or Varian 800 spectrometer. Chemical 
shifts (δ scale) are expressed in parts per million (ppm) and are calibrated using residual protic 
solvent as an internal reference (CHCl3: δ = 7.26 ppm, CD2HOD: δ = 3.31 ppm, DMSO-d5: 
δ = 2.50 ppm). Data for 1H NMR spectra are reported as follows: chemical shift (ppm) 
(multiplicity, coupling constants (Hz), integration). Couplings are expressed as: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, or combinations thereof. Carbon nuclear 
magnetic resonance (13C NMR) spectra were recorded on the same spectrometers at 100, 150 and 
200 MHz (±1 MHz variance). Carbon chemical shifts (δ scale) are also expressed in parts per 
million (ppm) and are referenced to the central carbon resonances of the solvents (CDCl3: 
δ = 77.16 ppm, CD3OD: δ = 49.00 ppm). In order to assign the 1H and 13C NMR spectra, a range 
of 2D-NMR experiments (COSY, HMQC, HMBC, NOESY) was used as appropriate. Infrared 
(IR) spectra were recorded on a Perkin Elmer Spectrum BX II (FTIR System) equipped with an 
attenuated total reflection (ATR) measuring unit. IR data are reported in frequency of 
absorption (cm−1). Mass spectroscopy (MS) experiments were performed on a Thermo Finnigan 
MAT 95 (electron ionization, EI) or on a Thermo Finnigan LTQ FT (electrospray ionization, ESI) 
instrument. 
  
 
 
 
Three drops of dibromoethane were added to Mg chips (49.0 mg, 2.00 mmol, 4.00 eq.) in THF 
(5 mL). After short heating the reaction mixture was cooled back to room temperature and (4-
bromobut-1-yn-1-yl)trimethylsilane (308 mg, 1.50 mmol, 3.00 eq.) was added dropwise. The 
reaction mixture was stirred at 50 °C for 1.5 h, then slowly cooled down to 78 °C. CuBr·SMe2 
(21 mg, 0.10 mmol, 0.20 eq.) was added in one portion. After stirring for 15 min, the enone 
(0.50 mmol, 1.0 eq.) in THF (1.0 mL), TMSCl (126 µL, 1.00 mmol, 2.0 eq.) and HMPA (174 µL, 
1.00 mmol, 2.0 eq.) were added sequentially to the brownish suspension. The reaction was 
stirred until judged complete by TLC analysis, then quenched with saturated aqueous NH4Cl 
(4 mL), warmed to room temperature, diluted with H2O (4 mL) and extracted with ether 
(3×5 mL). The combined organic layers were washed with H2O (10 mL) and saturated aqueous 
NaCl (10 mL), dried over MgSO4 and concentrated by vacuum evaporation. The residue was 
dissolved in THF (5 mL) and cooled to 0 °C. After dropwise addition of TBAF (1M in THF, 
1.50 mL, 1.50 mmol, 3.00 eq.), the reaction mixture was allowed to warm to room temperature 
and stirred until TLC analysis indicated full conversion. Saturated aqueous NH4Cl (10 mL) and 
H2O (5 mL) were added, followed by extraction with ether (3×15 mL). The combined organic 
layers were washed with H2O (10 mL) and saturated aqueous NaCl (20 mL), dried over MgSO4 
and concentrated by vacuum evaporation. The obtained brown oil was purified by column 
chromatography (pentane:Et2O) to give the ketone as an inconsequential mixture of 
diastereomers. 
 
 
To a solution of KOt-Bu (11 mg, 0.10 mmol, 1.0 eq.) in degassed DMSO (3.0 mL), ynone 
(0.10 mmol) in degassed DMSO (1.0 mL) was added dropwise. The mixture was stirred at room 
temperature, monitoring by TLC. After 30 min, pH 5.5 phosphate buffer (1.0 mL) and H2O 
(10 mL) were added and the aqueous phase was extracted with Et2O (3×15 mL). The combined 
organic phases were washed with H2O (10 mL) and saturated aqueous NaCl (15 mL), dried over 
 
MgSO4 and concentrated by vacuum evaporation. After purification by column 
chromatography over silica gel (pentane:Et2O 20:1), analytically pure products were obtained. 
 
Non-commercial starting materials were prepared according to literature procedures unless 
specified otherwise. Spectral data obtained matched literature values. 
(R)-2-iodo-5-methylcyclohex-2-en-1-one: Chem. Commun. 2006, 4928 
2-methyl-2-cyclohexen-1-one: J. Org. Chem. 1990, 55, 4995 
(4-bromobut-1-yn-1-yl)trimethylsilane: Chem. Commun. 2013, 49, 4012 
2-methyl-3-(4-(trimethylsilyl)but-3-yn-1-yl)cyclohexan-1-one: J. Am. Chem. Soc. 1988, 110, 3315. 
tert-butyl 4-oxo-3,4-dihydropyridine-1(2H)-carboxylate: J. Am. Chem. Soc. 2011, 133, 14566. 
1-methylquinolin-4(1H)-one: Chem. Eur. J. 2015, 21, 2339. 
4'-methoxy-4,5-dihydro-[1,1'-biphenyl]-2(3H)-one: J. Org. Chem. 2005 , 70, 8575. 
4'-bromo-4,5-dihydro-[1,1'-biphenyl]-2(3H)-one: J. Org. Chem. 2005 , 70, 8575. 
(R)-2-allyl-5-methylcyclohex-2-en-1-one: Angew. Chem. Int. Ed. 2007, 46, 7671. 
dimethyl 2-(3-oxocyclohexyl)-2-(prop-2-yn-1-yl)malonate: Angew. Chem. Int. Ed. 2005, 44, 5273. 
 
Note: In the following, the numbering corresponds to the numbering in the manuscript reprinted in 
chapter 1.2.2. 
 
 
 
 
3-(but-3-yn-1-yl)-2-methylcyclohexan-1-one (12). Compound 12 was prepared according to 
general procedure A in 79% yield. 
 
Rf   0.50 (hexanes:EtOAc 5:1). Colorless liquid. 
1H NMR  (599 MHz, CDCl3) δ = 2.64–2.57 (m, 1H), 2.45–2.38 (m, 1H), 2.34–2.24 (m, 2H), 
2.24–2.11 (m, 2H), 2.06 (ddq, J = 13.6, 6.0, 3.8, 1H), 2.02–1.96 (m, 1H), 1.96–1.94 
(m, 1H), 1.88 (dtd, J = 13.6, 8.2, 3.5, 1H), 1.83–1.75 (m, 1H), 1.75–1.69 (m, 1H), 
1.69–1.62 (m, 1H), 1.62–1.54 (m, 2H), 1.50–1.42 (m, 1H), 1.39 (dddd, J = 15.3, 9.5, 
4.6, 2.2, 1H), 1.08 (dd, J = 6.6, 0.6, 3H), 1.03 (dd, J = 7.1, 0.6, 1H). 
13C NMR  (151 MHz, CDCl3) δ = 214.4, 213.1, 84.0, 83.8, 68.9, 68.8, 50.0, 48.7, 44.6, 41.5, 41.0, 
39.8, 32.8, 29.9, 27.8, 26.6, 25.8, 24.0, 16.2, 15.8, 12.2, 11.6. 
IR   (ATR): 3290 w, 2934 m, 2866 w, 1708 s, 1457 w, 1445 w, 1312 w, 1220 w. 
HRMS   (EI): calculated for C11H16O 164.1201, found 164.1199. 
 
 
 
 
3-(but-3-yn-1-yl)-2-methylcyclopentan-1-one (14). Compound 14 was prepared according to 
general procedure A in 79% yield. 
 
Rf   0.48 (hexanes:EtOAc 5:1). Colorless liquid. 
1H NMR  (599 MHz, CDCl3) δ = 2.41–2.31 (m, 2H), 2.29–2.23 (m, 1H), 2.22–2.16 (m, 1H), 
2.16–2.08 (m, 1H), 1.98–1.92 (m, 2H), 1.84–1.76 (m, 1H), 1.77–1.69 (m, 1H), 1.53–
1.46 (m, 1H), 1.42–1.33 (m, 1H), 1.08 (d, J = 6.8, 3H). major isomer. 
13C NMR  (151 MHz, CDCl3) δ = 220.75, 84.04, 68.92, 50.36, 43.86, 37.48, 33.38, 26.99, 16.55, 
12.80. major isomer. 
IR   (ATR): 3292 w. 2932 w, 2873 w, 1735 s, 1653 w, 1558 w, 1456 w, 1163 w, 1036 w. 
HRMS   (EI): calculated for C10H14O 150.1045, found 150.1051 
 
 
 
 
(3R,5R)-3-(but-3-yn-1-yl)-2-methyl-5-(prop-1-en-2-yl)cyclohexan-1-one (18). Compound 18 was 
prepared according to general procedure A in 81% yield. 
 
Rf   0.56 (hexanes:EtOAc 5:1). Pale-yellow oil. 
1H NMR  (599 MHz, CDCl3) δ = 4.83 (d, J = 1.3, 1H), 4.79 (t, J = 1.5, 1H), 4.76–4.74 (m, 1H), 
4.72–4.70 (m, 1H), 2.71–2.65 (m, 1H), 2.65–2.61 (m, 1H), 2.61–2.55 (m, 1H), 2.50 
(td, J = 12.0, 6.0, 1H), 2.44 (ddd, J = 13.3, 4.5, 1.9, 2H), 2.39 (ddt, J = 14.3, 5.3, 1.1, 
 
1H), 2.34–2.19 (m, 4H), 2.19–2.15 (m, 1H), 2.15–2.09 (m, 2H), 2.04 (dddd, J = 13.8, 
7.6, 4.0, 1.2, 1H), 2.01–1.96 (m, 1H), 1.95 (t, J = 2.6, 1H), 1.87–1.75 (m, 2H), 1.75 (s, 
3H), 1.63 (m, 2H), 1.48 (dddd, J = 13.6, 8.7, 7.5, 6.0, 1H), 1.25–1.17 (m, 1H), 1.15 
(d, J = 6.9, 3H), 1.03 (d, J = 6.8, 3H). 
13C NMR  (151 MHz, CDCl3) δ = 213.6, 212.6, 147.4, 146.9, 111.6, 110.3, 83.8, 83.6, 69.0, 49.6, 
48.5, 46.4, 43.8, 41.1, 40.6, 39.9, 39.2, 32.8, 32.3, 30.8, 25.7, 21.6, 20.8, 16.4, 16.1, 
14.4, 11.8. 
HRMS   (EI): calculated for C14H20O 204.1514, found 204.1516. 
 
 
 
 
Tert-butyl allyl(hex-4-yn-1-yl)carbamate (S1). Sodium hydride (60%, 312 mg, 7.80 mmol, 
1.30 eq.) was added in one portion to Boc-protected allylamine (943 mg, 6.00 mmol, 1.00 eq.) in 
dry DMF (21 mL) at 0 °C to give an orange suspension. After 20 min, 4-hexynyl iodide (1.87 g, 
9.00 mmol, 1.50 eq.) was added dropwise at 0 °C. After the addition was complete, the ice bath 
was removed and the reaction was stirred at room temperature for 22 h. When the reaction was 
judged complete by TLC, saturated aqueous NH4Cl (15 mL) and H2O (10 mL) were added 
carefully. The aqueous phase was extracted with Et2O (3×30 mL), then the combined organic 
phases were washed with saturated aqueous NaCl (30 mL), dried, filtered and evaporated to 
give a yellow residue that was purified by column chromatography (hexanes:EtOAc 15:1) to 
give the desired product S1 as a colorless oil (1.33 g, 5.60 mmol, 93%). 
 
Rf   0.67 (hexanes:EtOAc 5:1). Colorless oil. 
NMR spectra were obtained at 353 K due to extensive rotamer line broadening. 
1H NMR  (400 MHz, DMSO-d6) δ = 5.84–5.73 (m, 1H), 5.16–5.06 (m, 2H), 3.78 (dt, J = 5.7, 
1.5, 2H), 3.21 (t, J = 7.2, 2H), 2.09 (tq, J = 7.2, 2.5, 2H), 1.73 (t, J = 2.6, 3H), 1.64 (p, 
J = 7.1, 2H), 1.42 (s, 9H). 
13C NMR  (101 MHz, DMSO-d6) δ = 154.2, 134.2, 115.4, 78.0, 75.1, 48.8, 45.3, 27.6, 27.2, 15.3, 
2.4. Note: one alkyne carbon could not be observed. 
IR  (ATR): 3617 w, 3081 w, 2975 m, 2921 w, 1690 s, 1644 w, 1462 m, 1407 m, 1365 m, 
1245 m, 1162 s, 1099 m, 997 w, 916 m, 772 m. 
HRMS  (EI): calculated for C10H15NO2 (-tBu) 181.1103 found 181.1082, Calculated for 
C9H14N (-Boc) 136.1126 found 136.1131. 
 
 
 
 
Tert-butyl (R)-hex-4-yn-1-yl(3-(4-methyl-6-oxocyclohex-1-en-1-yl)propyl)carbamate (S2). 
To a solution of S1 (855 mg, 3.60 mmol, 1.00 eq.) in THF (5 mL) at 0 °C was added a 9-BBN 
solution (0.5 M in THF, 8.60 mL, 4.30 mmol, 1.20 eq.) dropwise. After 30 min at 0 °C, the mixture 
was warmed to room temperature and stirred for 2.5 h. In a separate flask, SPhos-Pd G2 
(108 mg, 0.15 mmol, 0.04 eq.), SPhos (62 mg, 0.15 mmol, 0.04 eq.) and cesium carbonate (1.95 g, 
6.00 mmol, 2.00 eq.) were dissolved in a degassed mixture of DMF (27 mL) and H2O (3 mL) 
before the contents of the first flask were cannulated in (rinsed with 1 mL to quantitate 
transfer). The now cloudy reaction mixture was then heated to 50 °C for 3 h, at which point TLC 
indicated full conversion. The reaction was treated with saturated aqueous NH4Cl (20 mL), 
extracted with EtOAc (3×30 mL), washed with saturated aqueous NaCl (2×20 mL), then dried 
filtered and concentrated. The brown residue was purified by column chromatography 
(pentane:Et2O 6:1) to give S2 as a brown oil (788 mg, 2.28 mmol, 76%). 
 
Rf   0.37 (hexanes:EtOAc 5:1) Brown oil. 
1H NMR  (599 MHz, CDCl3) δ = 6.69 (s, 1H), 3.22 (d, J = 7.2, 2H), 3.15 (d, J = 23.9, 3H), 2.50–
2.43 (m, 1H), 2.39 (d, J = 18.3, 1H), 2.14 (t, J = 8.0, 2H), 2.12–2.04 (m, 2H), 2.05–
1.98 (m, 1H), 1.76 (t, J = 2.6, 3H), 1.70–1.63 (m, 2H), 1.65–1.56 (m, 2H), 1.43 (s, 
9H), 1.03 (d, J = 6.5, 3H). 
13C NMR  (151 MHz, CDCl3) δ = 199.7, 155.7, 144.9, 144.4, 138.9, 79.3, 78.5, 76.0, 47.5, 46.8, 
46.4, 34.5, 30.8, 29.8, 28.6, 28.2, 27.8, 27.1, 26.9, 21.3, 16.4, 3.6. 
IR  (ATR): 3486 w, 2954 m, 2923 m, 2360 w, 1690 s, 1675 s, 1470 m, 1455 m, 1365 m, 
1298 m, 1251 m, 1167 s, 1122 m, 922 w, 889 w, 773 w. 
HRMS   (ESI): calculated for C21H34NO3+ 348.2533, found 348.2533. 
 
 
 
 
Tert-butyl (R)-hex-4-yn-1-yl(3-(4-methyl-6-oxocyclohex-1-en-1-yl)propyl)carbamate (1). 
 Compound 1 was prepared according to general procedure A in 65% yield. 
 
Rf   0.31 (hexanes:EtOAc 5:1). Pale-yellow oil. 
1H NMR  (599 MHz, CDCl3) δ 3.27–3.12 (m, 4H), 2.49 (d, J = 22.0, 1H), 2.36 (d, J = 11.6, 1H), 
2.21 (d, J = 8.7, 2H), 2.15–2.08 (m, 4H), 2.01–1.98 (m, 1H), 1.94 (td, J = 2.7, 1.2, 
1H), 1.77 (t, J = 2.5, 5H), 1.68 (dq, J = 14.6, 6.3, 5.2, 7H), 1.45 (s, 15H), 1.19–1.13 
(m, 1H), 1.01 (d, J = 5.9, 3H), 0.99 (d, J = 6.3, 2H). 
13C NMR  (151 MHz, CDCl3) δ = 211.9, 155.5, 83.5, 79.2, 78.4, 75.9, 68.8, 54.5, 53.5, 50.2, 
(46.9, 46.3), 39.2, 36.2, 33.4, 31.9, 30.0, 29.7, 29.5, 28.4, 28.0, 27.7, 26.7, 26.2, (25.6, 
25.4), 23.4, 23.3, 22.2, 21.7, 16.3, 16.2, 3.5. (not all peaks of both isomers can be 
observed, some peaks are doublets due to rotamers), 
IR  (ATR): 3473 w, 3288 w, 2958 m, 2928 m, 2358 w, 1815 w, 1690 s, 1478 m, 1454 m, 
1416 m, 1366 m, 1299 m, 1247 m, 1166 m, 1056 w, 889 w. 
HRMS   (ESI): calculated for C25H40NO2 402.3003, found 402.3004. 
 
 
 
 
(5R)-5-Methyl-2-(2-methylhex-5-yn-2-yl)cyclohexan-1-one (22). Compound 22 was prepared 
according to general procedure A in 84% yield. 
 
Rf   0.69 (hexanes:EtOAc 5:1). Colorless liquid. 
1H NMR  (800 MHz, CDCl3) δ = 2.29 (ddd, J = 12.3, 4.1, 2.2, 1H), 2.20 (ddd, J = 13.1, 4.8, 1.2, 
1H), 2.15–2.11 (m, 3H), 2.04 (td, J = 12.5, 1.3, 1H), 1.96–1.90 (m, 2H), 1.90–1.83 (m, 
2H), 1.63–1.57 (m, 1H), 1.48 (qd, J = 13.1, 3.3, 1H), 1.39–1.31 (m, 1H), 1.03–1.01 
(m, 6H), 0.98 (s, 3H). 
13C NMR  (201 MHz, CDCl3) = 211.9, 85.5, 77.4, 68.1, 57.4, 52.7, 38.9, 36.6, 34.9, 28.4, 24.9, 
24.4, 22.5, 13.6. 
IR   (ATR): 3312 w, 2954 m, 1709 s, 1559 w, 1457 w, 1364 w. 
HRMS   (EI): calculated for C13H19O (-Me) 191.1436, found 191.1443. 
 
 
 
 
3-(4-Chlorobut-3-yn-1-yl)-2-methylcyclohexan-1-one (24). To 2-methyl-3-(4-(trimethylsilyl)but-
3-yn-1-yl)cyclohexan-1-one (95 mg, 0.40 mmol, 1.0 eq.), NCS (107 mg, 0.80 mmol, 2.0 eq.) and 
AgNO3 (20 mg, 0.12 mmol, 0.30 eq.) suspended in MeCN (2 mL) was added a TBAF solution 
(1.0 M in THF, 0.24 mL, 0.24 mmol, 0.60 eq.) dropwise at 0 °C under exclusion of light. After 
20 h, the suspension was concentrated and directly purified by column chromatography 
(pentane:Et2O 7:1) to give 24 as a colorless oil (70 mg, 0.35 mmol, 88%). 
 
Rf   0.54 (hexanes:EtOAc 5:1), colorless oil. 
1H NMR  (800 MHz, CDCl3) δ 2.63–2.56 (m, 1H), 2.44–2.38 (m, 1H), 2.32–2.26 (m, 2H), 
2.23–2.08 (m, 3H), 2.06 (ddq, J = 13.6, 6.0, 3.8, 1H), 1.98–1.94 (m, 1H), 1.92–1.83 
(m, 1H), 1.82–1.76 (m, 1H), 1.75–1.69 (m, 1H), 1.68–1.62 (m, 1H), 1.55–1.52 (m, 
1H), 1.48–1.31 (m, 2H), 1.07 (d, J = 6.6, 3H), 1.02 (d, J = 7.0, 1H). 
13C NMR  (201 MHz, CDCl3) δ =.214.1, 212.8, 69.0, 68.8, 57.7, 57.7, 49.8, 48.5, 44.5, 41.3, 40.9, 
39.6, 32.6, 29.8, 27.7, 26.5, 25.6, 23.8, 16.5, 16.1, 12.0, 11.4. 
IR  (ATR): 2935 m, 2866 w, 2241 w, 1708 s, 1447m, 1430 m, 1313 w, 1219 w, 1082 w, 
957 w. 
HRMS   (EI): calculated for C11H15ClO 198.0811, found 198.0824. 
 
 
 
 
 
3-(But-3-yn-1-yl)-2-(4-methoxyphenyl)cyclohexan-1-one (26). Compound 26 was prepared 
according to general procedure A in 75% yield. 
 
Rf   0.22 (hexanes:EtOAc 5:1). colorless liquid. 
1H NMR  (800 MHz, CDCl3) δ = 6.99 (d, J = 8.7, 2H), 6.88 (d, J = 8.7, 2H), 3.80 (s, 3H), 3.24 
(d, J = 12.2, 1H), 2.57–2.51 (m, 1H), 2.43 (tdd, J = 13.7, 5.9, 1.1, 1H), 2.20–2.11 (m, 
4H), 2.11–2.05 (m, 1H), 1.89 (t, J = 2.6, 1H), 1.83–1.76 (m, 1H), 1.55–1.46 (m, 2H), 
1.32–1.25 (m, 1H). 
13C NMR  (201 MHz, CDCl3) δ = 210.2, 158.7, 130.4, 129.1, 114.1, 83.9, 68.8, 62.9, 55.4, 44.1, 
42.0, 33.4, 30.7, 25.9, 16.0. 
IR  (ATR): 3289 w, 2937 w, 2863 w, 1710 s, 1612 w, 1513 s, 1444 w, 1284 w, 1247 s, 
1179 m, 1034 m, 818 w. 
HRMS   (EI): calculated for C17H20O2 256.1463, found 256.1467. 
 
 
 
 
2-(4-Bromophenyl)-3-(but-3-yn-1-yl)cyclohexan-1-one (28). Compound 28 was prepared 
according to general procedure A in 70% yield. 
 
Rf   0.33 (hexanes:EtOAc 5:1). colorless liquid. 
1H NMR  (599 MHz, CDCl3) δ = 7.47 (d, J = 7.6, 2H), 6.95 (d, J = 8.0, 2H), 3.27 (d, J = 11.8, 
1H), 2.59–2.51 (m, 1H), 2.44 (td, J = 13.6, 5.8, 1H), 2.24–2.04 (m, 7H), 1.90 (td, 
J = 2.5, 0.7, 1H), 1.85–1.74 (m, 1H), 1.59–1.40 (m, 3H), 1.33–1.24 (m, 1H). 
13C NMR  (151 MHz, CDCl3) δ = 209.2, 136.1, 131.7, 131.3, 121.2, 83.6, 69.0, 63.2, 43.9, 42.0, 
33.3, 30.6, 25.9, 16.0. 
IR  (ATR): 3296 w, 2941 w, 2863 w, 1709 s, 1488 s, 1446 w, 1406 w, 1313 w, 1271 w, 
1159 w, 1072 m, 1010 s, 805 s. 
HRMS   (EI): calculated for C17H20O2 304.0461, found 304.0463. 
 
 
 
 
3-(pent-4-yn-1-yl)indolin-2-one (30). To oxindole (0.13 g, 1.0 mmol, 2.0 eq.) and TMEDA 
(0.30 mL, 2.0 mmol, 4.0 eq.) in THF (5.0 mL) was added n-BuLi (0.81 mL, 2.0 mmol, 4.0 eq.) 
dropwise at −78 °C to give an orange solution. After 30 min, pentynyl iodide (97 mg, 0.50 mmol, 
1.0 eq.) was added dropwise at −78 °C. After 1 h at −78 °C, the mixture was warmed to room 
temperature over 1 h and stirred for a further 2 h. After addition of saturated aqueous 
NH4Cl (10 mL), the layers were separated and the aqueous phase was extracted with Et2O 
(3×20 mL). The combined organic phases were dried and evaporated and the residue was 
purified by column chromatography (hexanes:EtOAc 6:1→3:1) to give 30 as an off-white 
solid (61 mg, 0.31 mmol, 61%). 
 
Rf   0.51 (hexanes:EtOAc 1:1), off-white solid. 
1H NMR  (400 MHz, CDCl3) δ = 7.77 (s, 1H), 7.26–7.19 (m, 2H), 7.04 (td, J = 7.5, 1.0, 1H), 
6.87 (d, J = 7.7, 1H), 3.50 (t, J = 6.0, 1H), 2.22 (td, J = 7.1, 2.7, 2H), 2.12–2.04 (m, 
2H), 1.95 (t, J = 2.6, 1H), 1.73–1.52 (m, 2H). 
13C NMR  (101 MHz, CDCl3) δ = 179.4, 141.4, 129.5, 128.1, 124.4, 122.6, 109.6, 83.9, 68.9, 
45.5, 29.8, 24.8, 18.6. 
IR  (ATR): 3288 w, 3091 w, 2865 w, 1699 s, 1619 m, 1470 m, 1337 w, 1218 w, 1102 w, 
750 w. 
HRMS   (EI): calculated for C13H13NO 199.0997, found 199.0985. 
Mp.   101–103 °C. 
 
 
 
 
2-(But-3-yn-1-yl)-1,3-dimethyl-2,3-dihydroquinolin-4(1H)-one (32). Compound 32 was 
prepared according to general procedure A in 38% yield. 
 
 
Rf   0.40 (hexanes:EtOAc 5:1), fluorescent yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.66 (dd, J = 7.8, 1.8, 1H), 7.22 (ddd, J = 8.7, 7.0, 1.8, 1H), 
6.51 (t, J = 7.2, 1H), 6.43 (d, J = 8.5, 1H), 3.30–3.24 (m, 1H), 2.96 (s, 3H), 2.33 (qd, 
J = 7.3, 1.8, 1H), 2.07–2.01 (m, 2H), 1.84 (t, J = 2.6, 1H), 1.69 (dt, J = 13.9, 6.9, 1H), 
1.49 (dt, J = 13.9, 6.7, 1H), 1.07 (d, J = 7.2, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 197.0, 148.7, 135.8, 128.2, 117.0, 116.2, 112.7, 82.9, 69.7, 
65.6, 44.3, 39.0, 27.9, 16.2, 15.3. 
IR  (ATR):  3260 w, 2980 w, 2920 w, 2333 w, 1685 s, 1600 m, 1479 m, 1360 m, 1268 m, 
1233 w, 1160 s, 1115 m, 1047 w, 768 m. 
HRMS   (ESI): calculated for C15H18NO 228.1383, found 228.1383. 
 
 
 
 
2-(3-hydroxycyclohexyl)-2-(prop-2-yn-1-yl)propane-1,3-diol (S3). Dimethyl 2-(3-
oxocyclohexyl)-2-(prop-2-yn-1-yl)malonate (1.84 g, 6.93 mmol, 1.00 eq.) in THF (24 mL) was 
cannulated into a suspension of LiAlH4 (1.05 g, 27.7 mmol, 4.00 eq.) in THF (5 mL) cooled to 
0°C. The cooling bath was directly replaced with an oil bath and the mixture was heated to 
45 °C for5 h. After full conversion was observed by TLC, the mixture was cooled to 0 °C. 
Subsequently, the suspension was diluted with Et2O (20 mL) before sequential addition of water 
(1 mL), 2M NaOH (1 mL) and again H2O (3 mL). After stirring for 15 min at room temperature, 
the reaction was dried over MgSO4, filtered over celite and concentrated by vacuum 
evaporation. The residue can be used directly in the next step or purified by column 
chromatography (hexanes:EtOAc 1:1 →0:1) to give triol S3 (1.18 g, 5.54 mmol, 80%) as a highly 
viscous colorless oil contaminated with EtOAc (9%). 
 
Rf   0.14 (hexanes:EtOAc 1:2), viscous colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 3.84–3.71 (m, 4H), 3.58 (ddd, J = 14.8, 10.0, 4.0, 1H), 2.34 
(d, J = 2.7, 2H), 2.29–2.20 (m, 2H), 2.02 (t, J = 2.7, 1H), 1.98 (td, J = 4.4, 2.0, 1H), 
1.83 (dq, J = 12.9, 3.2, 1H), 1.70 (tt, J = 12.8, 2.9, 2H), 1.52 (s, 1H), 1.35–0.92 (m, 
5H). 
13C NMR  (101 MHz, CDCl3) δ = 81.5, 71.3, 71.0, 67.0, 66.9, 43.1, 38.0, 36.5, 35.7, 25.9, 24.2, 
20.2. 
IR   (ATR): 3295 (s), 2932 (s), 2858 (m), 2361 (w), 1450 (m), 1362 (m), 1045 (s), 964 (m). 
HRMS   (EI): calculated for C12H20O3 212.1412, found 212.1408. 
 
 
 
 
3-(2,2-Dimethyl-5-(prop-2-yn-1-yl)-1,3-dioxan-5-yl)cyclohexan-1-ol (S4). To triol S3 (1.55 g, 
7.30 mmol, 1.00 eq.) in CH2Cl2 (50 mL) was added PPTS (92 mg, 0.37 µmol, 0.050 eq.) and 2-
methoxypropene (3.50 mL, 36.0 mmol, 5.00 eq.). The reaction mixture was stirred for 2 h. The 
reaction was diluted with EtOAc (50 mL), washed with sat. NaHCO3 (20 mL) and saturated 
aqueous NaCl (20 mL), dried over MgSO4 and concentrated by vacuum evaporation. The crude 
product was purified by column chromatography (pentane:Et2O 1:1) to give alcohol S4 (1.79 g, 
7.09 mmol, 97%) as a yellow oil. 
 
Rf   0.57 (hexanes:EtOAc 1:2), yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 3.84–3.81 (m, 2H), 3.71–3.52 (m, 3H), 2.51–2.49 (m, 2H), 
2.05–1.93 (m, 3H), 1.84 (dt, J = 12.8, 3.2 Hz, 1H), 1.70–1.54 (m, 3H), 1.40 (s, 6H), 
1.32–1.19 (m, 1H), 1.18–0.96 (m, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 98.4, 81.6, 71.3, 65.3, 38.9, 37.3, 36.3, 35.8, 26.9, 25.7, 24.3, 
21.1, 21.0. 
IR  (ATR): 3299 (m), 2936 (vs), 2860 (m), 2360 (m), 2341 (m), 1451 (s), 1372 (m), 1261 
(m), 1196 (s), 1161 (m), 1067 (m), 830 (m). 
HRMS   (ESI): calculated for C14H21O3 237.1491 (-Me), found 237.1490. 
 
 
 
 
 
3-(2,2-Dimethyl-5-(prop-2-yn-1-yl)-1,3-dioxan-5-yl)cyclohexan-1-one (34). PDC (1.09 g, 
2.89 mmol, 1.50 eq.) was added in one portion to alcohol S4 (487 mg, 1.93 mmol, 1.00 eq.) in 
CH2Cl2 (30 mL) at 0 °C. The reaction was allowed to warm to room temperature. After 15 h of 
stirring, TLC indicated full conversion. The reaction was diluted with hexanes (10 mL) and 
Et2O (10 mL) and filtered through celite. After removing the solvent by vacuum evaporation, 
the crude product was submitted to column chromatography (hexanes:EtOAc 3:1) to give 
ketone 34 (358 mg, 1.43 mmol, 74%) as a yellow oil. 
 
Rf   0.25 (hexanes:EtOAc 3:1), colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 3.79–3.71 (m, 2H), 3.71–3.65 (m, 2H), 2.50–2.48 (m, 2H), 
2.46–2.21 (m, 4H), 2.19–2.09 (m, 1H), 2.05–2.03 (m, 1H), 2.01–1.84 (m, 1H), 1.65–
1.49 (m, 2H), 1.41–1.40 (m, 2H), 1.39 (s, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 210.9, 98.4, 80.9, 71.7, 65.4, 65.0, 42.8, 41.8, 41.3, 37.3, 25.4, 
21.3, 20.8. 
IR  (ATR): 3281 (w), 2990 (w), 2941 (m), 1710 (s), 1452 (w), 1372 (m), 1265 (m), 1229 
(m), 1197 (s), 828 (m). 
HRMS (EI):  Calculated for C15H23O3 251.1602, found 251.1630. 
 
 
 
 
3-(but-3-yn-1-yl)-4,4-dimethylcyclohexan-1-one (36). Compound 36 was prepared according to 
general procedure A in 83% yield. 
 
Rf   0.38 (hexanes:EtOAc 5:1). Colorless liquid. 
1H NMR  (800 MHz, CDCl3) δ = 2.47–2.38 (m, 2H), 2.35–2.24 (m, 2H), 2.13–2.02 (m, 2H), 
1.95 (t, J = 2.6, 1H), 1.87–1.80 (m, 1H), 1.74–1.66 (m, 2H), 1.63 (td, J = 13.4, 4.9, 
1H), 1.28–1.22 (m, 1H), 1.06 (s, 3H), 1.01 (s, 3H). 
13C NMR  (201 MHz, CDCl3) δ = 211.73, 83.92, 69.02, 45.70, 42.50, 40.43, 38.42, 32.93, 29.71, 
28.82, 19.79, 16.69. 
IR  (ATR): 3292 w, 2956 m, 2867 m, 1712 s, 1470 w, 1430 w, 1418 w, 1390 w, 1251 w, 
1146 w. 
HRMS   (EI): calculated for C12H18O 178.1358, found 178.1359. 
 
 
 
 
3-(but-3-yn-1-yl)-5-phenylcyclohexan-1-one (38). Compound 38 was prepared according to 
general procedure A in 72% yield. 
 
Rf   0.56 (hexanes:EtOAc 5:1), colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.35–7.30 (m, 2H), 7.25–7.16 (m, 3H), 3.32–3.30 (m, 1H), 
2.64–2.55 (m, 3H), 2.34–2.17 (m, 4H), 2.10 (ddd, J = 13.7, 9.6, 3.9, 1H), 1.99–1.95 
(m, 1H), 1.91 (t, J = 2.7, 1H), 1.62–1.57 (m, 2H). 
13C NMR  (101 MHz, CDCl3) δ = 211.1, 144.1, 128.8, 127.0, 126.8, 83.5, 69.1, 47.7, 46.3, 39.7, 
36.9, 33.5, 32.5, 16.3. 
IR  (ATR): 3288 (m), 2922 (m), 1708 (vs), 1495 (m), 1444 (m), 1229 (m), 1040 (m), 748 
(m), 700 (m). 
HRMS   (EI): calculated for C16H18O 226.1358, found 226.1349. 
  
 
Preparation and characterization of cyclized substrates 
 
 
 
 
3a-Methyl-3-methyleneoctahydro-4H-inden-4-one (13). Compound 13 was prepared according 
to general procedure B. 
 
Rf   0.60 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (800 MHz, CDCl3) δ = 4.92 (t, J = 2.1, 1H), 4.70 (t, J = 2.5, 1H), 2.56 (dtt, J = 17.6, 
9.0, 2.4, 1H), 2.48 (dddt, J = 17.5, 9.7, 3.3, 2.2, 1H), 2.39 (ddd, J = 14.7, 12.1, 5.4, 
1H), 2.31 (dtd, J = 14.7, 4.4, 1.7, 1H), 2.13 (ddt, J = 12.2, 5.9, 2.7, 1H), 1.96–1.90 (m, 
2H), 1.75 (dtdd, J = 14.0, 5.3, 3.3, 1.7, 1H), 1.69–1.63 (m, 1H), 1.59–1.55 (m, 2H), 
1.46 (dddd, J = 13.9, 11.5, 10.5, 3.5, 1H), 1.19 (s, 3H). 
13C NMR  (201 MHz, CDCl3) δ = 213.1, 155.6, 107.5, 60.1, 50.5, 38.9, 29.3, 29.0, 28.3, 24.8, 
23.5. 
IR   (ATR): 2925 w, 2855 m, 1705 s, 1653 m, 1457 w, 1370 w, 1257 w, 1085 w, 891 w. 
HRMS   (EI): calculated for C11H16O 164.1201, found 164.1198. 
 
 
 
 
6a-Methyl-6-methylenehexahydropentalen-1(2H)-one (15). Compound 15 was prepared 
according to general procedure B. 
 
Rf   0.56 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (599 MHz, CDCl3) δ = 5.02 (t, J = 2.3, 1H), 4.98 (t, J = 2.1, 1H), 2.49–2.45 (m, 2H), 
2.45–2.40 (m, 1H), 2.40–2.36 (m, 1H), 2.23 (ddd, J = 18.8, 9.2, 8.3, 1H), 2.04–1.90 
(m, 2H), 1.65–1.51 (m, 2H), 1.16 (s, 3H). 
13C NMR  (151 MHz, CDCl3) δ = 220.1, 154.0, 108.5, 59.7, 50.0, 37.0, 31.5, 29.0, 24.2, 22.8. 
IR  (ATR): 2924 m, 1736 s, 1700 w, 1684 w, 1653 w, 1635 w, 1558 w, 1540 w, 1521 w, 
1506 w, 1457 w, 894 w. 
HRMS   (EI): calculated for C10H14O 150.1045, found 150.1036. 
 
 
 
 
(3aS,6R,7aR)-3a-Methyl-3-methylene-6-(prop-1-en-2-yl)octahydro-4H-inden-4-one (19). 
Compound 19 was prepared according to general procedure B. Spectral data matched literature 
values. 
 
Rf   0.74 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 5.02 (t, J = 2.2, 1H), 4.84–4.80 (m, 2H), 4.71–4.66 (m, 1H), 
2.63 (q, J = 6.2, 1H), 2.58–2.35 (m, 4H), 2.18–2.09 (m, 1H), 1.94–1.75 (m, 3H), 1.75 
(dt, J = 1.4, 0.6, 3H), 1.51 (ddd, J = 12.9, 6.4, 2.9, 1H), 1.24 (s, 3H). 
IR  (ATR): 3080 w, 2932 m, 2360 w, 2252 w, 1700 s, 1646 m, 1449 m, 1377 m, 1220 w, 
906 s, 776 s, 647 s. 
HRMS   (EI): calculated for C14H20O 204.1514, found 204.1516. 
 
 
 
 
Tert-butyl hex-4-yn-1-yl(3-((3aS,6R,7aR)-6-methyl-3-methylene-4-oxooctahydro-3aH-inden-3a-
yl)propyl)carbamate (3). Compound 3 was prepared according to general procedure B in 70% 
yield. 
 
Rf   0.70 (hexanes:EtOAc 5:1). Colorless liquid. 
 
1H NMR  (599 MHz, CDCl3) δ = 5.01 (t, J = 2.0, 1H), 4.75 (t, J = 2.5, 1H), 3.23 (d, J = 8.9, 3H), 
3.16–3.09 (m, 2H), 2.56–2.42 (m, 3H), 2.38 (dt, J = 14.2, 6.9, 1H), 2.19 (s, 1H), 2.14–
2.09 (m, 3H), 2.08–2.01 (m, 1H), 1.83 (ddt, J = 13.2, 9.1, 6.8, 1H), 1.77 (t, J = 2.5, 
4H), 1.55 (dt, J = 13.5, 6.5, 1H), 1.51–1.45 (m, 2H), 1.44 (s, 12H), 0.96 (d, J = 6.9, 
3H). 
13C NMR  (151 MHz, CDCl3) δ = 212.4, 155.7, 153.7, 108.5, 79.3, 78.5, 76.0, 63.0, (48.0, 47.4), 
(46.6, 46.4), 46.2, 42.8, 34.2, 32.8, 32.7, 30.4, 29.5, 28.9, 28.6, 28.2, 27.8, (24.6, 24.0), 
20.5, 16.4, 3.6. (carbons next to the NBoc moiety form rotamers, indicated by 
parentheses) 
IR  (ATR): 2952 s, 2833 m, 2360 m, 2340 m, 1691 s, 1680 s, 1510 m, 1422 m , 1367 m, 
1251 m, 1165 s, 773 s, 1001 m. 
HRMS   (ESI): calculated for C25H40NO3 402.3003, found 402.3005. 
 
 
 
 
(8R)-1,1,8-Trimethyl-4-methylenespiro[4.5]decan-6-one (23). Compound 23 was prepared 
according to general procedure B. 
 
Rf   0.70 (hexanes:EtOAc 5:1). Colorless liquid. 
1H NMR  (800 MHz, CDCl3) δ = 5.18 (t, J = 2.4, 1H), 5.05 (t, J = 2.2, 1H), 5.02 (t, J = 2.1, 1H), 
4.87 (t, J = 2.5, 1H), 2.56 (ddd, J = 14.9, 4.4, 1.7, 1H), 2.52 (dtd, J = 12.1, 4.7, 2.3, 
1H), 2.44–2.39 (m, 1H), 2.39–2.32 (m, 2H), 2.31–2.24 (m, 2H), 2.23–2.18 (m, 1H), 
2.10–2.05 (m, 2H), 2.05–1.99 (m, 1H), 1.97 (ddd, J = 14.2, 4.4, 3.8, 1H), 1.92–1.86 
(m, 2H), 1.85–1.75 (m, 3H), 1.75–1.69 (m, 1H), 1.62–1.57 (m, 1H), 1.57–1.50 (m, 
1H), 1.45 (ddd, J = 12.8, 8.7, 4.4, 1H), 1.38 (ddd, J = 12.2, 9.4, 3.5, 1H), 1.07–0.99 
(m, 15H), 0.80 (s, 3H). 
13C NMR  (201 MHz, CDCl3) δ = 213.4, 211.7, 157.6, 156.8, 109.0, 108.4, 64.4, 64.3, 50.5, 48.4, 
45.6, 45.3, 38.3, 36.9, 32.8, 32.3, 31.9, 31.5, 30.4, 30.3, 30.2, 29.9, 26.7, 26.4, 25.8, 
22.4, 22.2, 22.1. 
IR  (ATR): 2952 s, 2870 m, 1698 s, 1646 w, 1457 m, 1385 w, 1364 w, 1202 w, 1126 w, 
882 w. 
HRMS   (EI): calculated for C13H20O 191.1436, found 191.1433. 
 
 
 
 
(3aS,7aS)-3a-(4-Methoxyphenyl)-3-methyleneoctahydro-4H-inden-4-one (27). Compound 27 
was prepared according to general procedure B in 52% yield. 
 
Rf   0.42 (hexanes:EtOAc 5:1). colorless liquid. 
1H NMR  (800 MHz, CDCl3) δ = 7.09 (d, J = 8.8, 2H), 6.86 (d, J = 8.8, 2H), 5.23 (t, J = 2.2, 1H), 
4.71 (t, J = 2.5, 1H), 3.79 (s, 3H), 2.82 (ddd, J = 11.0, 9.4, 5.2, 1H), 2.64–2.58 (m, 
1H), 2.47 (dddd, J = 14.8, 9.6, 5.1, 2.7, 2H), 2.41 (dddd, J = 14.7, 6.3, 4.7, 1.3, 1H), 
2.07–2.01 (m, 1H), 1.90–1.81 (m, 1H), 1.65–1.59 (m, 2H), 1.58–1.53 (m, 2H). 
13C NMR  (201 MHz, CDCl3) δ = 211.9, 158.4, 152.8, 133.3, 129.1, 113.9, 111.5, 70.1, 55.3, 
50.2, 39.6. 
IR  (ATR): 2938 m, 1703 s, 1609 w, 1510 s, 1457 w, 1295 w, 1249 s, 1182 m, 1036 m, 
823 m. 
HRMS   (EI): calculated for C17H20O 256.1463, found 256.1459. 
 
 
 
 
3a-(4-Bromophenyl)-3-methyleneoctahydro-4H-inden-4-one (29). Compound 29 was prepared 
according to general procedure B in 28% yield. 
 
Rf   0.68 (hexanes:EtOAc 5:1). colorless liquid. 
 
1H NMR  (400 MHz, CDCl3) δ = 7.48–7.38 (m, 2H), 7.09–6.98 (m, 2H), 5.28 (t, J = 2.2, 1H), 
4.76 (t, J = 2.6, 1H), 2.76 (dq, J =10.0, 4.9, 1H), 2.63 (dtt, J = 17.3, 8.5, 2.3, 2H), 2.56–
2.33 (m, 3H), 2.12–1.98 (m, 1H), 1.91–1.76 (m, 2H), 1.67–1.54 (m, 2H). 
13C NMR  (101 MHz, CDCl3) δ = 211.3, 151.9, 140.7, 131.5, 130.0, 112.3, 70.5, 50.7, 39.4, 29.4, 
27.8, 27.2, 24.7. 
IR  (ATR): 2929 m, 2885 m, 2360 m, 1701 s, 1488 m, 1457 w, 1395 w, 1245 w, 1140 w, 
1010 m, 811 m. 
HRMS   (EI): calculated for C16H17BrO 304.0463, found 304.0462. 
 
 
 
 
(3aS,7aS,Z)-3-(Chloromethylene)-3a-methyloctahydro-4H-inden-4-one (25). Compound 25 was 
prepared according to general procedure B in 65% yield. The configuration of the double bond 
was assigned using NOESY experiments as indicated below: 
 
 
 
Rf   0.56 (hexanes:EtOAc 5:1), colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 5.91 (t, J = 2.2, 1H), 2.72 (dtd, J = 17.7, 9.0, 2.2, 1H), 2.60–
2.47 (m, 2H), 2.39 (dtd, J = 12.3, 4.0, 1.6, 1H), 2.17–2.07 (m, 1H), 2.07–1.92 (m, 
2H), 1.76–1.63 (m, 2H), 1.63–1.56 (m, 1H), 1.56–1.41 (m, 1H), 1.25 (s, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 213.1, 147.9, 110.8, 60.4, 53.7, 40.2, 29.5, 29.5, 28.8, 27.1, 
19.6. 
IR  (ATR): 2933 m, 2863 w, 2363 w, 1711 s, 1640 w, 1445 w, 1372 w, 1316 w, 1256 w, 
1080 w , 1015 w, 806 m. 
HRMS   (EI): calculated for C11H15ClO 198.0811, found 198.0809. 
 
 
 
Tert-butyl 2-methylene-2'-oxospiro[cyclopentane-1,3'-indoline]-1'-carboxylate (S5). 
Compound S5 was prepared according to general procedure B with the following modification: 
Instead of an aqueous workup, EtOAc (5 mL) was added, stirred for 5 min, then evaporated 
under reduced pressure to give crude 31. The yellow solution was diluted with CH2Cl2 (1 mL) 
and Et3N (14 µL, 0.10 mmol, 1.0 eq.) as well as DMAP (2.5 mg, 20 µmol, 0.20 eq.) were added. 
The solution was cooled to 0 °C and Boc2O (33 mg, 0.15 mmol, 1.5 eq.) was added. The mixture 
was warmed to room temperature and stirred for 3 h. When full conversion was observed by 
TLC, it was diluted with Et2O (10 mL) and H2O (10 mL) and the aqueous phase was extracted 
with Et2O (3×15 mL). The combined organic phases were washed with 10% aqueous LiCl 
solution (20 mL) and saturated aqueous NaCl (20 mL), then dried, filtered and concentrated to 
give a yellow oil that was purified by column chromatography (pentane:Et2O 9:1) to give 31 
colorless crystals (15 mg, 50 µmol, 50% over 2 steps). 
 
Note: A crude NMR using 1,1,2,2-tetrachloroethane as an internal standard indicated a 75% yield for the 
cyclization and exclusive formation of the exo-isomer. 
 
Rf   0.75 (hexanes:EtOAc 5:1). 
1H NMR  (400 MHz, CDCl3) δ = 7.86 (dt, J = 8.2, 0.8, 1H), 7.33–7.25 (m, 1H), 7.15 (td, J = 7.5, 
1.0, 1H), 7.15–7.06 (m, 2H), 5.79 (d, J = 1.6, 1H), 5.01 (t, J = 2.1, 1H), 4.43 (t, J = 2.3, 
1H), 2.85–2.72 (m, 1H), 2.70–2.53 (m, 2H), 2.38 (ddd, J = 12.6, 7.2, 5.6, 1H), 2.32–
2.13 (m, 1H), 2.07 (dt, J = 12.5, 7.4, 1H), 2.01–1.87 (m, 1H), 1.65 (s, 3H), 1.64 (s, 
9H), 1.38 (d, J = 1.8, 1H). 4:1 mixture of exo/endo olefin isomers. 
13C NMR  (101 MHz, CDCl3) δ = 178.8, 178.1, 155.0, 149.7, 149.5, 140.3, 139.8, 139.4, 133.7, 
132.4, 130.7, 128.3, 128.1, 124.9, 124.8, 123.3, 123.1, 114.9, 114.9, 109.7, 84.4, 84.3, 
64.1, 58.8, 39.7, 38.1, 33.8, 31.6, 28.3, 24.3, 13.2. 4:1 mixture of exo/endo olefin 
isomers. 
IR  (ATR): 2980 w, 2360 w, 1764 s, 1730 s, 1607 w, 1479 m, 1348 s, 1290 s, 1250 m, 
1148 s, 1099 m, 754 m. 
HRMS   (ESI): calculated for C18H21NO3 299,1521, found 299.1512. 
 
 
 
 
4,9a-Dimethyl-1-methylene-1,2,3,3a,4,9a-hexahydro-9H-cyclopenta[b]quinolin-9-one (33). 
Compound 33 was prepared according to general procedure B in 40% yield. 
 
Rf  0.48 (hexanes:EtOAc 5:1), fluorescent yellow oil. 
1H NMR  (600 MHz, CDCl3) δ = 7.89 (dt, J = 7.9, 1.5, 1H), 7.40 (ddt, J =8.7, 7.2, 1.6, 1H), 6.69 
(ddt, J = 8.0, 7.0, 1.2, 1H), 6.66 (dd, J = 8.5, 1.2, 1H), 3.41–3.33 (m, 1H), 3.08 (d, 
J = 1.2, 3H), 2.49–2.41 (m, 1H), 2.33–2.24 (m, 1H), 1.94–1.87 (m, 1H), 1.74–1.62 (m, 
1H), 1.31 (s, 3H). 
13C NMR  (151 MHz, CDCl3) δ = 195.0, 150.5, 149.0, 135.8, 129.1, 117.3, 116.5, 113.0, 110.7, 
71.8, 55.8, 38.3, 27.4, 23.6, 21.5. 
IR  (ATR): 2925 m, 2830 w, 2333 w, 1700 s, 1600 m, 1460 m, 1360 m, 1268 m, 1233 w, 
1160 s, 1115 m, 1047 w, 778 m. 
HRMS   (ESI): calculated for C15H18NO 228.1383, found 228.1382. 
 
 
 
 
2',2',3-Trimethyl-5,6,7,7a-tetrahydrospiro[indene-1,5'-[1,3]dioxan]-4(2H)-one (35). Compound 
35 was prepared according to general procedure B. 
 
Rf   0.16 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 3.88 (dd, J = 11.3, 6.8, 2H), 3.66 (dd, J = 11.4, 1.6, 1H), 3.52 
(dd, J = 11.5, 1.6, 1H), 2.71–2.60 (m, 1H), 2.50–2.34 (m, 4H), 2.20 (ddd, J = 17.5, 
13.1, 6.2, 1H), 2.06–2.04 (m, 3H), 2.03 (dt, J = 3.8, 2.0, 1H), 1.76–1.54 (m, 2H), 1.43 
(s, 3H), 1.42 (s, 3H). major isomer quoted. 
13C NMR  (151 MHz, CDCl3) δ = 200.4, 150.6, 133.6, 98.1, 69.3, 65.3, 52.8, 47.6, 42.4, 41.1, 
26.5, 24.2, 16.4. major isomer quoted. 
IR  (ATR): 3451 w, 2991 m, 2938 m, 2862 m, 2169 w, 1707 m, 1677 s, 1617 s, 1453 m, 
1433 m, 1383 m, 1371 s, 1255 s, 1213 s, 1198 s, 1155 m, 1078 s, 1066 s, 1030 m, 
932 w, 840 m, 830 m. 
HRMS   (ESI): calculated for C15H23O3 251.1642, found 251.1643. 
 
 
 
 
3,7,7-trimethyl-1,2,5,6,7,7a-hexahydro-4H-inden-4-one (37). Compound 37 was prepared 
according to general procedure B. 
 
Rf   0.60 (hexanes:EtOAc 5:1). Pale-yellow liquid. 
1H NMR  (400 MHz, CDCl3) δ = 2.76 (ddq, J = 10.2, 5.3, 2.6, 1H), 2.46–2.23 (m, 3H), 2.10 (dt, 
J = 2.4, 1.2, 3H), 1.88 (dtd, J = 12.7, 8.1, 2.2, 1H), 1.74–1.47 (m, 3H), 0.97 (s, 3H), 
0.83 (s, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 200.7, 154.9, 133.6, 56.6, 39.1, 38.7, 37.6, 32.9, 29.1, 24.5, 
19.2, 16.5. 
IR   (ATR): 3440 s, 2966 s, 2359 m, 1708 s, 1371 m, 1440 m, 1229 w. 
HRMS   (EI): calculated for C12H18O 178.1358, found 178.1359. 
 
 
 
 
3-Methyl-6-phenyl-1,2,5,6,7,7a-hexahydro-4H-inden-4-one (39). Compound 39 was prepared 
according to general procedure B. 
 
Rf   0.74 (hexanes:EtOAc 5:1). Pale-yellow liquid. 
1H NMR  (400 MHz, CDCl3) δ = 7.40–7.04 (m, 5H), 3.48 (dq, J = 5.9, 4.5 Hz, 1H), 2.78–2.68 
(m, 1H), 2.64 (dd, J = 17.2, 6.0 Hz, 1H), 2.47–2.34 (m, 1H), 2.35–2.14 (m, 2H), 2.14 
 
(dt, J = 2.4, 1.1 Hz, 3H), 2.02 (dtd, J = 12.2, 7.4, 1.4 Hz, 1H), 1.82–1.71 (m, 1H), 
1.47 (ddt, J = 12.3, 11.0, 9.6 Hz, 1H), 1.28–1.19 (m, 1H). 
13C NMR  (101 MHz, CDCl3) δ = 200.4, 154.6, 144.7, 135.3, 128.5, 127.4, 126.3, 45.7, 41.4, 
39.7, 38.9, 38.8, 31.8, 16.6. 
IR  (ATR): 3026 (w), 2923 (m), 2857 (m), 1673 (s), 1617 (s), 1449 (m), 1430 (m), 1259 
(m), 1133 1133 (m), 785 (m), 699 (s). 
HRMS   (EI): calculated for C16H18O 226.1358, found 226.1351. 
  
Total synthesis of lycoposerramine R 
 
 
 
 
Tert-butyl (R)-(3-(4-methyl-6-oxocyclohex-1-en-1-yl)propyl)carbamate (42). To a solution of 41 
(1.41 g, 9.00 mmol, 1.50 eq.) in THF (30 mL) at 0 °C was added a 9-BBN solution (0:5 M in THF, 
36 mL, 18.0 mmol, 3.00 eq.) dropwise. After 30 min at 0 °C, the mixture was warmed to room 
temperature and stirred for 4.5 h. At this point a degassed aqueous solution of cesium carbonate 
(3.00 M, 4.00 mL, 12.0 mmol, 2.00 eq.) was added, followed by DMF (27 mL), AsPh3 (147 mg, 
0.48 mmol, 0.08 eq.) and 40 (1.41 g, 6.00 mmol, 1.00 eq.). This mixture was degassed by sparging 
with nitrogen for 5 min before Pd(dppf)Cl2 (351 mg, 0.48 mmol, 0.08 eq.) was added. After 
stirring at room temperature for 18 h, the mixture was poured on aqueous NH4Cl (40 mL) and 
the phases were separated. The aqueous phase was extracted with Et2O (3×70 mL), then washed 
with 10% aqueous LiCl (100 mL) and saturated aqueous NaCl (100 mL), then dried, filtered and 
concentrated. The resulting black oil was purified by column chromatography (hexanes:EtOAc 
8:1→4:1) to give 42 (1.39 g, 5.20 mmol, 87%) as a yellow oil. 
 
Rf   0.18 (hexanes:EtOAc 5:1). Yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 6.70 (dd, J = 5.8, 2.6, 1H), 4.69 (s, 1H), 3.07 (q, J = 6.6, 2H), 
2.51–2.44 (m, 1H), 2.40 (dt, J = 18.3, 4.6, 2H), 2.19 (t, J = 7.6, 3H), 2.02 (ddt, 
J = 10.2, 7.8, 2.1, 1H), 1.57 (p, J = 7.2, 2H), 1.43 (s, 9H), 1.04 (d, J = 6.3, 3H). 
13C NMR  (100 MHz, CDCl3) δ = 199.9, 156.0, 145.3, 138.6, 79.0, 46.6, 39.9, 34.4, 30.6, 29.0, 
28.4, 26.5, 21.2. 
IR  (ATR): 3356 w, 2928 w, 1699 s, 1673 s, 1521 m, 1456 w, 1389 w, 1365 m, 1251 m, 
1171 s. 
HRMS   (EI): calculated for C15H26NO3 268.1907, found 268.1910. 
[α]D20   −34 (0.6, CH2Cl2). 
 
 
 
 
 
Tert-butyl (3-((2R,4R)-2-(but-3-yn-1-yl)-4-methyl-6-oxocyclohexyl)propyl)carbamate (20). 
Three drops of dibromoethane were added to Mg chips (490 mg, 20.3 mmol, 4.50 eq.) in THF 
(30 mL). After short heating the reaction mixture was cooled back to room temperature and 43 
(3.23 g, 15.8 mmol, 3.5 eq.) was added dropwise. The reaction mixture was stirred at 50 °C for 
1.5 h, then slowly cooled down to 78 °C. CuBr·SMe2 (185 mg, 0.90 mmol, 0.20 eq.) was added in 
one portion and after stirring for 15 min, enone 42 (1.20 mg, 4.50 mmol, 1.00 eq.) in THF 
(15 mL), TMSCl (1.14 mL, 9.00 mmol, 2.0 eq.) and HMPA (1.60 mL, 9.00 mmol, 2.0 eq.) were 
added sequentially to the brownish suspension. The reaction was stirred for 2.5 h, then was 
quenched with saturated aqueous NaHCO3 (40 mL), warmed to room temperature and 
extracted with Et2O (3 × 60 mL). The combined organic layers were washed with saturated 
aqueous NH4Cl (30 mL) and saturated aqueous NaCl (30 mL), dried over MgSO4 and 
concentrated by vacuum evaporation. The yellow residue was dissolved in THF (12 mL) and 
cooled to 0 °C. After dropwise addition of TBAF (1M in THF, 11.3 mL, 11.3 mmol, 2.50 eq.), the 
now bright red reaction mixture was allowed to warm to room temperature and stirred for 
35 min. H2O (25 mL) was added, followed by extraction with Et2O (3 × 30 mL). The combined 
organic layers were washed with H2O (25 mL) and saturated aqueous NaCl (30 mL), dried over 
MgSO4 and concentrated by vacuum evaporation. The obtained brown oil was purified by 
column chromatography (pentane:Et2O 2:1) to give the ketone 20 as an inconsequential mixture 
of diastereomers (1.29 g, 4.00 mmol, 89% over 2 steps). 
 
Rf   0.24 (hexanes:EtOAc 5:1). Pale-yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 4.60 (br, 1H), 3.09–3.07 (m, 2H), 2.52–2.42 (m, 1H), 2.39–
2.25 (m, 2H), 2.23–2.18 (m, 2H), 2.15–1.96 (m, 3H), 1.96–1.94 (m, 1H), 1.91–1.61 
(m, 3H), 1.61–1.47 (m, 2H), 1.43 (s, 9H), 1.36–1.01 (m, 2H), 1.02–0.95 (m, 3H) 
(mixture of both diastereomers and rotamers). 
13C NMR  (100 MHz, CDCl3) δ = 214.2, 212.4, 156.1, 154.2, 133.0, 122.8, 84.7, 83.6, 80.2, 79.3, 
69.1, 68.5, 54.6, 53.7, 50.4, 45.0, 40.6, 40.5, 38.4, 34.5, 34.3, 33.8, 32.3, 32.1, 30.8, 
30.1, 29.6, 28.6, 28.1, 27.6, 26.5, 25.6, 25.2, 24.1, 23.5, 22.4, 21.8, 21.3, 19.9, 17.0, 
16.3 (mixture of both diastereomers and rotamers). 
IR   (ATR): 3306 w, 2927 w, 1700 s, 1521 w, 1507 w, 1456 w, 1364 w, 1172 w. 
HRMS   (EI): calculated for C19H32NO3 322.2377, found 322.2344. 
[α]D20   −3.6 (0.56, CH2Cl2). 
 
 
 
 
tert-butyl (3-((3aS,6R,7aR)-6-methyl-3-methylene-4-oxooctahydro-3aH-inden-3a-yl)propyl) 
carbamate (21). A solution of KOt-Bu (247 mg, 2.20 mmol, 1.10 eq.) in degassed DMSO (12 mL) 
was added dropwise to a solution of 20 (643 mg, 2.00 mmol, 1.00 eq.) in degassed DMSO 
(24 mL). The mixture was stirred at room temperature, monitoring by TLC. After 1.5 h, the 
reaction was diluted with Et2O (25 mL) and cooled to 0 °C before phosphate buffer (pH = 5.5, 
30 mL) was added. The aqueous phase was extracted with Et2O (3 × 40 mL). The combined 
organic phases were washed with 10% aqueous LiCl (3 × 30 mL) and saturated aqueous NaCl 
(15 mL), dried over MgSO4 and concentrated by vacuum evaporation. After purification by 
column chromatography over silica gel (pentane:Et2O 5:1), 21 was obtained as pale yellow 
liquid (398 mg, 1.24 mmol, 62%). 
 
Note: in this reaction, the yield varied between 52% and 62%, depending on the purity of KOt-Bu. 
 
Rf   0.24 (hexanes:EtOAc 5:1). Pale-yellow liquid. 
1H NMR  (800 MHz, CDCl3) δ = 5.02 (t, J = 2.2, 1H), 4.75 (t, J = 2.5, 1H), 4.67–4.62 (m, 1H), 
3.16–3.06 (m, 2H), 2.59–2.51 (m, 2H), 2.49–2.45 (m, 1H), 2.45–2.39 (m, 1H), 2.27–
2.18 (m, 1H), 2.07 (ddd, J = 14.8, 6.4, 1.4, 1H), 1.90–1.84 (m, 1H), 1.82–1.77 (m, 
1H), 1.71 (ddd, J = 13.9, 8.5, 3.8, 1H), 1.60–1.55 (m, 1H), 1.55–1.49 (m, 1H), 1.49–
1.41 (m, 12H), 0.97 (d, J = 6.9, 3H). 
13C NMR  (201 MHz, CDCl3) δ = 212.6, 156.2, 153.9, 108.6, 79.2, 63.1, 46.1, 42.6, 41.1, 34.3, 
32.7, 30.3, 29.6, 29.0, 28.6, 25.8, 20.3. 
IR  (ATR): 3364 w, 2952 m, 1699 w, 1521 m, 1457 w, 1365 w, 1272 w, 1248 w, 1173 m, 
887 w. 
HRMS   (EI): calculated for C19H32NO3 322.2377, found 322.2383. 
[α]D20   −13 (0.26, CH2Cl2). 
 
 
 
 
Tert-butyl (3-((3aS,6R,7aS)-6-methyl-3-methylene-2,4-dioxooctahydro-3aH-inden-3a-
yl)propyl)carbamate (44). To a turbid solution of tert-butyl hydroperoxide (5.5 M solution in 
anhydrous decane, 80 µL, 0.40 mmol, 2.0 eq.) and SeO2 (11 mg, 0.10 mmol, 0.5 eq.) in CH2Cl2 
(1.0 mL) was added a solution of 21 (64 mg, 0.20 mmol, 1.0 eq.) in CH2Cl2 (0.50 mL) at room 
temperature. The mixture was stirred at room temperature for 24 h before TLC analysis showed 
full conversion and NaHCO3 (34 mg, 0.40 mmol, 2.0 eq.) as well as Dess-Martin 
periodinane (102 mg, 0.24 mmol, 1.2 eq.) were added sequentially at room temperature. The 
colorless suspension was stirred at room temperature for 3 h before TLC analysis indicated full 
conversion. A 1:1 mixture of saturated aqueous NaHCO3 and 10% aqueous Na2S2O3 (8 mL) was 
added and the biphasic mixture was stirred vigorously until two clear phases formed (ca. 
30 min). Extraction with Et2O (3 × 15 mL) and washes with H2O (20 mL) and saturated aqueous 
NaCl (20 mL) gave a yellow oil. Column chromatography (pentane:Et2O 2:1) yielded 44 as a 
colorless oil (41 mg, 0.12 mmol, 61% over two steps). 
 
Rf   0.32 (hexanes:EtOAc 2:1). Colorless oil. 
1H NMR  (800 MHz, CDCl3) δ = 6.19 (s, 1H), 5.24 (s, 1H), 4.61 (s, 1H), 3.16–3.02 (m, 2H), 
2.68 (tq, J = 9.5, 4.8, 3.9, 1H), 2.59–2.51 (m, 1H), 2.49 (dd, J = 18.1, 7.8, 1H), 2.23–
2.10 (m, 3H), 1.93–1.81 (m, 1H), 1.78–1.52 (m, 3H), 1.52–1.45 (m, 1H), 1.43 (s, 
9H), 1.01 (d, J = 6.4, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 210.3, 204.1, 155.9, 146.5, 120.8, 59.9, 45.6, 42.3, 40.6, 36.0, 
34.8, 32.9, 28.4, 25.6, 20.4. 
IR (ATR):  3373 w, 2956 m, 2956 m, 2360 w, 1697 s, 1519 m, 1455 w, 1365 w, 1250 w, 1168 s, 
737 w. 
HRMS   (ESI): calculated for C19H30NO4 336.2169, found 336,2170. 
[α]D20  34 (0.6, CH2Cl2). 
 
 
 
Lycoposerramine R. To a solution of 44 (56 mg, 0.16 mmol, 1.0 eq.) in n-BuOH (1.6 mL) were 
added acetic acid (38 µL, 0.66 mmol, 4.0 eq.), piperidine (66 µL, 0.66 mmol, 4.0 eq.) and 
piperidinium salt 45 (83 mg, 0.48 mmol, 3.0 eq.) at room temperature. The mixture was stirred at 
115120 °C for 48 h before TLC analysis showed full conversion and H2O (5 mL) was added 
after cooling to room temperature. After extraction with CH2Cl2:MeOH (19:1, 3×10 mL), the 
combined organic phases were dried and evaporated to give a brown oil that was passed over a 
short column with 1:1 acetone:CH2Cl2. Half of the residue obtained was dissolved in 
CH2Cl2 (1.2 mL) and TFA (60 µL, 0.80 mmol, 20 eq.) was added dropwise at room temperature 
and stirred for 2 h before LC-MS analysis indicated full conversion. All volatiles were 
evaporated and the residue was redissolved in THF (0.8 mL). After addition of AcOH (4 µL, 
72 µmol, 2.0 eq.) and NaBH(OAc)3 (15 mg, 72 µmol, 2.0 eq.), the mixture was stirred at room 
temperature for 2.5 h, at which time LC-MS analysis showed full conversion. The reaction was 
basified using 1M NaOH (2 mL) and the aqueous phase was extracted with CH2Cl2 (3×8 mL). 
The combined organic phases were washed with saturated aqueous NaHCO3 (5 mL), then dried 
over K2CO3 and concentrated to give a yellow oil. Column chromatography (CH2Cl2:MeOH 19:1 
+ 0.5% aqueous NH3) gave lycoposerramine R as a slightly yellow oil (7.2 mg, 28 µmol, 35% 
over three steps). 
 
Rf   0.09 (CH2Cl2:MeOH 9:1). Slightly yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 8.32 (d, J = 9.1, 1H), 6.34 (d, J = 9.1, 1H), 3.20 (dd, J = 16.9, 
6.9, 2H), 2.90 (dd, J = 12.1, 4.8, 1H), 2.79 (td, J = 11.3, 3.1, 1H), 2.33 (d, J = 16.8, 
1H), 2.19 (dd, J = 6.5, 1H), 1.82–1.73 (m, 1H), 1.71–1.64 (m, 1H), 1.65–1.55 (m, 
1H), 1.55–1.38 (m, 6H), 1.29–1.14 (m, 2H), 0.96 (d, J = 7.0, 2H). 
13C NMR  (101 MHz, CDCl3) δ = 166.2, 150.5, 143.5, 124.6, 114.9, 57.3, 49.5, 48.1, 41.9, 38.2, 
36.2, 36.1, 34.9, 25.8, 22.9, 20.7. 
IR  (ATR): 3292 w, 2923 s, 2850 m, 2799 m, 1650 s, 1598 m, 1462 m, 1333 m, 1093 w, 
832 w. 
HRMS   (ESI): calculated for C16H23NO2 259.1805, found 259.1805. 
[α]D20   −21 (0.05, CHCl3).  
 
Comparison of natural and synthetic Lycoposerramine R 
 1H NMR (400 MHz, δ in ppm, J in Hz) 13C NMR (101 MHz, δ in ppm) 
 Natural Synthetic Natural Synthetic  
1   165.8 166.2 
2 6.34 (d, J = 9.2) 6.34 (d, J = 9.1) 115.0 114.9 
3 8.33 (d, J = 9.2) 8.32 (d, J = 9.1) 143.3 143.5 
4   124.5 124.6 
5   150.4 150.5 
6a 3.17–3.23 (m) 3.20 (dd, J = 16.9, 6.9) 36.2 36.2 
6b 2.33 (d, J = 17.0) 2.33 (d, J = 16.8)   
7 2.19 (ddd, J = 6.9, 6.9, 6.9) 2.19 (dd, J = 6.5, 1H) 42.0 41.9 
8a 1.47–1.55 (m)  36.0 36.1 
8b 1.20–1.25 (m)    
9a 3.17–3.23 (m) 3.20 (dd, J = 16.9, 6.9) 47.8 48.1 
9b 2.80 (td, J = 11.6, 3.0) 2.79 (td, J = 11.3, 3.1)   
10a 1.41–1.59 (m) 1.55–1.38 (m) 22.7 22.9 
10b 1.41–1.59 (m) 1.55–1.38 (m)   
11a 1.66–1.69 (m) 1.71–1.64 (m) 38.1 38.2 
11b 1.39–1.50 (m) 1.55–1.38 (m)   
12   49.4 49.4 
13 2.92 (dd, J = 12.1, 4.8) 2.90 (dd, J = 12.1, 4.8) 57.1 57.3 
14a 1.42–1.50 (m) 1.55–1.38 (m) 34.6 34.9 
14b 1.20–1.25 (m)   - 
15 1.72–1.79 (m) 1.82–1.73 (m) 25.6 25.8 
16 0.96 (d, J = 6.9, 3 H) 0.96 (d, J = 7.0) 20.6 20.7 
 
  
Formal total synthesis of sieboldine A 
 
 
 
 
(3R,5R)-2-Allyl-3-(but-3-yn-1-yl)-5-methylcyclohexan-1-one (16). Three drops of 
dibromoethane were added to Mg chips (263 mg, 10.8 mmol, 4.00 eq.) in THF (25 mL). After 
short heating the reaction mixture was cooled back to room temperature and (4-bromobut-1-yn-
1-yl)trimethylsilane (1.66 g, 3.54 mmol, 3.00 eq.) was added dropwise. The reaction mixture was 
stirred at 50 °C for 1.5 h, then slowly cooled down to −78 °C. CuBr·SMe2 (111 mg, 0.54 mmol, 
0.20 eq.) was added in one portion and after stirring for 15 min, (406 mg, 2.70 mmol, 1.00 eq.) in 
THF (5.0 mL) and TMSCl (680 µL, 5.40 mmol, 2.00 eq.) were added simultaneously to the 
yellow suspension, followed by HMPA (950 µL, 5.40 mmol, 2.00 eq.) to give an orange 
suspension. After 2.5 h at −78 °C, the reaction was quenched with saturated aqueous NaHCO3 
(20 mL), warmed to room temperature, diluted with H2O (10 mL) and extracted with Et2O 
(3×30 mL). The combined organic layers were washed with saturated aqueous NaCl (20 mL), 
dried over MgSO4 and concentrated. The residue was dissolved in THF (15 mL) and cooled to 
0 °C. After dropwise addition of TBAF (1M in THF, 8.10 mL, 8.10 mmol, 3.00 eq.), the reaction 
mixture was allowed to warm to room temperature. After 1 h, H2O (10 mL) was added, 
followed by extraction with Et2O (2 × 30 mL). The combined organic layers were washed with 
saturated aqueous NaCl (20 mL), dried and concentrated. The brown residue was purified by 
column chromatography (pentane:Et2O 6:1) to yield 16 as a yellow oil (397 mg, 1.94 mmol, 72% 
over two steps). 
 
Rf  0.63 (hexanes:EtOAc 5:1). yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 5.79–5.66 (m, 1H), 5.09–4.98 (m, 2H), 2.60–1.89 (m, 10H), 
1.94 (t, J = 2.6, 1H), 1.75–1.43 (m, 2H), 1.23–1.12 (m, 1H), 1.02 (t, J = 6.1, 2H), 1.00 
(d, J = 6.2, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 213.6, 211.8, 136.4, 135.5, 116.9, 116.4, 83.7, 83.7, 68.9, 54.4, 
53.8, 50.3, 47.3, 38.5, 37.6, 36.4, 34.7, 33.6, 32.0, 30.5, 30.0, 29.6, 25.4, 22.4, 21.7, 
16.3. 
 
IR  (ATR): 3297 w, 2953 m, 2926 w, 2870 w, 2360 w, 2118 w, 1707 s,1641 w, 1456 m, 
1333 w, 1234 w, 995 w, 914 m. 
HRMS   (EI): calculated for C13H17O (−Me): 189.1279, found 189.1289. 
[α]D20   8 (0.1, CH2Cl2). 
 
 
 
 
(3aS,6R,7aR)-3a-Allyl-6-methyl-3-methyleneoctahydro-4H-inden-4-one (17). A slightly yellow 
solution of KOt-Bu (218 mg, 1.94 mmol, 1.00 eq.) in degassed DMSO (10 mL) was cannulated 
into a solution of ketone 16 (397 mg, 1.94 mmol, 1.00 eq.) in degassed DMSO (20 mL), resulting 
in a dark-red solution within seconds. After stirring at room temperature for 10 min, the 
mixture was diluted with Et2O (25 mL) and pH 5.5 phosphate buffer solution (35 mL) was 
added dropwise at 0 °C. The aqueous phase was extracted with Et2O (2 × 50 mL) and the 
combined organic phases were washed with 10% aqueous LiCl solution (30 mL) and saturated 
aqueous NaCl (20 mL), dried over MgSO4 and concentrated. The resulting yellow oil was 
purified by column chromatography (pentane:Et2O 15:1) to give hydrindanone 17 as a colorless 
oil (281 mg, 1.38 mmol, 71%). 
 
Rf  0.74 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (400 MHz, CDCl3): δ = 5.71 (dddd, J = 19.9, 9.4, 8.1, 6.3, 1H), 5.08–5.03 (m, 1H), 
5.03 (t, J = 2.1, 2H), 4.80 (t, J = 2.5, 1H), 2.64 (ddt, J = 13.9, 6.3, 1.1, 1H), 2.53 
(dddd, J = 22.9, 11.5, 5.2, 2.8, 3H), 2.41 (dddt, J = 16.9, 9.5, 4.9, 2.3, 1H), 2.26–2.17 
(m, 1H), 2.17–2.11 (m, 1H), 2.08 (ddd, J = 14.7, 6.4, 1.3, 1H), 1.92–1.78 (m, 1H), 
1.69 (ddd, J = 12.6, 8.6, 3.8, 1H), 1.61–1.43 (m, 2H), 0.94 (d, J = 6.9, 3H).  
13C NMR  (101 MHz, CDCl3): δ = 212.1, 153.6, 135.1, 117.8, 108.7, 62.8, 46.1, 42.2, 40.5, 34.1, 
30.3, 29.7, 28.7, 20.1. 
IR (ATR): 3075 (w), 2952 (s), 1699 (s), 1645 (m), 1459 (w), 1431 (w), 1383 (w), 
1332 (w), 1282 (w), 1229 (w), 912 (m), 890 (m). 
HRMS   (EI): calculated for C14H20O 204.1509, found 204.1507. 
[α]D20   −9.4 (0.17, CH2Cl2). 
 
 
 
(3aS,6R,7aR)-3a-(3-((Tert-butyldiphenylsilyl)oxy)propyl)-6-methyl-3-methyleneoctahydro-
4H-inden-4-one (47). BH3·Me2S (24 µL, 0.25 mmol, 2.5 eq.) was added to a solution of 
cyclohexene (56 µL, 0.55 mmol, 5.5 eq.) in THF (1 mL) at 0 °C, which resulted in the formation 
of a precipitate after 1 h. After 2.5 h, a solution of hydrindanone 17 (20 mg, 0.10 mmol, 1.0 eq.) 
in THF (1 mL) was added dropwise, then the ice bath was removed. After stirring at room 
temperature for 2 h, aqueous NaOH (2 M, 1.0 mL) and aqueous H2O2 (30%, 1.0 mL) were added. 
The mixture was stirred at room temperature for 2 h before H2O (10 mL) was added and the 
aqueous phase was extracted with EtOAc (3 × 15 mL). The combined organic phases were 
washed with saturated aqueous NaCl (20 mL), dried over MgSO4 and concentrated by vacuum 
evaporation. The crude alcohol was taken on directly to the next step. To a solution of crude 
alcohol in CH2Cl2 (0.8 mL), TBDPSOTf (37 µL, 0.12 mmol, 1.2 eq.) and 2,6-lutidine (23 µL, 
0.20 mmol, 2.0 eq.) were added at 0 °C. The mixture was stirred for 2 h at 0 °C before H2O 
(2 mL) and CH2Cl2 (5 mL) were added. The aqueous phase was extracted with CH2Cl2 
(2 × 10 mL) and the combined organic layers were washed with saturated aqueous NaCl 
(5 mL), dried over MgSO4 and concentrated by vacuum evaporation. Column chromatography 
(pentane:Et2O 15:1) gave TBDPS-protected alcohol 47 as a colorless oil (27 mg, 0.058 mmol, 58% 
over 2 steps). 
 
Rf  0.90 (hexanes:EtOAc 5:1). Colorless liquid. 
1H NMR  (400 MHz, CDCl3): δ = 7.69–7.62 (m, 4H), 7.45–7.33 (m, 6H), 5.03 (t, J = 2.2, 1H), 
4.77 (t, J = 2.5, 1H), 3.71–3.57 (m, 2H), 2.55–2.28 (m, 4H), 2.23–2.12 (m, 1H), 2.08 
(ddd, J = 14.2, 8.0, 1.0, 1H), 1.79 (ddd, J = 12.6, 9.5, 6.8, 2H), 1.70 (dddd, J = 14.0, 
7.1, 3.8, 1.0, 1H), 1.59–1.46 (m, 5H), 1.04 (s, 9H), 0.96 (d, J = 6.7, 3H). 
13C NMR  (101 MHz, CDCl3): δ = 212.5, 153.3, 135.7, 134.1, 129.7, 127.7, 108.7, 64.2, 62.8, 
46.4, 43.1, 33.9, 31.6, 30.5, 29.5, 28.6, 28.3, 27.0, 20.8, 19.4. 
IR  (ATR): 3071 w, 2953 s, 2950 m, 2857 m, 2360 w, 1701 s, 1458 m, 1428 m, 1386 w, 
1207 w, 1111 s, 997 w, 888 w, 823 m, 740 m, 702 s. 
HRMS   (ESI): calculated for C30H41O2Si 461.2870, found 461.2876. 
 
[α]D20   25 (0.10, CH2Cl2). 
 
 
 
 
(3aS,6R,7aS)-3a-(3-((Tert-butyldiphenylsilyl)oxy)propyl)-6-methyl-3-methylenehexahydro-
1H-indene-2,4-dione (48). To a suspension of SeO2 (5.3 mg, 48 µmol, 1.7 eq.) and TBHP (5.5 M in 
decane, 28 µL, 0.14 mmol, 5.0 eq.) in CH2Cl2 (0.5 mL), TBDPS-protected alcohol 47 (12.9 mg, 
0.028 mmol, 1.0 eq.) in CH2Cl2 (0.5 mL) was added dropwise at room temperature. After stirring 
for 16 h, DMP (14 mg, 34 µmol, 1.2 eq.) and NaHCO3 (3.0 mg, 34 µmol, 2.0 eq.) were added at 
room temperature and the mixture was stirred for 3 h. Saturated aqueous NaHCO3 solution 
(0.5 mL) and saturated aqueous NaS2O3 solution (0.5 mL) were added and the biphasic mixture 
was vigorously stirred for 0.5 h. The aqueous phase was extracted with CH2Cl2 (3 × 10 mL) and 
the combined organic phases were washed with saturated aqueous NaCl (5 mL), dried over 
MgSO4 and concentrated by vacuum evaporation. Purification by column chromatography 
(pentane:Et2O 7:1) gave diketone 7 as a colorless oil (6.0 mg, 13 µmol, 45%). 
 
Rf  0.46 (hexanes:EtOAc 5:1). Colorless oil. 
1H-NMR  (400 MHz, CDCl3): δ = 7.68–7.57 (m, 4H), 7.39 (ddd, J = 14.0, 7.6, 6.0, 6H), 6.22 (s, 
1H), 5.27 (s, 1H), 3.73–3.54 (m, 2H), 2.64 (ddd, J = 13.4, 7.6, 5.7, 1H), 2.53–2.38 (m, 
2H), 2.24–2.08 (m, 3H), 1.92 (ddd, J = 13.8, 12.0, 4.7, 1H), 1.78–1.63 (m, 3H), 1.63–
1.40 (m, 2H), 1.04 (s, 9H), 1.02 (d, J = 6.4, 3H). 
13C-NMR  (101 MHz, CDCl3): δ = 210.5, 204.3, 146.5, 135.7, 133.8, 129.8, 127.8, 121.3, 63.7, 
60.1, 46.1, 42.1, 36.9, 34.1, 32.1, 28.5, 28.0, 27.0, 21.0, 19.3. 
IR   (ATR) 3007 w, 2954 s, 2857 m , 1727s , 1705 s , 1458 m, 1425 m, 1111 s, 880 m. 
HRMS   (ESI): calculated for C30H38O3SiNa 497.2488, found, 497.2481. 
[α]D20   27.4 (0.1, CH2Cl2). 
 
All data obtained are in full agreement with those by Overman. 
  
 
 
 
 
net formula C18H21NO3 
Mr/g mol−1 299.36 
crystal size/mm 0.100 × 0.070 × 0.040 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system orthorhombic 
space group 'P 21 21 21' 
a/Å 14.0471(8) 
b/Å 14.6566(8) 
c/Å 15.7115(9) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 3234.7(3) 
Z 8 
calc. density/g cm−3 1.229 
µ/mm−1 0.083 
absorption correction Multi-Scan 
transmission factor range 0.8890–0.9580 
refls. measured 43436 
Rint 0.0550 
mean σ(I)/I 0.0357 
 
θ range 3.135–25.394 
observed refls. 5074 
x, y (weighting scheme) 0.0458, 2.4112 
hydrogen refinement constr 
Flack parameter 0.5 
refls in refinement 5914 
parameters 394 
restraints 0 
R(Fobs) 0.0569 
Rw(F2) 0.1400 
S 1.087 
shift/errormax 0.001 
max electron density/e Å−3 0.358 
min electron density/e Å−3 −0.241 
  
 
 1H NMR (400 MHz, δ in ppm, J in Hz) 13C NMR (101 MHz, δ in ppm) 
 Natural Synthetic Natural Synthetic  
1 8.30 (dd, J = 5.0, 1.4) 8.30 (dd, J = 5.1, 1.4) 148.8 148.7 
2 7.67 (dd, J = 7.7, 1.4) 7.68 (dd, J = 7.8, 1.5) 136.1 136.2 
3 7.24 (dd, J = 7.7, 5.0) 7.25 (dd, J = 7.7, 5.1) 123.0 123.1 
4 -- -- 140.0 140.0 
5 -- -- 164.3 164.3 
9 3.53 (m) 3.54 (td, J = 6.3, 1.8) 62.8 62.8 
6a 3.09 (dd, J = 16.5, 8.2) 3.09 (dd, J = 16.1, 8.1) 38.6 38.5 
6b 2.83 (dd, J = 16.5, 9.1) 2.83 (dd, J = 16.1, 8.9) 62.8 62.8 
7 2.97 (m) 3.02–2.92 (m) 43.5 43.5 
12 -- -- 62.7 62.7 
13 -- -- 214.6 214.6 
14 2.29 (m) 2.29 (d, J = 8.0) 47.7 47.7 
15 2.12 (m) 2.18–2.00 (m,) 29.5 29.6 
11a 2.06 (ddd, J = 13.6, 13.6, 
4.6) 
2.18–2.00 (m) 43.5 43.5 
11b 1.90, 1.88, 1.83 (m) 1.94–1.77 (m) 43.5 43.5 
8a 1.90, 1.88, 1.83 (m) 1.94–1.77 (m) 34.8 34.7 
8b 1.90, 1.88, 1.83 (m) 1.94–1.77 (m) 34.8 34.7 
10a 1.56 (m) 1.62–1.50 (m) 29.1 29.1 
10b 1.35 (m) 1.41–1.30 (m) 29.1 29.1 
16 1.08 (d, J = 6.5) 1.09 (d, J = 6.5) 22.0 22.0 
All data obtained are in full agreement with those by Takayama. 
  
 
 1H NMR (400 MHz, δ in ppm, J in Hz) 13C NMR (101 MHz, δ in ppm) 
 Natural Synthetic Natural Synthetic  
1 8.30 (dd, J = 5.1, 1.3) 8.40 (d, J = 5.0) 149.5. 149.5 
2 7.18 (dd, J = 7.7, 5.1) 7.28 (dd, J = 7.6, 5.1) 123.3 123.3 
3 7.43 (dd, J = 7.7, 1.3 7.53 (d, J = 7.6) 134.2 134.2 
4 – – 141.8 141.8 
5 – – 165.0 165.0 
6a 3.48 (dd, J = 17.3, 7.1) 3.58 (dd, J = 17.3, 7.5) 40.7 40.7 
6b 2.60 (dd, J = 17.3, 7.1) 2.70 (d, J = 17.5) 40.7 40.7 
7 2.66 (q, J = 7.1) 2.76 (q, J = 7.0) 45.3 45.3 
8a 1.50 (dt, J = 14.0, 7.1) 1.50 (dt, J = 14.0, 7.1) 38.5 38.5 
8b 1.36 (ddd, J = 14.0, 7.1, 3.1) 1.45 (ddd, J = 13.8, 7.0, 
3.2) 
38.5 38.5 
9 3.90 (m) 4.00 (m) 59.0 59.1 
10 1.92, 1.91, 1.83, 1.75 (m) 2.05–1.82 (m) 19.5 19.5 
11 1.92, 1.91, 1.83, 1.75 (m) 2.05–1.82 (m) 32.9 32.9 
12 – – 52.6 52.5 
13 – – 156.2 156.2 
14a 2.94 (dd, J = 17.1, 7.1) 3.04 (dd, J = 17.4, 3.8) 33.9 33.9 
14b 2.01 (m) 2.16–2.06 (m) 33.9 33.9 
15 1.60 (m) 1.74–1.65 (m) 27.9 27.9 
16 0.84 (d, J = 6.8) 0.94 (d, J = 6.8) 20.1 20.1 
All data obtained are in full agreement with those by Takayama and Meng, who observed the 
same minor differences in the 1H NMR spectrum. 
  
 
 
 
 
 
7-Methoxy-1-methyl-3-(pent-4-yn-1-yl)-3,4-dihydroquinolin-2(1H)-one (1.285). To 1.283 
(0.12 g, 0.60 mmol, 1.00 eq.) in THF (4 mL) was added n-BuLi (0.44 mL, 1.2 mmol, 2.0 eq.) 
dropwise at −78 °C to give a yellow solution. After 30 min, the solution was warmed to room 
temperature for 35 min, then cooled back to −78 °C. 4-Pentynyl iodide (1.284) (0.13 g, 0.66 mmol, 
1.1 eq.) was added dropwise at −78 °C. After 1 h at −78 °C, the mixture was warmed to room 
temperature overnight. After addition of saturated aqueous NH4Cl (10 mL), the layers were 
separated and the aqueous phase was extracted with Et2O (3 × 20 mL). The combined organic 
phases were washed with saturated aqueous NaCl (20 mL),dried and evaporated to give a 
yellow oil that was purified by column chromatography (hexanes:EtOAc 6:1 to 3:1) to give 1.285 
as a yellow oil (37 mg, 0.14 mmol, 25%). 
 
Rf   0.58 (hexanes:EtOAc 2:1), yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.05 (d, J = 8.9, 1H), 6.56–6.51 (m, 2H), 3.81 (s, 3H), 3.32 (s, 
3H), 2.92 (dd, J = 15.0, 5.2, 1H), 2.63 (dd, J = 15.0, 9.3, 1H), 2.56–2.48 (m, 1H), 2.21 
(tdd, J = 6.9, 4.1, 2.7, 2H), 1.93 (t, J = 2.6, 1H), 1.88 (ddt, J = 12.1, 10.0, 3.4, 1H), 
1.75–1.45 (m, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 172.6, 159.3, 141.3, 128.6, 117.7, 106.5, 102.4, 84.2, 68.7, 
55.6, 40.6, 30.0, 29.9, 29.0, 26.2, 18.5. 
IR  (ATR): 3290 w, 2934 m, 2837 w, 2115 w, 1167 s, 1612 s, 1590 s, 1513 s, 1467 m, 
1356 m, 1272 s, 1225 m, 1120. 
HRMS   (EI): calculated for C16H19NO2 257.1416, found 257.1409. 
 
 
 
 
4-(Pent-4-yn-1-yl)isochroman-3-one (1.288). To 1.287 (0.12 g, 0.75 mmol, 1.0 eq.) and 4-pentynyl 
iodide (1.284) (0.15 g, 0.75 mmol, 1.00 eq.) in THF (4 mL) and HMPA (0.2 mL) was added 
KHMDS (1.5 mL, 0.75 mmol, 1.0 eq.) dropwise at room temperature to give a yellow solution. 
After 13 h at room temperature, H2O (5 mL) was added. The layers were separated and the 
aqueous phase was extracted with Et2O (3 × 15 mL). The combined organic phases were washed 
with aqueous HCl (1 M, 15 ML) and saturated aqueous NaCl (20 mL), dried with MgSO4 and 
evaporated to give a yellow oil that was purified by column chromatography (hexanes:EtOAc 
6:1 to 3:1) to give the desired product 1.288 (37 mg, 0.17 mmol, 23%) as a yellow 
oil  contaminated with 10% of the double alkynylation product. 
 
Rf   0.78 (hexanes:EtOAc 1:1), yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.37 (td, J = 7.4, 1.5, 1H), 7.31 (td, J = 7.4, 1.6, 1H), 7.26–7.21 
(m, 2H), 5.48–5.38 (m, 1H), 5.27 (d, J = 14.2, 1H), 3.64 (t, J = 7.2, 1H), 2.32–2.25 (m, 
2H), 2.22–1.99 (m, 3H), 1.97 (t, J = 2.7, 1H), 1.82–1.64 (m, 2H), 1.48–1.20 (m, 1H). 
13C NMR  (101 MHz, CDCl3) δ = 172.6, 134.6, 131.3, 128.9, 127.4, 126.7, 124.9, 83.6, 69.7, 
69.2, 45.5, 29.1, 25.9, 18.3. 
IR  (ATR): 3290, 2938, 2044, 1736, 1609, 1546, 1492, 1461, 1390, 1334, 1240, 1185, 1157, 
1126, 1079, 1047, 1033, 889, 756, 697. 
HRMS   (EI): calculated for C14H15O2 215.1067, found 215.1071. 
 
 
 
 
2-Oxo-1,2-diphenylethyl 2,2-dimethylbut-3-ynoate (1.291). DCC (0.10 g, 0.50 mmol, 1.0 eq.) 
was added to a solution of benzoin (1.289) (0.10 g, 0.50 mmol, 1.0 eq.), 2,2,-dimethylbut-3-ynoic 
acid (1.290) (62 mg, 0.55 mmol, 1.1 eq.) and DMAP (6.1 mg, 50 µmol, 0.10 eq.) in CH2Cl2 (3 mL) 
at room temperature. After stirring for 20 h, additional DCC (52 mg, 0.25 mmol, 0.50 eq.) was 
added. After stirring for 8 h, the mixture was diluted with EtOAc (80 mL) and filtrated over a 
silica plug. The organic phase was washed sequentially with hydrochloric acid (1 M, 10 mL), 
saturated aqueous NaHCO3 solution (10 mL) and saturated aqueous NaCl (10 mL), dried over 
MgSO4 and concentrated. Purification by column chromatography (pentane:Et2O 6:1) gave the 
desired product 1.291 as a colorless solid (85 mg, 0.28 mmol, 55%). 
 
Rf   0.49 (hexanes:EtOAc 5:1), colorless amorphous solid. 
1H NMR  (400 MHz, CDCl3) δ = 7.97–7.89 (m, 2H), 7.55–7.50 (m, 1H), 7.48 (dd, J = 7.7, 1.9, 
2H), 7.44–7.32 (m, 6H), 6.82 (s, 1H), 2.28 (s, 1H), 1.59 (s, 3H), 1.57 (s, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 193.7, 173.0, 133.5, 133.3, 129.2, 129.0, 128.8, 128.6, 128.3, 
78.3, 70.3, 38.2, 27.1, 27.0. 
IR (ATR):  3292 (w), 3065 (w), 2986 (w), 2939 (w), 2359 (w), 1738 (s), 1696 (s), 1598 (m), 1449 
(m), 1387 (w), 1249 (s), 1141 (s), 969 (m), 761 (w), 696 (s). 
HRMS   (EI): calculated for C18H18O3 306.1256, found 306.1250. 
 
 
 
 
2-(But-3-yn-1-yloxy)-1,2-diphenylethan-1-one (1.293). To benzoin (1.289) (425 mg, 2.00 mmol, 
1.00 eq.) in THF (6 mL) were added anhydrous FeCl3 (81 mg, 0.50 mmol, 0.25 eq.) and 3-butyn-1-
ol (1.292) (4.20 mL, 56.0 mmol, 28.0 eq.) to give a deep-red solution. After nitrogen sparging for 
15 min, the mixture was heated to 80 °C for 18 h, at which point no further conversion was 
observed.by GC-MS analysis. After filtration over a silica plug with CH2Cl2 (20 mL), all volatiles 
were removed in vacuo at 50 °C and the residue was purified by column chromatography 
(pentane:Et2O 15:1 to 13:1) to give the desired product 1.293 as a fluorescent yellow oil (81 mg, 
0.30 mmol, 15%) as well as benzil (15%) and recovered starting material (25%). 
 
Rf   0.48 (hexanes:EtOAc 5:1), fluorescent yellow oil. 
1H NMR  (400 MHz, Chloroform-d) δ = 8.01 (dd, J = 8.5, 1.4, 2H), 7.49–7.44 (m, 2H), 7.41–
7.30 (m, 5H), 5.66 (s, 1H), 3.77–3.60 (m, 2H), 2.55 (dddd, J = 7.4, 6.8, 2.7, 1.9, 2H), 
1.97 (t, J = 2.7, 1H). 
13C NMR  (101 MHz, CDCl3) δ = 197.2, 136.2, 135.0, 133.4, 130.1, 129.4, 129.2, 129.0, 128.7, 
128.6, 127.6, 85.6, 81.1, 69.8, 68.0, 20.1. 
 
IR  (ATR): 3296 w, 3064 w, 2730 w, 1688 s, 1598 m, 1583 w, 1450 m, 1274 s, 1213 m, 
1112 m, 1026 m, 708 s. 
HRMS   (ESI): calculated for C15H18NO 228.1383, found 228.1382. 
 
 
 
 
2-Methyl-3-(pent-3-yn-1-yl)cyclohexan-1-one (1.296). Compound 1.296 was prepared according 
to general procedure A (chapter 4.2.1.1) in 82% yield. 
 
Rf   0.46 (hexanes:EtOAc 5:1). Colorless liquid. 
1H NMR  (599 MHz, Chloroform-d) δ = 2.34–2.27 (m, 1H), 2.22–2.10 (m, 2H), 2.09–1.97 (m, 
2H), 1.97–1.92 (m, 1H), 1.86 (dqd, J = 13.0, 3.7, 1.5, 1H), 1.76–1.68 (m, 1H), 1.66 (t, 
J = 2.6, 3H), 1.56–1.51 (m, 1H), 1.48–1.39 (m, 1H), 1.35–1.25 (m, 2H), 0.96 (d, 
J = 6.6, 3H). 
13C NMR  (151 MHz, cdcl3) δ = 213.37, 78.73, 76.09, 50.09, 44.78, 41.58, 33.47, 29.99, 25.90, 
16.18, 12.22, 3.63. 
IR   (ATR): 2920 m, 2862 w, 1709 s, 1445 w, 1312 w, 1218 w, 1035 w, 956 w. 
HRMS   (EI): calculated for C12H18O 178.1358, found 178.1332. 
 
 
 
 
3-(4-Bromobut-3-yn-1-yl)-2-methylcyclohexan-1-one (1.298). AgNO3 (38 mg, 0.23 mmol, 
0.25 eq.) was added to a solution of 2-methyl-3-(4-(trimethylsilyl)but-3-yn-1-yl)cyclohexan-1-one 
(75 mg, 0.90 mmol, 1.0 eq.) and NBS (0.24 g, 1.4 mmol, 1.5 eq.) in dry acetone (3 mL). After 
stirring for 16 h at room temperature under exclusion of light, the crude mixture was passed 
over a plug of silica to give an orange oil that was concentrated and purified by column 
chromatography (pentane:Et2O 8:1) to give bromide 1.298 as a colorless oil (174 mg, 0.72 mmol, 
80%). 
Rf  0.52 (hexanes:EtOAc) 5:1, colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 2.47–2.01 (m, 6H), 2.00–1.20 (m, 6H), 1.07 (d, J = 6.6, 2H), 
1.02 (d, J = 7.1, 1H). 
13C NMR  (101 MHz, CDCl3): = 214.2, 213.1, 84.0, 83.8, 79.7, 79.5, 68.8, 49.9, 48.6, 44.6, 41.5, 
41.1, 41.0, 39.8, 38.5, 38.4, 32.8, 32.6, 29.9, 27.8, 27.7, 26.6, 25.7, 23.9, 17.5, 17.1, 
16.2, 15.8, 12.1, 11.6. 
IR  (ATR): 3301 (w), 2933 (m), 2865 (w), 1708 (s), 1447 (m), 1429 (m), 1378 (w), 
1219 (w), 1082 (w), 957 (w), 848 (w). 
HRMS   (EI): calculated for C8H14NO 242.0306, found 242.0297. 
 
 
 
 
3-(4-(4-Bromophenyl)but-3-yn-1-yl)-2-methylcyclohexan-1-one (1.301). Pd(PPh3)2Cl2 (28 mg, 
40 µmol, 0.05 eq.) was added to a solution of ketone 1.300 (0.13 g, 0.80 mmol, 1.0 eq.), 1-bromo-
4-iodobenzene (0.25 g, 0.88 mmol, 1.1 eq.), copper iodide (15 mg, 80 µmol, 0.10 eq.) and 
triethylamine (0.44 mL, 3.2 mmol, 4.0 eq.) in THF (8 mL) at room temperature. After stirring for 
23 h, saturated aqueous NH4Cl solution (1 mL) was added and the aqueous phase was extracted 
with EtOAc (3 × 10 mL). The combined organic phases were washed with saturated aqueous 
NaCl (5 mL), dried over MgSO4 and the solvent was removed by vacuum evaporation. 
Purification by column chromatography (pentane:Et2O 6:1) gave the desired product 1.301 
(150 mg, 0.47 mmol, 59%) as a brown oil. 
 
Rf   0.53 (hexanes:EtOAc 5:1), yellow solid. 
1H NMR  (400 MHz, CDCl3) δ = 7.40 (d, J = 8.2, 2H), 7.22 (d, J = 8.2, 2H), 2.69–1.87 (m, 8H), 
1.85–1.36 (m, 5H), 1.07 (2 d, J = 6.8, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 214.4, 213.1, 133.1, 133.1, 131.6, 122.8, 121.9, 90.9, 90.7, 
80.2, 80.1, 50.0, 48.7, 44.8, 41.5, 41.4, 39.8, 32.9, 30.0, 28.0, 26.7, 25.8, 24.0, 17.3, 
16.9, 12.2, 11.6. 
 
IR  (ATR): 3377, 2944, 2866, 2220, 1703, 1585, 1485, 1447, 1393, 1331, 1283, 1224, 1166, 
1098, 1070, 1011, 955, 844, 820, 742. 
HRMS   (EI): calculated for C17H19OBr 318.0619, found 318.0615. 
Mp.  130–132 °C. 
 
 
 
 
3-(2,2-Dimethyl-5-(3-phenylprop-2-yn-1-yl)-1,3-dioxan-5-yl)cyclohexan-1-one (1.303). 
Pd(PPh3)2Cl2 (21 mg, 30 µmol, 0.05 eq.) was added to a solution of cyclohexanone derivative 
1.302 (0.15 g, 0.59 mmol, 1.0 eq.), iodobenzene (65 µL, 0.59 mmol, 1.0 eq.), copper iodide (5.6 mg, 
30 µmol, 0.05 eq.) and triethylamine (0.33 mL, 2.4 mmol, 4.0 eq.) in THF (1.5 mL) at room 
temperature. After stirring for 23 h, saturated aqueous NH4Cl solution (1 mL) was added and 
the aqueous phase was extracted with EtOAc (3 × 10 mL). The combined organic phases were 
washed with saturated aqueous NaCl (5 mL), dried over MgSO4 and the solvent was removed 
by vacuum evaporation. Purification by column chromatography (pentane:Et2O 2:1) gave the 
desired product 1.303 as a brown oil (0.16 g, 0.48 mmol, 82%). 
 
Rf   0.70 (hexanes:EtOAc 1:1), colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.39–7.35 (m, 2H), 7.30–7.27 (m, 3H), 3.81 (dd, J = 11.9, 3.6, 
2H), 3.78–3.73 (m, 2H), 2.70 (s, 2H), 2.49 (ddd, J = 11.7, 4.6, 2.4, 1H), 2.46–2.39 (m, 
2H), 2.28 (td, J = 13.5, 6.4, 1H), 2.14 (ddd, J = 12.4, 6.1, 3.2, 1H), 2.06–1.93 (m, 2H), 
1.70–1.56 (m, 2H), 1.43 (s, 3H), 1.41 (s, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 211.2, 131.6, 128.4, 128.1, 123.5, 98.5, 86.6, 83.8, 65.8, 65.4, 
43.0, 42.1, 41.5, 37.9, 26.1, 25.8, 25.7, 21.9, 21.7. 
IR  (ATR): 2990 (m), 2941 (m), 2866 (m), 1708 (s), 1490 (m), 1443 (m), 1372 (m), 1261 
(m), 1197 (s), 1120 (m), 934 (w), 829 (m), 758 (s), 692 (s). 
HRMS   (EI): calculated for C21H26O3 326.1882, found 326.1871. 
 
 
3-(5-(3-(4-Bromophenyl)prop-2-yn-1-yl)-2,2-dimethyl-1,3-dioxan-5-yl)cyclohexan-1-one 
(1.304). Pd(PPh3)2Cl2 (21 mg, 30 µmol, 0.05 eq.) was added to a solution of ketone 1.302 (0.15 g, 
0.59 mmol, 1.0 eq.), 1-bromo-4-iodobenzene (0.17 g, 0.59 mmol, 1.0 eq.), copper iodide (5.6 mg, 
30 µmol, 0.05 eq.) and triethylamine (0.33 mL, 2.4 mmol, 4.0 eq.) in THF (1.5 mL) at room 
temperature. After stirring for 23 h, saturated aqueous NH4Cl solution (1 mL) was added and 
the aqueous phase was extracted with EtOAc (3 × 10 mL). The combined organic phases were 
washed with saturated aqueous NaCl (5 mL), dried over MgSO4 and the solvent was removed 
by vacuum evaporation. Purification by column chromatography (pentane:Et2O 3:1 to 5:2) gave 
the desired product 1.304 as a brown oil (192 mg, 0.47 mmol, 80%). 
 
Rf   0.71 (hexanes:EtOAc 1:1), brown oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.43–7.40 (m, 2H), 7.25–7.20 (m, 2H), 3.84–3.78 (m, 2H), 
3.73 (d, J = 11.9, 2H), 2.70 (d, J = 2.6, 2H), 2.47 (ddt, J = 13.6, 4.1, 2.1, 1H), 2.39 (t, 
J = 13.3, 2H), 2.28 (td, J = 13.4, 6.6 Hz, 1H), 2.18–2.11 (m, 1H), 2.04–1.91 (m, 2H), 
1.67–1.56 (m, 2H), 1.42 (s, 3H), 1.41 (s, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 211.0, 133.1, 131.7, 122.5, 122.2, 98.6, 88.0, 82.8,65.7, 65.3, 
43.0, 42.2, 41.5, 38.0, 26.3, 25.8, 25.7, 21.9, 21.4. 
IR  (ATR): 2989 (m), 2940 (m), 2866 (m), 1708 (s), 1485 (m), 1450 (m), 1371 (m), 1263 
(m), 1195 (s), 1159 (m), 1069 (s), 1010 (m), 934 (w), 822 (m), 734 (s). 
HRMS   (EI): calculated for C21H25O3Br 404.0987, found 404.0975. 
 
 
 
 
(R)-1-(But-3-yn-1-yl)pyrrolidin-3-ol (1.312). To a suspension of (R)-pyrrolidin-3-ol 
hydrochloride (1.310) (124 mg, 1.00 mmol, 1.00 eq.) and K2CO3 (553 mg, 4.00 mmol, 4.00 eq.) in 
 
acetonitrile (2.5 mL), was added 4-bromo-1-butyne (1.311) (113 µL, 1.20 mmol, 1.20 eq.) 
dropwise. After stirring at 50 °C for 15 h, the mixture was cooled to room temperature and H2O 
(5 mL) was added. The aqueous phase was extracted with Et2O (3 × 10 mL) and the combined 
organic phases were washed with saturated aqueous NaCl (10 mL) and dried over MgSO4. 
Removal of the solvent by vacuum evaporation yielded alkylated pyrrolidinol 1.312 as a yellow 
oil (80 mg, 0.57 mmol, 57%). The product was used in subsequent steps without further 
purification. 
 
Rf  0.14 (CH2Cl2:MeOH 9:1). 
1H NMR  (400 MHz, CDCl3) δ = 4.34 (ddt, J = 7.3, 4.9, 2.3, 1H), 2.91 (td, J = 8.6, 5.1, 1H), 
2.73–2.69 (m, 1H), 2.67 (t, J = 7.6, 2H), 2.56 (dd, J = 10.0, 5.2, 1H), 2.39 (td, J = 7.5, 
2.6, 2H), 2.33 (td, J = 8.9, 6.4, 1H), 2.28 (s, 1H), 2.18 (dddd, J = 13.9, 8.7; 7.1, 5.2, 
1H), 1.98 (t, J = 2.7, 1H), 1.78–1.70 (m, 1H). 
13C NMR  (151 MHz, CDCl3) δ = 82.5, 71.1, 69.0, 62.8, 54.4, 52.2, 34.8, 18.4. 
IR  (ATR): 3305, 3290, 2946, 2812, 2361, 2118, 1653, 1479, 1435, 1382, 1336, 1242, 1144, 
1123, 1095, 999, 880. 
HRMS   (EI): calculated for C8H14NO 140.1070, found 140.1069. 
 
 
 
 
1-(But-3-yn-1-yl)pyrrolidin-3-one (1.313). To a solution of oxalyl chloride (2 M in CH2Cl2, 
0.15 mL, 0.30 mmol, 2.0 eq.) in CH2Cl2 (1 mL), DMSO (42 µL, 0.60 mmol, 4.0 eq.) was added 
dropwise at −78 °C. After 25 min, alkylated pyrrolidinol 1.312 (21 mg, 0.15 mmol, 1.0 eq.) in 
CH2Cl2 (0.5 mL) was added dropwise. The solution was stirred at −78 °C for 10 min before 
triethylamine (0.17 mL, 1.2 mmol, 8.0 eq.) was added dropwise. After further stirring for 30 min 
at −78 °C, the mixture was allowed to warm to room temperature and stirred for additional 
1.5 h. H2O (5 mL) was added and the aqueous phase was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic phases were sequentially washed with saturated aqueous NaHCO3 solution 
(10 mL) and saturated aqueous NaCl (10 mL), dried over MgSO4 and concentrated by vacuum 
evaporation to give pyrrolidinone 1.313 as a brown oil (17 mg, 0.12 mmol, 82%). 
 
Rf  0.55 (CH2Cl2:MeOH 9:1). 
1H NMR  (400 MHz, CDCl3) δ = 3.00 (s, 2H), 2.95 (t, J = 7.0, 2H), 2.74 (t, J = 7.2, 2H), 2.45–
2.35 (m, 4H), 2.00 (t, J = 2.7, 1H). 
13C NMR  (101 MHz, CDCl3) δ = 213.9, 82.3, 69.5, 61.6, 55.2, 51.6, 38.0, 18.1. 
IR  (ATR): 3496, 3282, 2926, 2809, 1754, 1478, 1430, 1378, 1340, 1267, 1246, 1188, 1134, 
1030, 923, 865, 751. 
MS  (ESI): calculated for C8H12NO 138.09, found 138.10. (high resolution mass could not 
be obtained) 
Note: This compound decomposes at room temperature, but is stable for at least three months at −20 °C. 
It was therefore usually used directly in subsequent reactions. 
 
 
 
 
Diethyl (S)-2-(3-hydroxypyrrolidin-1-yl)malonate (1.315). To a suspension of (R)-pyrrolidin-3-
ol hydrochloride (1.310) (247 mg, 2.00 mmol, 1.00 eq.) and K2CO3 (332 mg, 2.40 mmol, 1.20 eq.) 
in DMF (2 mL), diethyl bromomalonate (1.314) (340 µL, 2.00 mmol, 1.00 eq.) was added 
dropwise. After the mixture was stirred for 24 h at room temperature, a solution of concentrated 
aqueous NH3 and NH4Cl (3:2, 15 mL) was added. The aqueous phase was extracted with EtOAc 
(3 × 30 mL) and the combined organic phases were washed with concentrated aqueous NaCl 
(20 mL), dried over MgSO4 and concentrated. Purification by column chromatography 
(hexanes:EtOAc 1:1 to 1:2) gave 1.315 as a slightly yellow oil (301 mg, 1.06 mmol, 53%). 
 
Rf  0.10 (hexanes:EtOAc 1:1), yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 4.34–4.27 (m, 1H), 4.26–4.15 (m, 5H), 3.11 (dd, J = 10.5, 5.0, 
1H), 3.03 (q, J = 8.1, 1H), 2.90–2.82 (m, 2H), 2.05 (dtd, J = 14.0, 8.3, 5.7, 1H), 1.86–
1.77 (m, 1H), 1.26 (t, J = 7.2, 6H). 
13C NMR  (101 MHz, CDCl3) δ = 167.9, 167.6, 71.5, 67.7, 61.7, 58.9, 48.9, 34.9, 14.2. 
IR  (ATR): 3402 (br), 2981 (w), 2941 (w), 1728 (s), 1446 (m), 1391 (m), 1299 (m), 1209 
(s), 1150 (s), 1095 (s), 1025 (s), 860 (w), 733 (w). 
HRMS   (ESI): calculated for C11H20NO5 246.1336, found 246.1330. 
 
 
 
 
 
Diethyl (R)-2-(3-hydroxypyrrolidin-1-yl)-2-(prop-2-yn-1-yl)malonate (1.316). Alkylated 
pyrrolidinol 1.315 (0.25 g, 1.0 mmol, 1.0 eq.) in DMF (1.5 mL) was added dropwise to a 
suspension of NaH (60% dispersion in mineral oil, 40 mg, 1.0 mmol, 1.0 eq.) in DMF (1 mL) at 
0 °C. After the suspension was stirred for 80 min at 0 °C, propargyl bromide (80 wt.% in 
toluene, 0.17 mL, 1.5 mmol, 1.5 eq.) was added dropwise. The mixture was stirred at 0 °C for 6 h 
and additional 14 h at room temperature. A solution of concentrated aqueous NH3 and NH4Cl 
(3:2, 5 mL) was added dropwise at 0 °C and the aqueous phase was extracted with Et2O 
(3 × 20 mL). The combined organic phases were washed with concentrated aqueous NaCl 
(10 mL), dried over MgSO4 and the solvent was removed by vacuum evaporation. Purification 
by column chromatography (pentane:Et2O 1:2 to 1:3) yielded alkynylated pyrrolidinol 
derivative 1.316 (0.23 g, 0.81 mmol, 81%) as a yellow oil. 
 
Rf  0.18 (hexanes:EtOAc 1:1), yellow oil. 
1H NMR  (400 MHz, CDCl3) δ 4.30 (s, 1H), 4.26 (q, J = 7.1, 4H), 3.21–3.09 (m, 2H), 3.05 (d, 
J = 10.5, 1H), 2.98 (d, J = 2.7, 2H), 2.93 (td, J = 8.6, 3.6, 1H), 2.54 (d, J = 7.7, 1H), 
2.07 (t, J = 2.7, 1H), 2.07–1.94 (m, 1H), 1.84 (dddt, J = 12.9, 7.2, 3.6, 1.7, 1H), 1.29 
(t, J = 7.1, 6H). 
13C NMR  (101 MHz, CDCl3) δ =168.6, 168.5, 78.9, 72.0, 71.5, 71.2, 61.8, 57.1, 45.8, 34.4, 25.9, 
14.1. 
IR  (ATR): 3428, 3281, 2981, 2872, 2360, 1724, 1466, 1446, 1391, 1368, 1232, 1194, 1096, 
1039, 1018, 944, 857. 
HRMS   (ESI): calculated for C14H22NO5 284.1492, found 284.1491. 
 
 
 
 
Diethyl 2-(3-oxopyrrolidin-1-yl)-2-(prop-2-yn-1-yl)malonate (1.317). DMP (0.13 g, 0.30 mmol, 
1.5 eq.) was added in one portion to a solution of 1.316 (48 mg, 0.20 mmol, 1.0 eq.) in CH2Cl2 
(1 mL) and MeCN (1 mL) at room temperature. After stirring for 2.5 h, Et2O (5 mL) and then 
saturated aqueous NaS2O3 solution (1 mL) were added. After stirring for 30 min, H2O (5 mL) 
was added. The aqueous phase was extracted with Et2O (3 × 10 mL) and the combined organic 
phases were washed with concentrated aqueous NaCl (10 mL), dried over MgSO4 and 
concentrated. The crude product was dry loaded on a chromatography column (pentane:Et2O 
2:1) to yield alkynylated pyrrolidinone 1.317 (24 mg, 90 µmol, 43%) as a colorless oil. 
 
Rf   0.75 (hexanes:EtOAc 1:1), colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 4.34–4.22 (m, 4H), 3.46 (s, 2H), 3.29 (t, J = 7.1, 2H), 3.02 (d, 
J = 2.7, 2H), 2.49 (t, J = 7.1, 2H), 2.10 (t, J = 2.7, 1H), 1.30 (t, J = 7.1, 6H). 
13C NMR  (101 MHz, CDCl3) δ = 213.2, 167.6, 78.2, 72.1, 72.1, 62.1, 56.4, 45.9, 37.7, 24.9, 14.3. 
IR   (ATR): 3279, 2983, 2966, 1758, 1729, 1446, 1368, 1235, 1192, 1129, 1041, 857. 
HRMS   (ESI): calculated for C14H20NO5 282.1336 Found 282.1338. 
 
 
 
 
Tert-butyl 2-(but-3-yn-1-yl)-4-oxopiperidine-1-carboxylate (1.321). Compound 1.321 was 
prepared according to general procedure A (chapter 4.2.1.1) in 59% yield. 
 
Rf   0.18 (hexanes:EtOAc 5:1). Pale-yellow liquid. 
1H NMR  (599 MHz, CDCl3) δ = 4.72 (s, 1H), 4.40, (br s, 1H), 3.14 (br, 2H), 2.66 (ddd, 
J = 14.5, 6.8, 1.0, 1H), 2.52–2.40 (m, 1H), 2.34–2.25 (m, 2H), 2.22–2.12 (m, 2H), 1.94 
(t, J = 2.6, 1H), 1.81–1.72 (m, 1H), 1.69–1.60 (m, 1H), 1.48 (s, 9H). 
13C NMR  (151 MHz, CDCl3) δ = 207.92, 154.80, 83.10, 80.86, 69.19, 51.58, 45.48, 41.4, 40.84, 
31.33, 28.55, 15.40. 
IR  (ATR): 3276 w, 2975 w, 2931 w, 1719 m, 1690 s, 1412 m, 1366 m, 1240 w, 1160 s, 
1115 w. 
HRMS   (EI): calculated for C10H14NO3 196.0968 (-t-Bu), found 196.0969. 
 
 
 
Tert-butyl 2-(but-3-yn-1-yl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (1.323). Compound 
1.323 was prepared according to general procedure A (chapter 4.2.1.1) in 20% yield. 
 
Rf   0.75 (hexanes:EtOAc 1:1), yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.05 (d, J = 8.9, 1H), 6.56–6.51 (m, 2H), 3.81 (s, 3H), 3.32 (s, 
3H), 2.92 (dd, J = 15.0, 5.2, 1H), 2.63 (dd, J = 15.0, 9.3, 1H), 2.56–2.48 (m, 1H), 2.21 
(tdd, J = 6.9, 4.1, 2.7, 2H), 1.93 (t, J = 2.6, 1H), 1.88 (ddt, J = 12.1, 10.0, 3.4, 1H), 
1.75–1.45 (m, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 193.3, 153.1, 141.4, 134.4, 126.9, 125.1, 124.8, 124.0, 83.1, 
82.4, 69.2, 53.0, 43.3, 30.5, 28.4, 15.8. 
IR  (ATR): 3294 w, 2977 w, 2931 w, 2338 w, 1704 s, 1688 s, 1600m, 1479 m, 1459 m, 
1368 m, 1347 m, 1233 w, 1159 s, 1135 m, 1047 w, 768 m. 
HRMS   (ESI): calculated for C18H20NO3 298.1449, found 298.1449. 
 
 
 
 
Dimethyl 2-(but-3-yn-1-yl)-2-(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)malonate 
(1.327). Propargylated dimethyl malonate 1.326 (0.13 g, 0.67 mmol, 1.0 eq.) in DMF (2 mL) was 
added to a suspension of NaH (30 mg, 0.74 mmol, 1.1 eq.) in DMF (4 mL) at 0 ° C. After stirring 
for 1.5 h, brominated tetralone 1.325 (0.23 g, 0.87 mmol, 1.3 eq.) was added dropwise at 0 °C and 
the mixture was allowed to warm to room temperature. After 14 h, the solvent was removed by 
vacuum evaporation and the residue was directly purified by column chromatography 
(pentane:Et2O 7:1) to give tetralone 1.327 as a yellow oil (94 mg, 0.26 mmol, 39%). 
 
Rf   0.78 (hexanes:EtOAc 1:1), yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.99 (dd, J = 8.8, 4.1, 1H), 6.82 (dd, J = 8.8 , 2.5, 1H), 6.68 (d, 
J = 2.4, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.71 (s, 3H), 3.26 (dd, J = 13.5 , 4.1, 1H), 
3.11–2.98 (m, 1H), 2.95 (dt, J = 16.6, 3.5, 1H), 2.55–2.10 (m, 5H), 2.02 (td, J = 13.0, 
4.4, 1H), 1.96 (t, J = 2.6, 1H). 
IR  (ATR): 3287 (w), 2951 (m), 2842 (w), 1730 (s), 1674 (s), 1599 (s), 1495 (w), 1434 
(m), 1249 (s), 1201 (m), 1097 (m), 1028 (m). 
HRMS   (EI): calculated for C20H22O6 358.1416, found 358.1411. 
 
 
 
 
3-(But-3-yn-1-yl)-2,3-dimethylcyclohexan-1-one (1.330). Compound 1.330 was prepared 
according to the general procedure A (chapter 4.2.1.1) and obtained in 45% yield. 
 
Rf   0.57 (hexanes:EtOAc 5:1), colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 2.44–2.15 (m, 7H), 2.11–2.04 (m, 1H), 1.95 (dt, J = 12.4, 2.7, 
2H), 1.90–1.68 (m, 3H), 1.66 (t, J = 8.2, 2H), 1.62–1.35 (m, 4H), 1.02–0.93 (m, 7H), 
0.76 (s, 3H). 
13C NMR  (101 MHz, CDCl3) δ = 213.3, 84.5, 84.4, 68.4, 68.3, 55.4, 52.3, 41.3, 40.9, 40.8, 40.3, 
40.1, 35.3, 34.4, 32.4, 25.3, 22.2, 22.0, 19.6, 13.1, 12.8, 8.8, 8.3. 
IR  (ATR): 3248 (w), 2941 (m), 2874 (w), 1705 (vs), 1452 (m), 1385 (m), 1070 (m), 
939 (m), 695 (m) 
HRMS   (EI): calculated for C12H18O 178.1358, found 178.1342. 
 
 
 
 
 
2-(But-3-yn-1-yl)-3-methyl-2,3-dihydro-4H-spiro[naphthalene-1,2'-[1,3]dioxolan]-4-one (1.332). 
Compound 1.332 was prepared according to the general procedure A (chapter 4.2.1.1) in 20% 
yield. 
 
Rf   0.25 (hexanes:EtOAc 9:1), colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.66 (dd, J = 8.0, 3.7, 1H), 7.26 (d, J = 7.4, 2H), 7.20–7.06 (m, 
1H), 4.06–3.99 (m, 1H), 3.90 (q, J = 7.0, 1H), 3.84–3.75 (m, 2H), 3.12 (dtd, J = 10.9, 
7.1, 4.1, 1H), 2.13 (q, J = 5.2, 1H), 2.03 (tdd, J = 17.1, 8.2, 5.5, 2H), 1.63 (dt, J = 5.6, 
2.8, 1H), 1.20–1.12 (m, 2H), 1.11–1.07 (m, 1H), 0.97 (d, J = 6.8, 2H). 
13C NMR  (101 MHz, CDCl3) δ = 200.1, 199.4, 142.9, 141.2, 133.9, 133.4, 132.1, 131.6, 129.3, 
129.2, 127.6, 126.6, 126.1, 124.6, 109.1, 108.1, 84.4, 84.2, 68.9, 68.8, 66.5, 66.4, 64.7, 
64.3, 47.7, 47.4, 45.2, 44.5, 28.1, 25.3, 18.5, 17.8, 16.5, 12.7. 
IR  (ATR): 3292 (w), 2956 (w), 2889 (w), 1686 (s), 1600 (m), 1463 (w), 1364 (m), 1297 
(m), 1245 (s), 1224 (m), 1155 (m), 1118 (m), 1069 (s), 992 (s), 948 (s), 889 (w), 
796 (w), 763 (s), 699 (w). 
HRMS   (EI): calculated for C17H18O3 270.1243, found 207.1256. 
  
 
 
 
(R,E)-N-(Hex-4-en-1-yl)-N-(3-(4-methyl-6-oxocyclohex-1-en-1-yl)propyl)-2-nitrobenzene-
sulfonamide (1.385). Amine 1.383 (47 mg, 0.30 mmol, 1.5 eq.) was dissolved in THF (2.5 mL) 
and 9-BBN (0.5 M in THF, 0.80 mL, 0.40 mmol, 2.0 eq.) was added dropwise at room 
temperature. After 8 h, TLC analysis showed full conversion. H2O (0.1 mL) was degassed with 
Ar for 20 min, then added to the solution, immediately followed by addition of Cs2CO3 (98 mg, 
0.30 mmol, 1.5 eq.). After 50 min at room temperature, AsPh3 (9.0 mg, 30 µmol, 0.15 eq.), vinyl 
iodide 1.111 (47 mg, 0.20 mmol, 1.0 eq.) and DMF (2 mL) were added sequentially. The mixture 
was sparged with Argon for 20 min before Pd(dppf)Cl2 (7.3 mg, 10 µmol, 0.05 eq.) was added 
and the reaction was stirred at room temperature for 16 h. During this time, the reaction 
mixture turned from slightly yellow to dark red. The mixture was then poured on saturated 
aqueous NH4Cl solution (20 mL) and diluted with Et2O (20 mL). The aqueous phase was further 
extracted with Et2O (2 × 20 mL) and the organic phases were combined. After washing with 
H2O (2 × 25 mL) and saturated aqueous NaCl (25 mL), the organic phase was dried with MgSO4, 
filtered and concentrated to give a brown residue that was purified by column chromatography 
(pentane:EtOAc 3:1) to yield 1.385 (61 mg, 0.14 mmol, 70%) as a yellow oil. 
 
Rf   0.15 (hexanes:EtOAc 5:1). Slightly yellow oil. 
1H NMR  (400 MHz, CDCl3) δ = 8.04–7.90 (m, 1H), 7.69–7.65 (m, 2H), 7.62–7.59 (m, 1H), 
6.70 (ddd, J = 5.4, 2.6, 1.3, 1H), 5.45–5.27 (m, 2H), 3.30–3.23 (m, 4H), 2.50–2.45 (m, 
1H), 2.45–2.35 (m, 1H), 2.17–2.10 (m, 3H), 2.10–1.88 (m, 4H), 1.70–1.50 (m, 8H), 
1.04 (d, J = 6.3, 3H). 
13C NMR  (101 MHz, CDCl3)) δ = 199.7, 148.2, 145.6, 138.2, 133.8, 133.4, 131.6, 130.8, 129.8, 
126.1, 124.2, 47.1, 46.9, 46.7, 34.5, 30.7, 29.6, 28.0, 27.2, 26.9, 21.3, 18.1. 
IR  (ATR): 2953, 2927, 1670, 1545, 1454, 1439, 1373, 1348, 1297, 1264, 1204, 1161, 1125, 
1060, 967, 851, 779. 
HRMS   (EI): calculated for C22H31N2O5S 435.1948 found 435.1953. 
 
 
 
 
 
Benzyl (R,E)-hex-4-en-1-yl(3-(4-methyl-6-oxocyclohex-1-en-1-yl)propyl)carbamate (1.386). 
Amine 1.384 (0.41 mg, 0.15 mmol, 1.5 eq.) was dissolved in THF (1 mL) and 9-BBN (0.5 M in 
THF, 0.40 mL, 0.20 mmol, 2.0 eq.) was added dropwise at room temperature. After 8 h, TLC 
analysis showed full conversion. H2O (0.1 mL) was degassed with Ar for 20 min, then added to 
the solution, immediately followed by addition of Cs2CO3 (65 mg, 0.2 mmol, 2.0 eq.). After 
30 min at room temperature, AsPh3 (3.0 mg, 10 µmol, 0.10 eq.), iodide 1.111 (24 mg, 0.10 mmol, 
1.0eq.) and DMF (1 mL) were added sequentially. The mixture was sparged with Argon for 20 
min before Pd(dppf)Cl2 (6.0 mg, 8 µmol, 0.08 eq.) was added and the reaction was stirred at 
room temperature for 16 h. During this time, the reaction mixture turned from slightly yellow to 
dark red. The mixture was then poured on saturated aqueous NH4Cl solution (20 mL) and 
diluted with Et2O (20 mL). The aqueous phase was further extracted with Et2O (2 × 20 mL) and 
the organic phases were combined. After washing with H2O (2 × 25 mL) and saturated aqueous 
NaCl (25 mL), the organic phase was dried with MgSO4, filtered and concentrated to give a 
brown residue that was purified by column chromatography (pentane:Et2O 6:1) to yield 1.386 
(27 mg, 71 µmol, 71%) as a yellow oil. 
 
Rf   0.25 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 7.32–7.16 (m, 2H), 6.57 (2 d, J = 4.1, 1H), 5.31 (dt, J = 17.2, 
4.9, 2H), 5.03 (s, 2H), 3.14 (q, J = 8.4, 4H), 2.38 (t, J = 12.9, 1H), 2.31–2.16 (m, 1H), 
2.13–1.80 (m, 6H), 1.61–1.44 (m, 6H), 0.95 (2 d, J = 6.5, 3H). Note: 3 Cbz protons are 
obscured by the solvent signal. Due to extensive rotamer line broadening, not all 
integrals match. 
13C NMR  (101 MHz, CDCl3)) δ = 199.7, 199.5, 156.1, 156.1, 144.9, 144.6, 138.6, 137.0, 130.4, 
130.3, 128.4, 127.8, 127.7, 125.5, 125.4, 66.8, 47.2, 46.7, 46.5, 34.4, 34.3, 30.6, 29.9, 
29.8, 28.4, 27.9, 27.5, 26.9, 26.7, 21.2, 17.9. Note: due to rotamers, almost two complete 
sets of peaks were observed. 
IR  (ATR): 2954, 2926, 2858, 1694, 1472, 1416, 1366, 1288, 1255, 1225, 1169, 1054, 974, 
934, 894, 837, 777, 676. 
HRMS   (EI): calculated for C24H33NO3 384.2460, found 383.2447. 
 
 
 
Tert-butyl (3-((4R,6R)-6-allyl-4-methyl-2-((triisopropylsilyl)oxy) cyclohex-1-en-1-
yl)propyl)((E)-hex-4-en-1-yl)carbamate (1.390). Enone 1.385 (35 mg, 0.10 mmol, 1.0 eq.) was 
dissolved in CH2Cl2 (0.8 mL) and cooled to −78 °C before DTBPy (33 µL, 0.15 mmol, 1.5 eq) was 
added. After 15 min, TIPSOTf (32 µL, 0.12 mmol, 1.2 eq) was added dropwise, rendering a 
yellow solution to which allylSnBu3 (37 µL, 0.11 mmol, 1.1 eq) was added another 10 min later. 
After 2 h at −78 °C, the reaction was diluted with CH2Cl2 (10 mL) and warmed to room 
temperature before saturated aqueous NaHCO3 (5 mL) and H2O (2 mL) were added. The 
aqueous phase was extracted with CH2Cl2 (3 × 8 mL) and the combined organic phases were 
washed with saturated aqueous NaCl (5 mL), dried with MgSO4 and concentrated. The 
resulting yellow oil was purified using column chromatography (pentane:EtOAc 30:1 + 1% 
Et3N) to give 1.390 (26 mg, 45 µmol, 45%) as a colorless oil. 
 
Rf   0.20 (hexanes:EtOAc 30:1). Colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 5.75 (dddd, J = 15.5, 11.0, 8.1, 6.0, 1H), 5.49–5.32 (m, 2H), 
5.00 (d, J = 6.8, 1H), 4.96 (s, 1H), 3.21–3.01 (m, 4H), 2.42 (ddd, J = 13.1, 10.1, 6.2, 
1H), 2.27 (ddd, J = 15.3, 5.8, 3.1, 1H), 2.19–2.12 (m, 1H), 2.06 (dd, J = 15.9, 5.0, 
1H), 2.01–1.81 (m, 3H), 1.79–1.66 (m, 2H), 1.63 (d, J = 3.5, 3H), 1.62–1.46 (m, 3H), 
1.44 (s, 9H), 1.10 (s, 1H), 1.10–1.06 (m, 18H), 0.93 (d, J = 6.4, 3H). 
13C NMR  (101 MHz, CDCl3)) δ = 155.5, 144.4, 138.3, 130.6, 125.2, 116.4, 115.5, 78.8, 47.4, 
46.7, 39.0, 37.8, 35.8, 34.3, 30.0, 29.7, 28.5, 28.1, 25.3, 24.6, 21.9, 18.2, 17.9, 13.4. 
HRMS   (EI): calculated for C33H62NO3Si 548.4493, found 548.4503. 
 
 
 
 
Tert-butyl (3-((4S,6R)-6-allyl-4-methylcyclohex-1-en-1-yl)propyl)((E)-hex-4-en-1-yl)carbamate 
(1.399). Amine 1.363 (0.41 g, 0.15 mmol, 1.5 eq.) was dissolved in THF (6 mL) and 9-BBN (0.5 M 
in THF, 4.5 mL, 2.3 mmol, 2.0 eq.) was added dropwise at room temperature. After 8 h, TLC 
 
analysis showed full conversion and a degassed aqueous solution Cs2CO3 (3 M, 1.2 mL, 
3.4 mmol, 3.0 eq.) was added. After 30 min, iodide 1.398 (0.30 g, 1.1 mmol, 1.0 eq.) in degassed 
DMF (6 mL) and AsPh3 (35 mg, 0.11 mmol, 0.10 eq.) were added. After 10 min, Pd(dppf)Cl2 
(43 mg, 56 µmol, 0.05 eq.) was added, turning the reaction mixture dark brown within 2 min. 
After 15 h at room temperature, saturated aqueous NH4Cl (20 mL) and H2O (10 mL) were 
added. The heterogeneous mixture was extracted with Et2O (3 × 40 mL), the combined organic 
phases were washed with saturated aqueous NaCl (30 mL), dried with MgSO4 and concentrated 
to give a brown oil. Purification by column chromatography (pentane:EtOAc 30:1) gave 1.399 
(0.32 g, 0.87 mmol, 72%) as a colorless oil. 
 
Rf   0.77 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 5.82–5.67 (m, 1H), 5.48–5.39 (m, 2H), 5.41–5.36 (m, 1H), 
5.06–4.96 (m, 2H), 3.14 (br s, 4H), 2.36–2.22 (m, 1H), 2.08–2.03 (m, 2H), 2.03–1.90 
(m, 5H), 1.76–1.69 (m, 1H), 1.64 (d, J = 4.3, 4H), 1.59–1.52 (m, 4H), 1.44 (d, J = 1.8, 
9H), 1.19 (td, J = 12.4, 5.4, 1H), 0.91 (t, J = 6.7, 3H). Due to extensive rotamer line 
broadening, not all integrals match. 
13C NMR  (101 MHz, CDCl3)) δ = 155.7, 139.6, 138.2, 137.0, 130.7, 125.4, 123.2, 121.8, 116.2, 
115.8, 79.1, 47.3, 46.9, 38.3, 37.7, 37.6, 37.4, 36.7, 34.8, 34.6, 34.3, 32.5, 32.0, 30.1, 
29.1, 28.7, 28.3, 27.1, 26.9, 23.6, 22.3, 22.1, 18.1. Note: due to rotamers, almost two 
complete sets of peaks were observed. 
IR  (ATR): 2925, 2868, 1693, 1468, 1455, 1414, 1365, 1300, 1255, 1165, 1155, 1060, 994, 
965, 908, 808, 772, 733. 
HRMS   (EI): calculated for C24H42NO2 376.3210 found 376.3217. 
 
 
 
 
Tert-butyl (10aS,12S)-12-methyl-2,3,5,6,7,10,10a,11,12,13- decahydrobenzo-[e][1]-azacyclo-
dodecine-4(1H)-carboxylate (1.400). Alkene 1.399 (144 mg, 0.40 mmol, 1.0 eq.) was dissolved in 
CH2Cl2 (1.9 L) and the solution was degassed with argon for 20 min. At this point, Grubbs I 
(33 mg, 40 µmol, 0.10 eq.) was added and the mixture was heated to 40 °C. After 24 and 48 h, 
additional Grubbs I (two times 32 mg, 40 µmol, 0.10 eq.) was added. After 72 h, the solvent was 
removed and the residue purified by column chromatography (pentane:EtOAc 30:1) to give 
1.400 (92 mg, 0.28 mmol, 70%) as a colorless oil. 
 
Rf   0.70 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 5.68 –5.58 (m, 1H), 5.54–5.43 (m, 2H), 5.42–5.32 (m, 3H), 
3.80 (s, 4H), 3.42–3.25 (m, 1H), 3.27–2.99 (m, 4H), 2.95–2.79 (m, 3H), 2.45 (q, 
J=13.2, 12.6, 1H), 2.39–2.30 (m, 1H), 2.29–1.43 (m, 12H), 1.40 (d, J=1.5, 22H), 1.17 
(d, J=12.1, 4H), 0.92–0.82 (m, 7H). Due to extensive rotamer line broadening, not all 
integrals match. 
13C NMR  (101 MHz, CDCl3)) δ = 157.1, 156.9, 140.7, 140.5, 130.5, 130.1, 129.8, 129.1, 122.5, 
122.4, 79.3, 79.2, 49.5, 49.1, 48.9, 48.5, 41.8, 41.0, 40.2, 39.4, 38.7, 36.4, 34.6, 34.4, 
34.3, 32.1, 31.9, 31.1, 30.5, 29.6, 29.4, 28.7, 28.6, 24.7, 24.4, 24.2, 23.5, 22.3, 22.3. 
Note: due to rotamers, almost two complete sets of peaks were observed. 
IR  (ATR): 2947, 2924, 1694, 1459, 1414, 1365, 1300, 1282, 1240, 1171, 1121, 1058, 978, 
866, 769, 721. 
HRMS   (EI): calculated for C21H35NO2 333.2668 found 333.2662. 
 
 
 
 
Tert-butyl (10aS,12R)-8,9,14,14a-tetrahydroxy-12-methyltetradecahydrobenzo[e][1]-
azacyclododecine-4(1H)-carboxylate (1.401). 
 
Rf   0.55 (CH2Cl2:MeOH:AcOH:H2O 90:10:0.6:0.6). Colorless foam. 
IR  (ATR): 3451, 3417, 3404, 2950, 2926, 1690, 1666, 1480, 1464, 1417, 1366, 1311, 1249, 
1167, 1095, 1044, 982, 866, 757, 684. 
HRMS   (ESI): calculated for C21H40NO6 402.2850 found 402.2859. 
 
 
 
 
 
Tert-butyl (10aS,12R)-14a-hydroxy-12-methyl-8,9,14-trioxotetradecahydrobenzo-
[e][1]azacyclo-dodecine-4(1H)-carboxylate (1.402). 
 
Rf   0.25 (hexanes:EtOAc 1:1). Colorless foam. 
HRMS   (ESI): calculated for C24H34NO3 396.2381 found 396.2390. 
 
 
 
 
Tert-butyl allyl(pent-4-yn-1-yl)carbamate (1.413). Sodium hydride (60%, 24 mg, 0.60 mmol, 
1.2 eq.) was added in one portion to Boc-protected allylamine 1.412 (79 mg, 0.50 mmol, 1.0 eq.) 
in dry DMF (1.5 mL) at 0 °C to give an orange suspension. After 20 min, 4-pentynyl iodide 
(1.284) (0.15 g, 0.75 mmol, 1.50 eq.) was added dropwise at 0 °C. After the addition was 
complete, the ice bath was removed and the reaction was stirred at room temperature for 22 h. 
When the reaction was judged complete by TLC, saturated aqueous NH4Cl (15 mL) and H2O 
(10 mL) were added carefully. The aqueous phase was extracted with Et2O (3 × 30 mL), then the 
combined organic phases were washed with saturated aqueous NaCl (30 mL), dried, filtered 
and evaporated to give a yellow residue that was purified by column chromatography 
(hexanes:EtOAc 15:1) to give the desired product 1.413 as a colorless oil (89 mg, 0.40 mmol, 
80%). 
 
Rf   0.62 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 5.75 (ddt, J = 16.3, 10.6, 5.7, 1H), 5.09 (d, J = 11.4, 2H), 3.79 
(d, J = 18.3, 2H), 3.25 (t, J = 7.1, 2H), 2.17 (td, J = 7.1, 2.6, 2H), 1.93 (t, J = 2.7, 1H), 
1.72 (t, J = 7.2, 2H), 1.43 (s, 9H). 
13C NMR  (101 MHz, CDCl3) δ = 155.6, 152.4, 134.3, 116.6, 116.1, 83.8, 82.4, 79.6, 68.8, 50.2, 
49.6, 45.9, 45.7, 28.5, 27.4, 27.2, 16.1. (3 peaks were strongly broadened due to 
rotamers). 
IR  (ATR): 3309, 3255, 2976, 2932, 1688, 1463, 1408, 1365, 1273, 1246, 1162, 1137, 992, 
916, 772, 630. 
HRMS   (EI): calculated for C14H22NO2 224.1645 found 224.1645. 
 
 
 
 
Tert-butyl allyl(hex-4-yn-1-yl)carbamate (1.413). Full characterization for compound 1.413 can 
be found in section 4.2.1.1 (compound S1). 
 
 
 
 
Tert-butyl (R)-hex-4-yn-1-yl(3-(4-methyl-6-oxocyclohex-1-en-1-yl)propyl)-carbamate (1.417). 
Full characterization for compound 1.417 can be found in section 4.2.1.1 (compound S2). 
 
 
 
 
Tert-butyl hex-4-yn-1-yl(3-iodopropyl)carbamate (1.418). 9-BBN (0.5 M in THF, 2.2 mL, 
1.1 mmol, 1.2 eq.) was added dropwise to terminal alkene 1.413 (0.22 g, 0.90 mmol, 1.0 eq.) in 
THF (3 mL) at 0 °C. After stirring for 30 min at 0 °C and 3 h at room temperature, a solution of 
NaOMe in MeOH (0.72 mL, 3.9 mmol, 4.3 eq.), followed by I2 (0.82 g, 3.3 mmol, 3.6 eq.) in 
MeOH, (4 mL) were added via cannula. The resulting mixture was stirred at room temperature 
for 3 h, then diluted with saturated aqueous Na2S2O3 (10 mL) and extracted with EtOAc 
(3 × 15 mL). The organic extracts were washed with aqueous HCl (1 M, 10 mL), saturated 
aqueous NaCl (15 mL) and dried over MgSO4. The yellow solution was filtrated over a short 
silica plug and concentrated in vacuo to give 1.418 (0.23 g, 0.64 mmol, 71%) as a slightly yellow 
oil. 
 
 
Rf   0.37 (hexanes:EtOAc 5:1) Brown oil. 
1H NMR  (400 MHz, CDCl3) δ = 3.30–3.23 (m, 4H), 3.15 (t, J = 6.9, 2H), 2.13 (ddt, J = 7.0, 4.5, 
2.5, 1H), 2.06 (d, J = 7.8, 3H), 1.78 (t, J = 2.5, 3H), 1.70 (d, J = 8.8, 2H), 1.45 (s, 9H). 
13C NMR  (151 MHz, CDCl3) δ = 155.9, 80.0, 78.6, 48.4, 47.3, 32.8, 28.8, 28.5, 16.6, 3.9, 3.5, 
3.3. 
 
Note: This primary iodide decomposes quickly at room temperature, but is stable for at least three days at 
−20 °C. 
 
 
 
 
Tert-butyl (3-((4R,6S)-2-((tert-butyldimethylsilyl)oxy)-4-methyl-6-(prop-2-yn-1-yl)cyclohex-1-
en-1-yl)propyl)(hex-4-yn-1-yl)carbamate (1.421). Enone 1.417 (35 mg, 0.10 mmol, 1.0 eq.) was 
dissolved in CH2Cl2 (0.8 mL) and cooled to −78°C. 2,6-Di-tert-butylpyridine (22 µL, 0.10 mmol, 
1.0 eq.) and TBSOTf (29 µL, 0.12 mmol, 1.2 eq.) were added sequentially in one portion at −78°C, 
at which point the reaction turned bright yellow. After 10 min, allenyltributyltin (39 mg, 
0.12 mmol, 1.2 eq.) was added dropwise over 10 min. The reaction was stirred at −78 °C for 5 h, 
then saturated aqueous NaHCO3 solution (3 mL) was added. The biphasic mixture was allowed 
to warm to room temperature and was extracted with Et2O (3 × 15 mL). The organic phases 
were dried with MgSO4 and concentrated to give a colorless oil that was submitted to column 
chromatography (pentane:Et2O 12:1) to yield a colorless oil 1.421 (25 mg, 50 µmol, 50%) 
 
Rf   0.70 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (400 MHz, C6D6) δ = 3.47–3.02 (m, 5H), 2.58–2.28 (m, 3H), 2.21–1.93 (m, 6H), 
1.90–1.63 (m, 6H), 1.59 (s, 3H), 1.49 (s, 9H), 1.28 (dt, J = 11.9, 6.2, 1H), 1.02 (s, 9H), 
0.87 (d, J = 6.4, 3H), 0.12 (s, 6H). 
13C NMR  (101 MHz, C6D6) δ = 155.3, 145.2, 83.9, 78.9, 78.7, 75.9, 69.8, 48.0, 47.7, 46.8, 39.3, 
36.2, 35.3, 28.6, 27.6, 26.2, 25.5, 25.1, 23.4, 21.8, 18.5, 16.7, 3.5, −3.4, −3.4. 
IR  (ATR): 3312, 2954, 2928, 2858, 2349, 1694, 1471, 1414, 1365, 1288, 1253, 1223, 1170, 
1053, 933, 890, 837, 777, 626. 
HRMS   (EI): calculated for C30H51NO3Si 501.3638, found 501.3630. 
 
 
 
 
Tert-butyl (3-((4R,6S)-6-(but-2-yn-1-yl)-2-((tert-butyldimethylsilyl)oxy)-4-methylcyclohex-1-
en-1-yl)propyl)(hex-4-yn-1-yl)carbamate (1.422). Silyl enol ether 1.421 (10 mg, 19 µmol, 1.0 eq.) 
was dissolved in THF (0.7 mL) and cooled to −78 °C before n-BuLi (2.28 M, 10 µL, 21 µmol, 
1.1 eq.) was added dropwise, giving a bright yellow solution. After 35 min, methyl iodide (5 µL 
(1 drop), 29 µmol, 1.50 eq.) was added at −78 °C, immediately decolorizing the solution. After 
1.5 h, the cooling bath was removed and the reaction was stirred for another 3 h. The reaction 
mixture was evaporated to give a yellow residue that was purified by column chromatography 
(hexanes:Et2O 12:1) to give the desired product 1.422 as a colorless oil (7 mg, 12 mmol, 63%). 
 
Rf   0.75 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (400 MHz, CDCl3) δ = 3.21 (br s, 3H), 3.09 (br s, 2H), 2.37–2.21 (m, 3H), 2.11 (s, 
2H), 2.04 (dd, J = 16.5, 5.8, 1H), 1.86 (d, J = 12.0, 2H), 1.77 (2s, 6H), 1.74–1.58 (m, 
3H), 1.44 (s, 9H), 1.32–1.15 (m, 2H), 0.96 (d, J = 6.5, 3H), 0.93 (s, 9H), 0.12 (s, 6H). 
13C NMR  (101 MHz, C6D6) δ = 155.5, 144.8, 79.0, 78.5, 76.0, 75.7, 46.3, 39.0, 36.3, 34.8, 28.5, 
25.9, 24.7, 23.2, 21.8, 18.2, 16.3, 3.6, 3.5, -3.5, -3.6. 
IR  (ATR): 2954, 2926, 2858, 1694, 1472, 1416, 1366, 1288, 1255, 1225, 1169, 1054, 974, 
894, 837, 777, 676. 
HRMS   (EI): calculated for C30H51NO3Si 515.3795, found 515.3789. 
 
 
 
 
 
Tert-butyl (3-((2R,4R)-2-(but-3-yn-1-yl)-4-methyl-6-oxocyclohexyl)propyl)-(hex-4-yn-1-yl)-
carbamate (1.433). Full characterization for this compound can be found in section 4.2.1.1 
(compound 1). 
 
 
 
 
N-(3-((4R,6R)-6-Allyl-2-((tert-butyldimethylsilyl)oxy)-4-methylcyclohex-1-en-1-yl)propyl)-N-
((E)-hex-4-en-1-yl)-2-nitrobenzenesulfonamide (1.449). Enone 1.385 (43 mg, 0.10 mmol, 1.0 eq.) 
was dissolved in CH2Cl2 (0.8 mL) and cooled to −78 °C before DTBPy (33 µL, 0.15 mmol, 1.5 eq) 
and molecular sieves 4 Å (50 mg, powdered) were added. After 15 min, TBSOTf (28 µL, 
0.12 mmol, 1.2 eq) was added dropwise, rendering a yellow solution to which allylSnBu3 (37 µL, 
0.11 mmol, 1.1 eq) was added 10 min later. After 3 h at −78 °C, the reaction was diluted with 
CH2Cl2 (10 mL) and warmed to room temperature before saturated aqueous NaHCO3 (5 mL) 
and H2O (2 mL) were added. The aqueous phase was extracted with CH2Cl2 (3 × 10 mL) and the 
combined organic phases were washed with saturated aqueous NaHCO3 (5 mL), dried with 
MgSO4 and concentrated. The resulting yellow oil was purified by column chromatography 
(pentane:EtOAc 15:1 to 10:1) to give 1.449 (34 mg, 58 µmol, 58%) as a colorless oil. 
 
Rf   0.58 (hexanes:EtOAc 5:1). Colorless oil. 
1H NMR  (400 MHz, C6D6) δ = 7.79 (dd, J = 7.9, 1.2, 1H), 6.76–6.65 (m, 2H), 6.54 (td, J = 7.7, 
1.3, 1H), 5.74 (dtd, J = 17.8, 8.3, 6.0, 1H), 5.30 (p, J = 5.7, 2H), 5.13–4.97 (m, 2H), 
3.46–3.14 (m, 4H), 2.43 (ddd, J = 14.0, 9.8, 6.8, 1H), 2.29 (dt, J = 14.1, 4.7, 1H), 2.15 
(dd, J = 9.3, 4.9, 1H), 2.07 (dd, J = 15.9, 5.2, 1H), 1.98–1.91 (m, 1H), 1.91–1.60 (m, 
7H), 1.58–1.52 (m, 5H), 1.16 (td, J = 12.3, 5.5, 1H), 1.02 (s, 9H), 0.88 (d, J = 6.4, 3H), 
0.13 (s, 6H). 
13C NMR  (101 MHz, C6D6) δ = 148.5, 144.9, 138.4, 134.3, 132.7, 130.9, 130.8, 130.3, 125.9, 
123.9, 117.2, 116.0, 47.6, 47.2, 39.3, 38.3, 36.3, 34.7, 29.9, 28.4, 27.1, 26.2, 25.5, 25.0, 
22.0, 18.5, 18.1, -3.3, -3.4. 
IR  (ATR): 2951, 2928, 2856, 1709, 1671, 1639, 1544, 1471, 1461, 1439, 1370, 1350, 1252, 
1199, 1160, 1124, 1059, 966, 850, 836, 776, 736, 704. 
HRMS   (EI): calculated for C24H45N2O5SSi (−allyl) 549.2818 found 549.2866. 
 
 
 
 
Supplementary Figure 1. UV-Vis spectra and thermal stability of ATG. 
(a) UV-Vis spectra of ATG in the dark-adapted state and during illumination with 370, 405 and 
420 nm light in physiological buffer. (b) Kinetics of the conversion of trans- to cis-ATG during 
illumination with 460 and 365 nm light (high power LEDs) measured at the maximal absorption 
wavelength of trans-ATG (330 nm). 
 
 
Supplementary Figure 2. Action spectrum, kinetics and dose-response curve recorded in layer 
2/3 cortical neurons.  
(a) Wavelength screening for activation of ATG-mediated (200 µM) currents. Left: Raw data 
traces for 5 s light stimulation from 360 nm to 410 nm light (dark to light violet). Right: Current 
amplitude was measured after 5 s light stimulation with the respective wavelength and 
normalized to the maximal current amplitude at 360 nm. (b) Wavelength screening for off 
kinetics of ATG-mediated currents. Left: Raw data traces showing the off-kinetics after a 5 s 
 
light-stimulation with 370 nm. Best off kinetics were achieved at 425–450 nm light (red trace: 
exponential fit). Right: Measurement of off kinetics for wavelengths between 400 nm and 540 
nm light. (c) Relative light intensities depending on wavelengths used. Light intensity for trans-
cis isomerization (370 nm) approx. 5 mW cm-2 and for cis-trans isomerization approx. 9.5 mW 
cm-2. 
 
 
Supplementary Figure 3. ATG targets NMDARs  
Current-voltage relationship of ATG-mediated currents measured after 3 s of illumination (370 
nm) in the presence of NMDAR and AMPAR antagonists in layer 2/3 cortical neurons of acute 
brain slices. 200 µM ATG was used for all experiments. Black: control Red: 25 µM NBQX (n=8 
cells), a selective AMPAR antagonist. Green: 40 µM D-AP-5, a selective NMDAR antagonist (n=3 
cells). Blue: 50 µM MK-801, a selective NMDAR blocker (n=5 cells). Single data points represent 
mean ± SEM.  
 
 
Supplementary Figure 4. ATG activates different NMDA receptor compositions in Xenopus 
oocytes. 
NMDA- and cis-ATG-mediated currents in oocytes heterologously expressing NMDA receptor 
subunit combinations in the presence of 1.8 mM barium, 250 µM NFA and 10 µM glycine. 
Representative current traces in response to transient bath perfusion of 1 mM NMDA (left) and 
light-mediated currents (365 nm LED illumination, pink) in presence of 200 µM ATG (right) for 
the NMDA receptor combinations GluN1-1a and (a) GluN2A, (b) GluN2B, (c) GluN2C, and (d) 
GluN2D. Blue bar indicates 460 nm LED illumination. The insets in (a) and (b) show currents in 
response to non-saturating NMDA concentrations (10 µM), ruling out the presence of a 
calcium-induced chloride currents. 460 nm-evoked currents were present for GluN2C and 2D 
 
containing receptors. (e) Summary plots showing average steady-state current amplitudes 
induced by 1 mM NMDA (left) and by 200 µM cis-ATG (center) for all subtype combinations 
shown in (a). Summary plot of the average within-cell ratio of cis-ATG-mediated currents in 
relation to saturating NMDA-induced currents (right). Average NMDA-evoked currents were 
larger (GluN1-1a/2A = 14.93±1.21 µA, GluN1-1a/2B = 8.65±1.13 µA, GluN1-
1a/2C = 0.06±0.01 µA and GluN1-1a/2D = 0.29±0.05 µA) than cis-ATG-mediated currents 
(GluN1-1a/2A = 217.6±17.5 nA, GluN1-1a/2B = 400.9±65.4 nA, GluN1-1a/2C = 3.46±1.69 nA 
and GluN1-1a/2D = 5.91±0.57 nA). 
 
 
Supplementary Figure 5. Characterization of cis-STG in layer 2/3 cortical neurons. (a) 
Current-clamp recording in layer 2/3 cortical neuron with cis-STG. Puff-application of 200 µM 
cis-STG for 500 ms result in robust action potential firing. (b) Current-voltage relationship of 
cis-STG in cortical neurons. Ramps were performed between –70 mV and 50 mV. Single cell 
recording are depicted in grey (n=5), average trace of all experiments is shown in red.  
 
 
Supplementary Figure 6. Impact of ATG on GABAAR-mediated currents. (a) Spontaneous 
iGABAAR currents and evoked IPSCs (elicited with 0.1 Hz stimulation) recorded from a CA1 
pyramidal cell from an acute brain slice. (b) Peak amplitude of spontaneous events. After 10 
minutes of recording, ATG (400 µM) was washed in for twenty minutes, and then subsequently 
washed out. (c) Average spontaneous event currents from example cell shown in a) in control 
conditions and in the presence of 400 µM ATG. (d) Summary plots showing the time at which 
spontaneous IPSCs decayed by 50% in control and in 400 µM ATG (n=10 cells). (e) Summary 
plots showing the coefficient of variation and fractional block of IPSCs by 400 µM ATG (n=10). 
*, P<0.05, NS indicates comparisons that are not significantly different (Wilcoxon matched pairs 
signed rank test). 
 
Supplementary Figure 7. One-photon 375 nm and 405 nm laser spot sizes. Relative intensity 
profile resulting from scanning 100 nm green fluorescence with 375 nm (FWHM = 300 nm) or 
405 nm (FWHM = 4.25 µm) laser illumination.  
 
 
 
Supplementary Figure 8. NMDAR currents evoked in hippocampal CA1 pyramidal neurons 
in acute brain slices by one-photon activation of bath applied ATG. (a) Representative cis-
ATG-mediated currents in response to 100 ms, 500 ms, and 5 s 375 nm laser illumination of 
dendrites in the presence of 200 M ATG. (b) cis-ATG-mediated currents were evoked with 5 s 
375 nm laser pulses of 15 µW, 60 µW, and 150 µW. (c) The dependence of ATG-evoked peak 
response on activating laser power for 5 cells. Increasing the power from 50 to 150 µW produces 
a sublinear increase in cis-ATG-mediated current amplitudes, suggesting responses are 
maximal, potentially due to saturation of ATG conversion or NMDAR occupancy. (d) Top: 
Distance dependence of cis-ATG-mediated responses evoked by 100 ms, 375 nm light pulses 
using bath and local ATG application (100 M). A more localized response is achieved using 
local application of ATG. Traces are averages of 3 trials. Bottom: Decay kinetics of cis-ATG-
mediated responses (100 ms illumination) in bath and local application. Summary bar graph 
shows weighted decay time constants (weighted) for bath (27.1 ± 4.0 s, n = 6 cells) and local 
perfusion (local, 4.5 ± 0.4 s, n = 9 cells).*, P < 0.05, (Wilcoxon matched pairs signed rank test). 
 
 
Supplementary Figure 9. Concentration dependence of activation and fractional reduction of 
CA1 pyramidal cell NMDAR currents for ATG and MNI-glutamate. (a) NMDAR currents 
evoked by activation of locally applied ATG and uncaging of MNI-glutamate (ATG: 100 µM 
(n = 9 cells), and 750 µM (n = 12); MNI-glutamate: 100 µM (n = 5), 750 µM (n = 5)). MNI-glu 
experiments were performed in TBOA (500 µM)). There is no significant difference between rise 
times of NMDAR currents evoked by MNI-glu uncaging and ATG activation for the same 
concentration. (b) Comparison 405 nm- mediated reduction in NMDAR currents following 375 
nm activation at different concentrations 77 ± 5% for 100 µM (n = 8 cells) and 53 ± 6% for 750 µM 
(n = 6). Fractional reduction was calculated as 1 −
50 𝑚𝑠 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑖𝑚𝑚𝑒𝑑𝑖𝑎𝑡𝑒𝑙𝑦 𝑎𝑓𝑡𝑒𝑟 405 𝑛𝑚 𝑝𝑢𝑙𝑠𝑒
50 𝑚𝑠 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑖𝑚𝑚𝑒𝑑𝑖𝑎𝑡𝑒𝑙𝑦 𝑏𝑒𝑓𝑜𝑟𝑒 405 𝑛𝑚 𝑝𝑢𝑙𝑠𝑒
.  
*P<0.05 (Steel Dwass all pairs nonparametric multiple comparison test). The fractional reduction 
in NMDAR currents by 405 nm light was most effective when working at the lower ATG 
concentrations, 100 µM.  
  
 
 
 
(2S,4R)-2-(tert-Butoxycarbonylamino)-4-(prop-2-ynyl)pentanedioic acid (1). To a solution of 
propargylated pyroglutamate S1 (528 mg, 1.79 mmol) in THF (50 mL) cooled to 0 ºC was added 
aqueous LiOH (1 M, 50 mL). The resulting mixture was allowed to warm to room temperature 
and stirred at this temperature for 30 min. The solution was acidified to pH = 1 with aqueous 
HCl (1 N, 100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phase was 
washed with concentrated aqueous NaCl (400 mL), then dried (MgSO4) and concentrated in 
vacuo. Column chromatography (CH2Cl2:MeOH:AcOH:H2O 90:10:0.6:0.6) afforded diacid 1 
(510 mg, 1.79 mmol, 99%) as a white foam. 
 
Rf  0.23 (CH2Cl2:MeOH:AcOH:H2O 90:10:0.6:0.6); 
1H NMR  (400 MHz, CD3OD) δ = 4.21 (dd, J = 10.6, 4.2, 1H), 2.72–2.63 (m, 1H), 2.55–2.48 
(m, 2H), 2.35–2.31 (m, 1H), 2.31–2.24 (m, 1H), 1.84 (ddd, J = 14.2, 10.7, 4.0, 1H), 
1.44 (s, 9H). 
13C NMR  (101 MHz, CD3OD) δ = 176.9, 175.8, 158.1, 81.5, 80.5, 71.6, 53.2, 42.2, 33.9, 28.7, 
22.5. 
IR   (ATR): 3296, 2979, 2934, 2556 (br), 1706, 1515. 
HRMS  (ESI): calculated for C13H19NO6 284.1140, found 284.1147. 
[α]D22  −12.0 (3.1, MeOH). 
Mp.  47–49 °C. 
 
 
 
 
(E)-4-(Phenyldiazenyl)aniline (S3). To a solution of nitrosobenzene (749 mg, 7.0 mmol) in acetic 
acid (50 mL) was added 1,4-phenylenediamine (S2) (756 mg, 7.0 mmol) as a solid and the 
resulting mixture was stirred at 40 °C for 15 h. The dark solution was allowed to cool to room 
temperature, then diluted with H2O (300 mL) and extracted with EtOAc (3 x 300 mL). The 
combined organic phase was washed further with concentrated aqueous NaCl (2 x 500 mL), 
then dried (MgSO4) and concentrated in vacuo. Column chromatography (dry-loaded, 
hexanes:EtOAc 4:1) afforded (E)-4-(phenyldiazenyl)aniline (S3) (510 mg, 2.59 mmol, 37%) as an 
orange solid. 
 
Rf  0.24 (hexanes:EtOAc 4:1). 
1H NMR (400 MHz, CDCl3) δ = 7.87–7.80 (m, 4H), 7.49 (t, J = 7.5, 2H), 7.41 (t, J = 7.4, 1H), 
6.75 (d, J = 8.9, 2H), 4.04 (br s, 2H). 
13C NMR (101 MHz, CDCl3) δ = 152.9, 149.5, 145.5, 129.8, 128.9, 125.1, 122.3, 114.6. 
IR  (ATR): 3348, 1616, 1596. 
HRMS   (EI): calculated for C12H11N3 197.0947, found 197.0954. 
Mp.  116–119 °C. 
 
(E)-4-(Phenyldiazenyl)aniline can also be prepared via a modified literature procedure.2 To a 
suspension of aniline S2 (9.34 g, 100 mmol) in H2O (200 mL) was added solid sodium carbonate 
(5.30 g, 50 mmol) and the mixture was cooled to 0 ºC. A solution of sodium nitrite (7.40 g, 
107 mmol) in H2O (100 mL), half-concentrated aqueous HCl (40 mL), and a solution of aniline 
(9.34 g, 100 mL) in acetic acid (6 mL) were all slowly added in a sequential manner with careful 
monitoring of the temperature. The mixture was stirred at 0 ºC for 30 min, at which point 
aqueous NaOH (12%, 100 mL) was added, resulting in the formation of an orange solid. The 
mixture was allowed to warm to room temperature and vigorously stirred at this temperature 
for 2 h. The suspension was diluted with concentrated aqueous NaCl (200 mL) and extracted 
with CH2Cl2 (500 mL). The organic phase was dried (MgSO4) and concentrated in vacuo. Column 
chromatography (dry-loaded, hexanes:EtOAc 9:1 to 4:1) afforded (E)-4-(phenyldiazenyl)aniline 
(S3) (5.72 g, 30 mmol, 30%) as an orange solid. 
 
 
 
 
(E)-1-(4-Azidophenyl)-2-phenyldiazene (2). To a solution of (E)-4-(phenyldiazenyl)aniline 
(99 mg, 0.50 mmol) in MeCN at 0 °C was added tert-butyl nitrite (89 µL, 0.75 mmol) followed by 
trimethylsilyl azide (97%, 80 µL, 0.60 mmol). The mixture was allowed to warm to room 
temperature and stirred at this temperature for 1 h, then concentrated in vacuo. Flash column 
 
chromatography (dry-loaded, hexanes:CH2Cl2 9:1) afforded azide 2 (98 mg, 88%) as an orange 
solid. 
 
Rf  0.20 (hexanes:CH2Cl2 9:1). 
1H NMR  (400 MHz, CDCl3) δ = 7.95 (d, J = 9.0, 2H), 7.91 (dd, J = 8.3, 1.5, 2H), 7.55–7.44 (m, 
3H), 7.16 (d, J = 9.0, 2H). 
13C NMR (100 MHz, CDCl3) δ = 152.6, 149.8, 142.6, 131.0, 129.1, 124.6, 122.8, 119.5. 
IR   (ATR): 2107, 1592. 
HRMS   (EI): calculated for C12H9N5 223.0852, found 223.0858. 
Mp.   90–91 °C. 
 
 
 
 
(2S,4S)-2-(tert-Butoxycarbonylamino)-4-((1-(4-((E)-phenyldiazenyl)phenyl)-1H-1,2,3-triazol-4-
yl)methyl)pentanedioic acid (3). Alkyne 1 (215 mg, 0.75 mmol) and azide 2 (168 mg, 0.75 mmol) 
were dissolved in a mixture of MeOH (12 mL) and DMSO (4 mL) by means of ultrasound. 
Copper(II) sulfate pentahydrate (38 mg, 0.15 mmol), sodium ascorbate (37 mg, 0.19 mmol) and 
H2O (4 mL) were added, and the resulting suspension was stirred at room temperature for 24 h. 
The reaction was allowed to cool to room temperature, then quenched with aqueous HCl (1 N, 
50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phase was washed with 
aqueous LiCl (10%, 3 x 100 mL) and concentrated aqueous NaCl (100 mL), dried (MgSO4) and 
concentrated in vacuo. Column chromatography (CH2Cl2:MeOH:AcOH:H2O 90:10:0.6:0.6) 
afforded the Boc-protected amine 3 (353 mg, 0.69 mmol, 92%) as an orange solid. 
 
Rf  0.26 (CH2Cl2:MeOH:AcOH:H2O 90:10:0.6:0.6). 
1H NMR (400 MHz, CD3OD, major E isomer quoted) δ = 8.37 (s, 1H), 8.04 (d, J = 9.1, 2H), 
7.98 (d, J = 9.1, 2H), 7.92–7.88 (m, 2H), 7.56–7.50 (m, 3H), 4.25 (dd, J = 10.6, 3.9, 
1H), 3.21–3.12 (m, 1H), 3.07–2.93 (m, 2H), 2.29 (ddd, J = 13.5, 9.7, 3.9, 1H), 1.89 
(ddd, J = 13.6, 10.7, 3.3, 1H), 1.43 (s, 9H). 
13C NMR  (100 MHz, CD3OD, major E isomer quoted) δ = 177.5, 175.8, 158.1, 153.8, 153.3, 
147.1, 139.9, 132.8, 130.3, 125.3, 124.0, 122.2, 121.9, 80.5, 53.3, 43.3, 34.4, 29.3, 28.7. 
HRMS   (ESI): calculated for C25H28N6O6 509.2143, found 509.2145. 
IR  (ATR): 2978, 2930, 2508 (br), 1700, 1603, 1507. 
[α]D22   +4.9 (1.63, MeOH). 
Mp.   136 °C (decomposition). 
 
 
 
(2S,4S)-2-Amino-4-((1-(4-((E)-phenyldiazenyl)phenyl)-1H-1,2,3-triazol-4-
yl)methyl)pentanedioic acid hydrochloride (trans-ATG). To solid Boc-protected amine 3 
(338 mg, 0.67 mmol) was added concentrated HCl solution in EtOAc (20 mL), prepared by 
bubbling HCl gas through EtOAc for 1 h, and the resulting mixture was vigorously stirred at 
room temperature for 3 h. The suspension was diluted with Et2O (100 mL). The solid was 
separated, then washed with Et2O (2 x 50 mL) and dried in vacuo to afford amine hydrochloride 
trans-ATG (281 mg, 95%) as an orange solid. 
 
1H NMR  (600 MHz, CD3OD) δ = 8.48 (s, 1H), 8.13 (d, J = 8.7, 2H), 8.06 (d, J = 8.9, 2H), 7.96 
(dd, J = 8.1, 1.5, 2H), 7.60–7.53 (m, 3H), 4.15 (dd, J = 8.1, 6.0, 1H), 3.30–3.22 (m, 
1H), 3.20–3.12 (m, 2H), 2.48–2.41 (m, 1H), 2.05 (ddd, J = 14.7, 8.1, 4.6, 1H). 
13C NMR  (150 MHz, CD3OD) δ = 176.5, 171.4, 153.9, 153.6, 146.5, 139.9, 132.8, 130.4, 125.3, 
124.0, 122.7, 122.0, 52.4, 42.4, 32.7, 28.5. 
IR  (ATR): 2903 (br), 2612 (br), 1726, 1596, 1507. 
HRMS   (ESI): calculated for C20H20N6O4 409.1619, found 409.1618. 
[α]D22  +20.2 (0.27, MeOH). 
Mp.   171 °C (decomposition). 
UV/Vis  λmax = 331 nm. (5% DMSO in H2O). 
 
  
 
 
 
(Z)-4-styrylaniline (S5). (Z)-1-nitro-4-styrylbenzene (S4)5 (225 mg, 1.00 mmol) was dissolved in 
EtOH (6.0 mL) and CH2Cl2 (6.0 mL), followed by addition of Pd/C (20 mg) and cooling to 0 °C. 
N2H4·H2O (85%, 38 µL, 1.00 mmol) was then added dropwise under vigorous stirring and the 
resulting mixture was warmed to room temperature overnight. After 15 h, the mixture was 
filtered through a pad of celite with CH2Cl2 (30 mL). Concentration in vacuo gave (Z)-4-
styrylaniline S5 (196 mg, 1.00 mmol, 100%) as a yellow oil. The spectral data matched the one 
provided in the literature.6 
 
 
 
 
(Z)-1-azido-4-styrylbenzene (4). Amine S5 (293 mg, 1.50 mmol) was dissolved in MeCN (4 mL) 
and cooled to 0 °C before t-butyl nitrite (267 µL, 2.25 mmol) was added dropwise, immediately 
followed by trimethylsilyl azide (239 µL, 1.80 mmol). The reaction mixture was stirred at 0 °C 
for 1 h, then warmed to room temperature and concentrated in vacuo to give a dark-red oil. 
Column chromatography (hexanes:EtOAc 50:1) gave azide 4 (203 mg, 0.92 mmol, 61%) as a 
yellow oil. 
 
Rf  0.35 (hexanes:EtOAc 9:1). 
1H NMR  (400 MHz, C6D6) δ = 7.23–7.19 (m, 2H), 7.08–7.04 (m, 2H), 7.03 (m, 2H), 7.01 (m, 
2H), 6.52 (d, J = 8.5, 2H), 6.44 (d, J = 12.2, 1H), 6.33 (d, J = 12.1, 1H) 
13C NMR  (101 MHz, C6D6) δ = 139.2, 137.6, 134.2, 130.7, 130.6, 129.6, 129.2, 128.7, 127.6, 
126.9, 119.5. 
IR  (ATR): 3213 (w), 3054 (w), 2924 (m), 2412 (w), 2093 (s), 1599 (m), 1503 (s), 1285 
(s), 1244 (s), 1181 (m), 832 (s), 696 (s). 
HRMS  (EI): calculated for C14H11N3 221.0953 found 221.0957. 
 
 
 
(2S,4S)-2-((tert-Butoxycarbonyl)amino)-4-((1-(4-((Z)-styryl)phenyl)-1H-1,2,3-triazol-4-
yl)methyl)pentanedioic acid (5). Alkyne 1 (57 mg, 0.20 mmol) and azide 4 (44 mg, 0.20 mmol) 
were dissolved in a mixture of MeOH (3 mL), H2O (1 mL) and DMSO (1 mL) to give a yellow 
solution. Copper(II) sulfate pentahydrate (10 mg, 0.04 mmol) and sodium ascorbate (10 mg, 
0.05 mmol) were added in one portion, and the resulting suspension was stirred at room 
temperature for 72 h, then quenched with aqueous HCl (1 M, 10 mL) and extracted with EtOAc 
(3 x 40 mL). The organic phase was washed with aqueous LiCl (10%, 3 x 70 mL) and 
concentrated aqueous NaCl (100 mL), then dried (MgSO4), filtered and concentrated in vacuo to 
give a colorless foam. Column chromatography (CH2Cl2:MeOH:AcOH:H2O 90:10:0.6:0.6) gave 5 
(82 mg, 0.16 mmol, 81%) as a colorless oil, along with 10% reisolated starting materials. 
 
Rf  0.34 (CH2Cl2:MeOH:AcOH:H2O 90:10:0.6:0.6). 
1H NMR (400 MHz, CD3OD) δ = 8.26 (s, 1H), 7.77–7.62 (m, 2H), 7.42–7.32 (m, 2H), 7.29–
7.15 (m, 5H), 6.73 (d, J = 12.2, 1H), 6.65 (d, J = 12.2, 1H), 4.25–4.10 (m, 1H), 3.13 
(dt, J = 11.0, 5.4, 1H), 3.09–2.89 (m, 2H), 2.25 (ddd, J = 13.8, 9.5, 3.8, 1H), 1.85 
(ddd, J = 13.5, 10.3, 3.7, 1H), 1.42 (s, 9H), 1.35–1.21 (m, 1H). 
13C NMR  (101 MHz, CD3OD) δ = 177.8, 176.1, 158.1, 146.9, 139.4, 138.3, 137.0, 132.8, 131.3, 
129.9, 129.8, 129.5, 128.5, 122.1, 121.1, 80.5, 53.4, 43.4, 34.5, 29.3, 28.7. 
IR  (ATR): 3213 (w), 3054 (w), 2924 (m), 2515 (w), 1702 (s), 1516 (m), 1446 (s), 1231 
(s), 1161 (s), 1023 (m), 783 (s), 699 (s). 
HRMS   (ESI): calculated for C27H29N4O6 505.2093, found 505.2084. 
[α]D22   +8.5 (1.4, MeOH). 
 
  
 
 
 
(1S,3S)-1,3-Dicarboxy-4-(1-(4-((Z)-styryl)phenyl)-1H-1,2,3-triazol-4-yl)butan-1-aminium 
chloride (cis-STG). Boc-Protected cis-STG (5) (21 mg, 41 µmol) in EtOAc (0.5 mL) was treated 
with a solution of concentrated HCl in EtOAc (2 mL), prepared by bubbling HCl gas through 
anhydrous EtOAc for 40 min. The turbid solution was stirred for 2 h at room temperature. Upon 
addition of ice-cold Et2O (5 mL), a colorless precipitate formed, which was centrifuged with 
Et2O (3 x 10 mL) and dried in vacuo to give cis-STG (14 mg, 31 µmol, 80%) as a colorless solid. 
 
Rf  0.45 (MeCN:H2O 5:1). 
1H NMR (400 MHz, CD3OD) δ = 8.41 (s, 1H), 7.70 (d, J = 8.6 Hz, 2H), 7.41 (d, J = 8.5 Hz, 
2H), 7.31–7.13 (m, 5H), 6.76 (d, J = 12.2 Hz, 1H), 6.68 (d, J = 12.2 Hz, 1H), 4.14 
(dd, J = 8.0, 5.9 Hz, 1H), 3.28–3.21 (m, 1H), 3.21–3.05 (m, 2H), 2.42 (ddd, J = 14.6, 
8.5, 6.0 Hz, 1H), 2.02 (ddd, J = 14.6, 8.2, 4.3 Hz, 1H). 
13C NMR (101 MHz, CD3OD) δ = 176.4, 171.3, 146.0, 139.8, 138.2, 136.7, 133.0, 131.4, 129.9, 
129.7, 129.5, 128.5, 123.0, 121.3, 121.2, 52.4, 42.4, 32.6. 
IR  (ATR): 3376 (br), 2922 (s), 2515 (br), 1918 (br w), 1720 (s), 1599 (m), 1513 (s), 
1446 (m), 1222 (br s), 832 (s), 698 (s). 
HRMS   (ESI): calculated for C22H22N4O4Na: 429.1533 [M+Na]+, found 429.1539 [M+Na]+. 
[α]D22   +17.9 (0.96, MeOH). 
  
 
Note: The following compounds were prepared in addition to the compounds described in chapter 2.2.2 
and don’t appear in the main text. 
 
 
 
 
Methyl 4-chloro-2-(2-(4-nitrophenyl)acetamido)benzoate (2.1). 2-(4-nitrophenyl)acetic acid 
(362 mg, 2.00 mmol, 2.40 eq.) was dissolved in CH2Cl2 (7 mL) and cooled to 0 °C before oxalyl 
chloride solution (2M, 1.30 mL, 2.60 mmol, 3.10 eq.) was added dropwise over 30 min, followed 
by DMF (2 drops). The solution was warmed to room temperature and stirred for 5 h. After this 
time, the solvent was removed in a nitrogen stream. The residue was redissolved in CH2Cl2 
(4 mL) and methyl 2-amino-4-chlorobenzoate (155 mg, 0.83 mmol, 1.00 eq.) was added in one 
portion. The dark-yellow solution was stirred at room temperature or 15 h. Saturated aqueous 
NaHCO3 (5 mL) was added and the solution was extracted with CH2Cl2 (3 × 20 mL), then 
washed with H2O (15 mL) and saturated aqueous NaCl (15 mL), dried over MgSO4 and 
concentrated. The residue was purified by column chromatography (hexanes:EtOAc 2:1) to 
yield 2.1 (260 mg, 0.75 mmol, 90%) as an off-white solid. 
 
Rf   0.18 (hexanes:EtOAc 2:1). Off-white solid. 
1H NMR  (400 MHz, CDCl3) δ = 11.30 (s, 1H), 8.78 (d, J = 1.9, 1H), 8.24 (d, J = 8.3, 2H), 7.94 
(d, J = 8.6, 1H), 7.55 (d, J = 8.3, 2H), 7.07 (dd, J = 8.6, 2.0, 1H), 3.89 (s, 3H), 3.87 (s, 
2H). 
13C NMR  (101 MHz, CDCl3) δ = 168.3, 168.1, 147.4, 142.0, 141.4, 141.1, 131.9, 130.4, 124.0, 
123.3, 120.2, 113.2, 52.6, 45.2. 
IR   (ATR): 2956, 2924, 1695, 1692, 1581, 1521, 1431, 1347, 1313, 1254, 1104, 778. 
HRMS   (ESI): calculated for C16H12ClN2O5 347.0440, found 347.0439. 
Mp   159–163 °C. 
 
 
 
 
 
Methyl 2-(2-(4-aminophenyl)acetamido)-4-chlorobenzoate (2.2). Methyl 2-(2-(4-aminophenyl)-
acetamido)-4-chlorobenzoate (2.1) (45 mg, 0.13 mmol, 1.0 eq.) was dissolved in EtOH (4 mL) and 
H2O (2 mL) before zinc powder (0.26 g, 3.9 mmol, 30 eq.) and CaCl2·6H2O (29 mg, 0.26 mmol, 
2.0 eq.) were added in one portion. The suspension was stirred at 80 °C for 3 h, then cooled to 
room temperature and filtered over a plug of celite with EtOAc (30 mL). The filtrate was diluted 
with H2O (10 mL) and the phases were separated. The aqueous phase was extracted with EtOAc 
(3 × 20 mL). The combined organic phases were washed with saturated aqueous NaCl (30 mL), 
dried over MgSO4 and concentrated. The residue was purified by column chromatography 
(hexanes:EtOAc 2:1) to yield 2.2 (1.18 g, 3.38 mmol, 75%) as a yellow solid. 
 
Rf   0.18 (hexanes:EtOAc 1:1). Yellow solid. 
1H NMR  (400 MHz, CDCl3) δ = 11.01 (s, 1H), 8.82 (d, J = 1.9, 1H), 7.90 (d, J = 8.5, 1H), 7.15 
(d, J = 8.1, 2H), 7.01 (dd, J = 8.6, 2.0, 1H), 6.69 (d, J = 8.0, 2H), 3.85 (s, 3H), 3.76–
3.64 (br s, 2H), 3.64 (s, 2H). 
13C NMR  (101 MHz, CDCl3) δ = 171.1, 167.9, 145.8, 142.4, 140.9, 131.9, 130.5, 123.9, 122.8, 
120.4, 115.6, 113.4, 52.5, 45.1. 
IR   (ATR): 3362, 3259, 2923, 1688, 1599, 1579, 1513, 1437, 1412, 1252, 1104, 776. 
HRMS   (ESI): calculated for C16H16ClN2O3 319.0844, found 319. 0845. 
Mp   116–120 °C. 
 
 
 
 
Methyl 4-chloro-2-(2-(4-(phenyldiazenyl)phenyl)acetamido)benzoate (2.3). To a solution of 2.2 
(32 mg, 0.10 mmol, 1.0 eq) in MeOH (0.8 mL) was added acetic acid (0.8 mL) followed by 
nitrosobenzene (16 mg, 0.15 mmol, 1.5 eq) at room temperature. The mixture was stirred at 
45 °C for 24 h, at which point LC-MS analysis showed full conversion. Saturated aqueous 
NaHCO3 (5 mL) was added at room temperature after dilution with EtOAc (10 mL). After 
extraction of the aqueous phase with EtOAc (3 × 10 mL), the combined organic phases were 
washed with saturated aqueous NaCl (15 mL), dried and evaporated to give a red oil that was 
purified by column chromatography (hexanes:EtOAc 6:1) to give 32 (35 mg, 86 µmol, 86%) as an 
orange solid. 
 
Rf   0.35 (hexanes:EtOAc 5:1). orange solid. 
1H NMR  (400 MHz, CDCl3) δ = 11.22 (s, 1H), 8.83 (d, J = 2.1, 1H), 7.99–7.85 (m, 5H), 7.58–
7.43 (m, 5H), 7.04 (dd, J = 8.6, 2.1, 1H), 3.86 (s, 3H), 3.84 (s, 2H). (10:1 mixture of 
isomers, major isomer quoted). 
13C NMR  (101 MHz, CDCl3) δ = 168.0, 152.7, 152.0, 142.3, 141.1, 137.2, 132.0, 131.1, 130.3, 
129.2, 123.5, 123.1, 123.0, 120.4, 113.4, 52.6, 45.7. 
IR  (ATR): 3257, 3060, 2926, 1688, 1579, 1513, 1413, 1312, 1251, 1103, 1016, 836, 775, 
688. 
HRMS   (ESI): calculated for C22H19ClN3O3 408.1109, found 408.1114. 
 
  
 
 
 
 
 
Thiazolidine-2,4-dione (3.6). Thiazolidine-2,4-dione (3.6) was prepared according to a literature 
procedure in 27% yield. Recrystallization from EtOH yielded colorless crystals suitable for X-
ray diffraction. The data are in good agreement with the literature.[378] 
 
1H NMR  (400 MHz, DMSO-d6) δ = 12.03 (s, 1H), 4.14 (s, 2H). 
13C NMR  (101 MHz, DMSO) δ = 174.0, 173.2, 35.9. 
HRMS   (EI): calculated for C3H3NO2S 116.9879, found 116.9846. 
 
 
 
 
(E)-5-(4-Nitrobenzylidene)thiazolidine-2,4-dione (3.7). 4-Nitrobenzaldehyde (1.2 g, 8.0 mmol, 
1.0 eq.) and thiazoline-2,4-dione (0.94 g, 8.0 mmol, 1.0 eq.) were dissolved in absolute EtOH 
(16 mL) before piperidine (80 µL, 0.80 mmol, 0.10 eq.) and AcOH (46 µL, 0.80 mmol, 0.10 eq.) 
were added. The mixture was stirred at 80 °C for 24 h, then cooled to 0 °C, filtered and the 
residue washed with toluene (20 mL) to give 3.7 (1.2 g, 4.8 mmol, 60%) as a yellow solid. The 
data are in good agreement with the literature.[378] 
 
Rf  0.40 (hexanes:EtOAc 2:1). Yellow solid. 
1H NMR  (400 MHz, DMSO-d6) δ = 12.8 (s, 1H), 8.34 (d, J = 8.7, 2H)7.90 (s, 1H), 7.87 (d, 
J = 8.7, 2H). 
 
 
 
 
(E)-5-(4-Aminobenzylidene)thiazolidine-2,4-dione (3.8). Thiazolinedione 3.7 (90 mg, 
0.36 mmol, 1.0 eq.) was dissolved in toluene (5 mL) before oven-dried silica gel (0.36 g) and 
Hantzsch ester (0.12 g, 0.47 mmol, 1.3 eq.) were added. The mixture was stirred at 100 °C for 
24 h, then cooled to room temperature, filtered over Celite with EtOAc (30 mL). The solution 
was washed with 1 M HCl (2 × 10 mL) and saturated aqueous NaCl (20 mL), dried with MgSO4 
and concentrated to give a yellow oil which was purified by column chromatography 
(hexanes:EtOAc 4:1) to give 3.8 (43 mg, 0.17 mmol, 47%) as an off-white solid. The data are in 
good agreement with the literature.[378] 
 
Rf  0.40 (hexanes:EtOAc 2:1). Off-white solid. 
1H NMR  (400 MHz, CD3OD) δ = 8.20 (d, J = 8.2, 2H), 7.54 (d, J = 8.2, 2H), 4.84 (dd, J = 8.5, 
4.5, 1H), 3.56 (dd, J = 14.1, 4.6, 1H), 3.35 (dd, J = 14.2, 8.6, 1H). 
 
 
 
 
 
5-(4-aminobenzyl)thiazolidine-2,4-dione (3.9). 5-(4-Nitrobenzyl)thiazolidine-2,4-dione (3.8) 
(43 mg, 0.17 mmol, 1.0 eq) was dissolved in MeOH (1.5 mL) and DMSO (0.5 mL) before Pd/C 
(10wt%, spatula tip) was added. The headspace was purged with hydrogen three times and the 
suspension was stirred for 16 h. The reaction mixture was filtered over Celite with EtOAc 
(30 mL). The solution was washed with 10% aqueous LiCl (4 × 10 mL), dried with MgSO4 and 
concentrated to give 3.9 (35 mg, 0.16 mmol, 93%) a yellow oil. The data are in good agreement 
with the literature.[378] 
 
Rf  0.10 (hexanes:EtOAc 2:1). Yellow oil. 
 
1H NMR  (400 MHz, DMSO-d6) δ = 11.98 (br s, 1H), 6.88 (d, J = 7.9, 2H), 6.48 (d, J = 7.8, 
2H), 4.79 (dd, J = 9.3, 4.0, 1H), 3.19 (dd, J = 14.2, 4.3, 1H), 2.91 (dd, J = 14.0, 9.1, 
1H). 
 
 
 
 
5-(4-((4-(Diethylamino)phenyl)diazenyl)benzyl)thiazolidine-2,4-dione (3.10). To a solution of 
3.9 (22 mg, 0.10 mmol, 1.0 eq.) in MeOH (0.5 mL) was added NaNO2 (8.3 mg, 0.12 mmol, 1.2 eq.) 
in H2O (0.5 mL), followed by 1 M HCl (0.3 mL, 0.3 mmol). The resulting faintly yellow mixture 
was stirred at 0 °C for 1 h before NaOAc·3H2O (41 mg, 0.3 mmol, 3.0 eq.) and N,N-diethylaniline 
(19 µL, 0.12 mmol, 1.2 eq.) were added sequentially. The cloudy yellow solution was stirred at 
room temperature for 15 h. The resulting dark-red suspension was diluted with EtOAc (20 mL). 
The organic layer was washed with saturated aqueous NH4Cl (10 mL), saturated aqueous 
NaCl (10 mL), then dried with MgSO4 and concentrated in vacuo. The resulting red solid was 
purified via column chromatography (CH2Cl2:acetone 100:0.5) to afford 3.10 (15 mg, 39 µmol, 
39%) as an orange solid. 
 
Rf  0.69 (hexanes:EtOAc 1:1). Orange solid. 
1H NMR  (400 MHz, CDCl3) δ = 7.87–7.82 (m, 3H), 7.78 (d, J = 8.0, 3H), 7.33 (d, J = 8.0, 2H), 
6.72 (d, J = 8.8, 2H), 4.58 (dd, J = 9.8, 3.9, 1H), 3.59 (dd, J = 14.1, 3.9, 1H), 3.46 (q, 
J = 7.1, 4H), 3.21 (dd, J = 14.0, 9.7, 1H), 1.23 (t, J = 7.0, 6H). 
13C NMR  (101 MHz, CDCl3) δ = 173.4, 169.6, 152.8, 150.3, 143.1, 136.5, 129.9, 125.4, 122.5, 
110.9, 53.3, 44.7, 38.4, 12.7. 
IR (ATR): 3198, 3061, 2973, 2927, 1754, 1697, 1599, 1515, 1397, 1354, 1271, 1125, 1077, 
822. 
HRMS  (EI): calculated for C20H22N4O2S 382.1463, found 382.1457. 
Mp.   158–161 °C. 
UV-Vis  (50 µM in DMSO): max = 440 nm. 
 
 
 
 
5-(4-(Phenyldiazenyl)benzyl)thiazolidine-2,4-dione (3.11). To a solution of 3.9 (35 mg, 
0.16 mmol, 1.0 eq.) in AcOH (0.8 mL) and MeOH (0.8 mL) was added nitrosobenzene (19 mg, 
0.18 mmol, 1.1 eq.). The resulting mixture was stirred at room temperature for 16 h, during 
which it turned from light-green to dark-red. The dark-red solution was concentrated and the 
residue diluted with EtOAc (25 mL). The organic layer was washed with saturated aqueous 
NaHCO3 (8 mL), saturated aqueous NaCl (10 mL), then dried with MgSO4 and concentrated in 
vacuo. The resulting yellow oil was purified via column chromatography (CH2Cl2:acetone 
100:0.5) to afford 3.11 (23 mg, 74 µmol, 46%) as an orange solid. 
 
Rf  0.30 (hexanes:EtOAc 2:1). Yellow-orange solid. 
1H NMR  (400 MHz, CDCl3) δ = 8.23 (s, 1H), 7.96–7.85 (m, 4H), 7.56–7.48 (m, 3H), 7.39 (d, 
J = 8.0, 2H), 4.60 (dd, J = 9.6, 4.0, 1H), 3.61 (dd, J = 14.1, 4.0, 1H), 3.26 (dd, J = 14.1, 
9.5, 1H). 
13C NMR  (101 MHz, CDCl3) δ = 173.6, 169.8, 152.6, 152.1, 138.6, 131.2, 130.1, 129.1, 123.3, 
122.9, 53.0, 38.4. 
IR   (ATR): 3179, 3059, 2810, 1756, 1675, 1326, 1155. 
HRMS   (EI): calculated for C16H13N3O2S 311.0728, found 311.0721. 
Mp.  149–152 °C. 
UV-Vis  (50 µM in DMSO): max (trans-π-π*) = 326 nm, max (trans-n-π*) = 438 nm. 
 
 
 
 
5-(4-((4-(Trifluoromethyl)phenyl)diazenyl)benzyl)thiazolidine-2,4-dione (3.12). To a solution 
of 3.9 (22 mg, 0.10 mmol) in AcOH (0.5 mL) and MeOH (0.5 mL) was added 1-nitroso-4-
(trifluoromethyl)benzene (19 mg, 0.18 mmol, 1.8 eq.). The resulting mixture was stirred at 35 °C 
for 23 h, during which it turned from light-green gradually to dark-red. The dark-red solution 
was concentrated and the residue diluted with EtOAc (20 mL). The organic phase was washed 
 
with saturated aqueous NaHCO3 (6 mL), H2O (6 mL), saturated aqueous NaCl (6 mL), then 
dried with MgSO4 and concentrated in vacuo. The resulting orange oil was purified via column 
chromatography (CH2Cl2:acetone 100:0.5 to 100:1) to afford 3.12 (25 mg, 66%) as an orange solid. 
 
Rf  0.73 (hexanes:EtOAc 1:1). Yellow-orange solid. 
1H NMR (400 MHz, CDCl3) δ = 8.29–8.15 (m, 1H), 8.00 (d, J = 8.2, 2H), 7.93 (d, J = 7.9, 2H), 
7.79 (d, J = 8.1, 2H), 7.42 (d, J = 8.0, 2H), 4.61 (dd, J = 9.4, 3.9, 1H), 3.61 (dd, 
J = 14.2, 4.0, 1H), 3.28 (dd, J = 14.1, 9.4, 1H). 
13C NMR  (101 MHz, CDCl3) δ = 173.7, 169.8, 154.5, 151.9, 139.6, 133.8 (q, J = 32.2), 130.3, 
126.5 (q, J = 3.6), 124.1 (q, J = 270.1), 123.8, 123.2, 53.0, 38.5. 
19F NMR (400 MHz, CDCl3) δ = -62.58. 
IR   (ATR): 3196, 3059, 2925, 2759, 1758, 1675, 1661, 1500, 1414, 1328, 1160, 1125, 1064.  
HRMS   (EI): calculated for C17H12F3N3O2S 379.0602, found 379.0601. 
Mp  136–140 °C. 
UV-Vis  (50 µM in DMSO): max (trans-π-π*) = 332 nm, max (trans-n-π*) = 435 nm. 
 
 
 
The spectra are numbered and ordered as they appear in the main text. In the case of published 
manuscripts, the numbering is adapted from the manuscript. 
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Two-electrode voltage clamp electrophysiology of Xenopus ooctyes expressing GluN1-
1a+GluN2B, GluN1-1a+GluN2C or GluN1-1a+GluN2D channels 
Figure S1: Electrophysiological evaluation of PNRA with other NMDA receptor subunit 
combinations. 
a) 
 
b) 
 
c) 
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